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      Abstract    
Research in this thesis investigates a simple, rapid, reproducible and specific liquid 
chromatography-mass spectroscopy (LC-MS) method for the simultaneous 
detection, confirmation and quantitation of beclomethasone dipropionate (BDP) and 
its metabolites beclomethasone monopropionate (BMP) and beclomethasone (BOH) 
which has been developed and validated. The method was validated over a 
concentration range from 0.001-100 mg/L for BDP and 0.01-10 mg/L for BOH. The 
calibration graphs exhibited excellent linearity with typical R2 values for BDP of 0.997 
and for BOH of 0.999. The analytes stability was investigated and they were found to 
be stable for many weeks. BDP was introduced as the first inhaled glucocorticoid for 
the treatment of asthma in the 1970s and is still a major treatment for asthma 
nowadays. BDP is an inactive prodrug; for BDP to be effective, it needs to be 
activated to its active form, beclomethasone-17-monopropionate (17-BMP) and 
beclomethasone-21-monopropionate (21-BMP). The method involved in vitro 
metabolism of the BDP, incubated with esterase enzyme at 37° C for 2 hrs. The 
product was analysed by LC-MS. A liquid-liquid extraction procedure was used to 
purify the products, with four different solvents and five sequential extractions, for 
initial extraction steps. The extracts were analysed by LC-MS. Extraction with ether 
gave very good results with 99 % extraction of the required products.  
For the first time new methods of labelling steroids, including progesterone and 
testosterone, with rhenium-containing luminescent labels. For this purpose rhenium 
complex with 3,3’-diamino-2,2’-bipyridine (complex 1) was used as a fluorescent 
label for various biomolecules. Preparative HPLC, LC-MS, NMR spectroscopy and 
X-ray crystallography have been used to identify and characterize the products 
formed.  
 
The timed reaction of complex 1 with progesterone was run using the newly 
developed chromatographic method (55 % MeCN, 0.5 mL/min).  A solution of 
complex 1 and progesterone in acetonitrile was heated in the dark for 3 hrs followed 
by a timed NMR experiment for 6 hours, collecting data at regular intervals. The 
sample was separated using the preparative HPLC which showed some side 
 vi 
 
products and two overlapping peaks for the product isomers. The single-crystal X-ray 
structure of the Re-progesterone product was obtained and measurements of 
selected bond lengths showed a rearrangement of the double bond between C4 and 
C5 had occurred at the conjugated end of the progesterone. The refined structure 
further confirmed the shifting of the double bond. For the analagous product of 
complex 1 and testosterone attempts were made to crystallise the product both by 
slow evaporation and by refrigeration of an acetonitrile solution of fraction 2. To date 
these attempts have been unsuccessful. 
Finally, the research work was conducted to combine the work presented above by 
using enzymatic reactions to modify a biomolecule for reaction with the rhenium-
containing complex 1. Galactose oxidase catalyses the oxidations of primary 
alcohols to the corresponding aldehyde with the reduction of dioxygen to hydrogen 
peroxide. Research presented in this part of the thesis investigates different 
methodologies for the oxidation of methyl α-D-galactopyranoside with the help of 
galactose oxidase to form an aldehyde-containing sugar which will react with the 
diamino moieties of complex 1. The best method to work with was found to be 
method 2 using catalase suspension, galactose oxidase and HRP in deionised 
water. The reaction mixture gave a fairly pure product in good yields. 
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      Abbreviations 
AO  Alcohol Oxidase 
AUFS   Absorbance Units Full Scale 
BDP  Beclomethasone Dipropionate 
17-BMP  Beclomethasone-17-monopropionate 
21-BMP  Beclomethasone-21-monopropionate 
BOH  Beclomethasone 
BUD  Budesonide 
°C  Degree Celsius (Temperature)                 
C  Carbon 
C18 Column  Octadecyl carbon chain-bonded silica column 
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COPD  Chronic Obstructive Pulmonary Disease  
CO2  Carbon dioxide  
COSY  Correlation Spectroscopy 
CSA  Camphor Sulfonic Acid 
DCM  Dichloromethane 
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DET  Direct electron transfer  
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HMBC  Heteronuclear Multiple Bond Correlation 
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Spectroscopy 
HPLC-UV  High Performance Liquid Chromatography with Ultra violet spectroscopy  
HPPA  Hydroxyphenylpropionic acid  
hr/hrs Hour (s)  
HRP  Horse radish peroxidase 
ICH                          International Conference on Harmonisation of Technical Requirements 
for  Registration of Pharmaceuticals for Human Use (ICH) 
ICS  Inhaled Corticosteroids  
ICP-MS  Inductively coupled plasma mass spectroscopy     
IS  Internal Standard     
IUPAC  International Union of Pure and Applied Chemistry  
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kDa  KiloDalton 
LC-ESI-MS-MS  Liquid chromatography electrospray ionisation tandem mass 
spectroscopy  
LC-MS  Liquid Chromatography coupled with Mass Spectroscopy  
LC-MS-MS  Liquid Chromatography coupled with tandem Mass Spectroscopy  
LC-UV Liquid Chromatography with Ultra Violet Spectroscopy  
LLE  Liquid/Liquid Extraction  
LOD  Limit of Detection 
MALDI–MS  Matrix-assisted laser desorption/ionization coupled with mass 
spectroscopy 
MALDI-TOF–MS  Matrix assisted laser desorption ionization-Time of Flight mass                            
spectroscopy  
MDI  Metered-Dose Inhaler  
MeCN  Acetonitrile  
MeOH  Methanol  
mg  Milligram  
MgCl2  Magnesium Chloride  
mg/L  Milligrams per litre  
MgSO4  Magnesium Sulphate 
MicrOTOF-Q           Micro Time-of-Flight Quadrupole mass spectrometer  
min  Minute (s)  
mm  Millimeters  
MRI  Magnetic Resonance Imaging  
MWCO  Molecular Weight Cut Off  
m/z  Mass to Charge ratio  
N2  Nitrogen  
nm  Nano meter  
NMR  Nuclear Magnetic Resonance  
pg mL-1  Picogram per millilitre  
ppm  Parts Per Million  
prep-HPLC  Preparative High Performance Liquid Chromatography  
RIA  Radioimmunoassay  
Re(I)  Rhenium (I)  
RSD  Relative Standard Deviation  
RT  Retention Time   
Ru(II)  Ruthenium (II)  
SD  Standard Deviation  
SiO2  Silicon Dioxide (silica)  
SPE  Solid Phase Extraction 
SPME-LC-MS  Solid-phase microextraction coupled with liquid chromatography mass 
spectrophotometry  
SRM  Selected Reaction Monitoring Mode  
T/t   Time  
TBME/MTBE Tert-butyl-methyl ether  
Tc Technetium   
TLC  Thin Layer Chromatography   
TRH  Thyrotropin Releasing Hormone 
µL  Microlitres  
UFLC  Ultra Fast Liquid Chromatography  
UV-VIS Detector  Ultraviolet/Visible Spectroscopic Detector
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Chapter 1: In-vitro metabolism of a corticosteroid 
1.1 Introduction                                                                                                                             
       Hormones are groups of powerful chemicals that have a wide range of effects 
on the body and a range of vital hormonal functions. When a hormone reaches a 
target cell, it binds to a receptor to initiate a response.1 They can be divided into 
naturally-occurring and synthetic groups. The latter are important as therapeutic 
agents.                                              
1.1.1 Classification of hormones / chemical classes of hormones: 
        Hormones are classified according to their structure and function.1 Hormones 
can be classified by their structure, which divides them as water or fat soluble, which 
determines: 
• how they move in the blood, alone or attached to a protein;  
• how they bind to receptor sites outside or inside of the target cell (fat soluble 
can bind both whereas water soluble hormones usually bind on the outside) 
and;  
• how they will be metabolized.2 
Vertebrate hormones fall into three chemical classes: 
Amino acid derivatives: Some single amino acid derivatives can be classed as 
hormones. These are derived from the amino acid, phenylalanine.3 Examples include 
catecholamines and thyroid hormones. These hormones are stored in endocrine 
cells until needed.1,2,4  
Peptide hormones: They are made up of chains of amino acids. Examples of small 
peptide hormones are thyrotropin releasing hormones (TRH) and vasopressin. 
These vary from small peptides to long chain proteins, for example, insulin and 
growth hormone. Glycoprotein hormones have long carbohydrate side chains. 
Luteinizing hormone, follicle-stimulating hormone and thyroid-stimulating hormone 
are glycoprotein hormones1.  They are stored in endocrine cells until needed for 
processes like metabolism, lactation, growth and reproduction.2,3,4  
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Lipid and phospholipid-derived hormones: They are derived from lipids such as 
linoleic acid, arachidonic acid and phospholipids. The main classes are the steroid 
hormones that are derived from cholesterol. These are fat soluble hormones. 
Examples of steroid hormones are testosterone and cortisol. Among these are the 
three major sex hormones groups: estrogens, androgens and progesterones.1,2,3,4     
         Glucocorticoids are hormones synthesized in the adrenal cortex and secreted 
into the blood, where the levels of glucocorticoids fluctuate in a circadian mode. In 
humans, the naturally occurring glucocorticoid is hydrocortisone (cortisol), which is 
synthesized from its precursor cortisone. The beneficial effects of glucocorticoids in 
asthmatic patients were first described in 1950.5 Since then, many studies have 
focused on the therapeutic potential of glucocorticoids. Several synthetic 
glucocorticoids6 are now available and are powerful agents in the treatment of 
inflammatory diseases and are by far the most effective anti-inflammatory drugs 
used in the treatment of asthma.7 
1.1.2 History of corticosteroids 
 
         Glucocorticoids (also known as glucocorticosteroids or corticosteroids) are 
among the most widely used drugs in the world and are effective against many 
inflammatory and immune diseases. The most common use of corticosteroids is in 
the treatment of asthma, where inhaled corticosteroids have become first-line 
therapy and by far the most effective anti-inflammatory treatment. The treatment of 
chronic inflammatory diseases was revolutionized by the discovery of the therapeutic 
utility of glucocorticosteroids in the 1950s. Since this time they have been the 
mainstay of treatment for chronic inflammatory diseases.5  
         All major chronic inflammatory diseases (including inflammatory bowel disease, 
psoriasis, rheumatoid arthritis and asthma) can be treated with glucocorticoids. They 
are the most effective anti-inflammatory agents currently available. However, since 
the elucidation of their clinical effectiveness in 1948 for the treatment of rheumatoid 
arthritis by Kendall and Hench, who were awarded the Nobel Prize for Medicine for 
this work in 1950, it has become clear that the beneficial effects of ever increasing 
doses of glucocorticosteroids are countered by the onset of severe side-effects. 
Moreover, the recent developments in our understanding of the action of 
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glucocorticosteroids have suggested that it may be possible to develop new 
glucocorticosteroids with different pharmacology which lack the ability to induce 
many of the pathways involved in the manifestation of side-effects. 
       Enormous progress has been made in improving glucocorticosteroid treatment 
since the introduction of hydrocortisone as the first clinically used corticosteroid. 
Extensive drug development has resulted in highly potent molecules, the 
pharmacokinetic profiles of which have been optimized to minimize systemic 
exposure and to target activity to the lung.8  
1.1.3 Types of corticosteroids 
      Corticosteroids exist in two groups; endogenous (naturally produced) and 
exogenous (originally outside the body). Endogenous corticosteroids, such as 
cortisol, are important for physiological processes, including immune response, 
stress response, and growth.  
Exogenous corticosteroids, including  
a) systemic (e.g. prednisolone) 
b) inhaled (e.g. ciclesonide) and  
c) topical corticosteroids (e.g. hydrocortisone), are widely used for various 
indications, such as asthma, rheumatoid arthritis, eczema, and Crohn’s disease, due 
to their anti-inflammatory and immunosuppressive effects. However, both short-term 
and chronic exposure to corticosteroids could result in a variety of adverse effects, 
including growth retardation in pediatric patients, oropharyngeal candidiasis, skin 
atrophy, adrenal suppression, risk of cataracts, and osteoporosis.9,10,11  
1.1.4 Inhaled corticosteroids (ICS)  
      Inhaled corticosteroids (ICS) are currently the standard first-line therapy for the 
treatment of airway diseases, for example asthma. They reduce bronchial hyper- 
responsiveness by reducing the underlying inflammation in the airways through the 
inhibition of inflammatory cell migration and infiltration and the release of pro- 
inflammatory cytokines. The pharmacokinetic and pharmacodynamic properties of 
ICS determine their therapeutic efficacy as well as their propensity for local and 
systemic side effects.12,13,14 All corticosteroids are 21-carbon atom steroids, with a 
basic four-ring structure, as shown in Fig. 1. 
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Figure 1: The basic skeleton of a steroid showing the IUPAC numbering system.15,16,17 
 
1.1.5 Functions  
 
      Corticosteroid medicines are derivatives of the natural corticosteroid hormones 
that are produced by the adrenal glands.18 Corticosteroids are widely used as:  
I. Anti-inflammatory and immunosuppressive agents in a variety of chronic 
conditions. 
II. Replacement therapy (to replace hormones due to an underlying health 
condition). 
III. To the skin for the localised treatment of various inflammatory skin 
disorders.6,18 
IV. As a regulator of a number of physiological processes, including development, 
stress responses, and homeostasis. These activities have important 
therapeutic consequences, and today corticosteroids are indispensable for the 
treatment of a wide variety of inflammatory diseases.19 
       Corticosteroids should not be confused with anabolic steroids, which are 
sometimes used (illegally) by body builders and athletes. Unlike anabolic steroids, 
corticosteroids do not affect muscle strength.6 
1.1.6 Side Effects 
      The efficacy of ICS is now established in short and long-term studies in adults 
and children, but there are still concerns about side effects, particularly in children 
and when high inhaled doses are used. Several side effects have been recognized 
including systemic side effects. In the treatment of airway diseases side-effects can 
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be limited by targeted delivery to the airway and lung and significant progress has 
been made through the use of a variety of lung-targeting strategies.8  
        General side effects may include, cough, pneumonia in chronic obstructive 
pulmonary disease (COPD) patients and oropharyngeal candidiasis. Systemic side 
effects including adrenal and growth suppression, bruising, osteoporosis, cataracts 
and metabolic abnormalities (insulin, glucose) limit their systemic use; however, 
inhaled corticosteroids play a pivotal role in the treatment of asthma and chronic 
obstructive pulmonary disease.19,20 
1.1.7  Mechanism of action  
         Although glucocorticoids have been known for a long period of time, their 
precise mechanism of action is still not completely understood. However, recent 
studies have increased our understanding of their complex mechanisms of action.7 A 
general outline is shown in Fig. 2:                           
            
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: A general mechanism of action of ICS.21 
         As described in Fig. 2, the diverse actions of steroids are mediated through a 
single receptor, which is present in most cell types. Steroids are lipophilic and 
unbound glucocorticoids thus rapidly cross the cell membrane and enter the 
cytoplasm, where they combine with the glucocorticosteroid receptor.21 Protein 
molecules that hold the receptor in an inactive state (heat shock proteins) then 
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dissociate, and the glucocorticosteroid-receptor complex translocates to the nucleus. 
In the nucleus, the glucocorticosteroid-receptor complex acts as a transcription 
factor, binding to specific recognition sequences of steroid-sensitive genes resulting 
in gene activation or suppression. The results can include inhibition of leukocyte 
infiltration at the site of inflammation, interference in the function of mediators of 
inflammatory response, and suppression of humoral immune responses (i.e. 
upregulation of certain anti-inflammatory mediators, such as lipocortin-1 and neutral 
endopeptidases, and down regulation of pro-inflammatory mediators such as 
cytokines and chemokines). This is believed to be a major mechanism contributing to 
the anti-inflammatory effects of inhaled steroids in asthma.22,23 The use of ICS has 
represented a major breakthrough in the treatment of asthma since their introduction 
in the 1970s. Among the various ICS available in the market, beclomethasone 
dipropionate (BDP) was the first, introduced in 1972 in a pressurized metered-dose 
inhaler (MDI) and later in a dry powder inhaler and an aqueous nasal spray.  
1.1.8 Pharmacokinetics 
        The science of pharmacokinetics aims to quantify the ways in which the body 
absorbs, distributes, metabolizes, and eliminates drugs. The knowledge of the 
pharmacokinetic behaviour  of drugs is essential not only for understanding the basis 
of their safety, efficacy, and therapeutic ratios, but also for predicting their behaviour 
and secondary effects when administered.24 
      The pharmacokinetic behaviour of ICS is important in relation to systemic effects. 
The fraction of steroid which is inhaled into the lungs acts locally on the airway 
mucosa, but may be absorbed from the airway and alveolar surface. This fraction 
therefore reaches the systemic circulation. The fraction of ICS which is deposited in 
the oropharynx is swallowed and absorbed from the gut. This absorbed fraction may 
be metabolized in the liver before reaching the systemic circulation (first-pass 
metabolism). A high level of first-pass metabolism will decrease the risk of unwanted 
systemic effects from the GI fraction of the dose (Fig. 3). The ideal ICS should have 
high lung bioavailability, negligible oral bioavailability, low systemic absorption, high 
systemic clearance and high protein binding.19,20 
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Figure 3: In vivo pharmacokinetics of inhaled steroids.25 
 
1.1.9 Beclomethasone Dipropionate (BDP) 
      Beclomethasone dipropionate, (9-chloro-11β,17,21trihydroxy-16β- methylpregna-
1,4-diene-3,20-dione-17,21-dipropionate, BDP), the active component of Beconase 
AQ nasal spray, is a commonly-used anti-inflammatory steroid and a pro-drug with 
weak glucocorticoid receptor binding activity.26 BDP is an important glucocorticoid 
diester in the inhalation therapy of lung diseases such as asthma.27 BDP is a white to 
creamy-white, odourless powder, which is very slightly soluble in water, very soluble 
in chloroform, and freely soluble in acetone and in ethanol.26 The structure is shown 
in Fig. 4(a)(b). BDP is structurally complex since it has two side chains, as well as 
methyl groups at positions 18 and 19 and a chlorine atom at C9. It has four carbonyl 
and carboxyl groups available for hydrogen bonding.28 
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Figure 4 (a): 2D structure of BDP                     (b): 3D structure of BDP 
 
           Beclomethasone dipropionate is used in the treatment of bronchial asthma 
and allergic (seasonal) and vasomotor rhinitis.29,30  It is marketed, variously, as a 
solution or powder under the brand names Beclovent, Beconase, Qvar, Clenil, 
Modulite, Pulvinal and Vancenase. The actuated doses are usually in the range 0.04 
– 0.08 mg per actuation.31,32 
 
1.1.10 Metabolism of Beclomethasone dipropionate (BDP) 
          For several decades it has been recognised that the lungs contain non-specific 
esterases and as such a potential site for the hydrolysis of ester drugs and it is  
desirable to modify the physicochemical characteristics of a drug by the production 
of ester prodrugs.  It has been reported that ester prodrugs of xenobiotics whose site 
of action is in the lungs were synthesised.23,33 Despite this history, there are 
surprisingly few reports in the literature in which the pulmonary hydrolysis of esters 
has been investigated in vitro. As a preliminary investigation into pulmonary esterase 
activity, prior to the in vivo investigation of pulmonary first-pass ester metabolism, the 
hydrolysis of four aliphatic esters of biphenylacetic acid was studied.23 
            The aims of this study were to investigate whether the kinetic parameters of 
ester hydrolysis are dependent on the physicochemical nature of the esters; and 
whether enzyme kinetics derived in blood can be used to predict the pulmonary 
situation. It appeared that kinetic parameters for non-specific esterase catalysed 
hydrolysis are predictable from the ester’s physicochemical nature. The pulmonary 
enzyme kinetics for hydrolysis can be directed from the kinetics measured in blood.34 
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And three major metabolites of BDP, beclomethasone-17-monopropionate (17-
BMP), beclomethasone-21-monopropionate (21-BMP), and beclomethasone (BOH) 
are formed via hepatic cytochrome P450 3A-family catalyzed biotransformation  
(Fig. 5).11,21,34,35,36,37 More than 90% of inhaled beclomethasone is found as its active 
metabolite in the systemic circulation.22,36,38 In order to be effective, BDP needs to be 
converted to 17-BMP via hydrolysis, which is largely enzyme-catalysed in vivo.30 
 
 
 
 
 
 
         
Figure 5: BDP and its primary metabolites.39 
  
               The proposed degradation pathway of BDP in human plasma is presented in 
Fig. 6. Essentially, three reactions are involved: ester hydrolysis, transesterification, 
and loss of hydrochloric acid (HCl) to form an epoxide. In plasma, the hindered 17α- 
propionate group of BDP is more resistant to ester hydrolysis than that at the 21- 
position, giving rise to 17-BMP as the major product (Fig. 6).30 
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Figure 6: A proposed degradation pathway of BDP in human plasma.30 
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        The rapid formation of 17-BMP, a potent and more hydrophilic degradation 
product, may lead to extensive absorption of the drug from the lower respiratory tract 
because it may be cleared more rapidly into the systemic circulation which results in 
substantial systemic effects, such as adrenal suppression, osteoporosis, reduced 
total bone mass and mineral density, as well as the inhibition of body growth in 
children. The metabolic biotransformation of BDP has been studied and reviewed by 
many authors.37,40 For the oral inhalation route, some metabolism occurs in the lungs 
before entering the systemic circulation; the lung tissues metabolize 
Beclomethasone dipropionate rapidly to 17-BMP and more slowly to BOH. The mean 
elimination half-life of 17-BMP is 2.8 hrs; the biological half-life of beclomethasone is 
roughly 15 hrs. Irrespective of the route of administration (injection, oral or 
inhalation), beclomethasone and its metabolites are excreted predominantly in the 
faeces. Less than 10% of the drug and its metabolites are excreted in the urine.22,38 
         The decomposition kinetics of BDP have been studied extensively. For 
example, Foe, Brown and Seale proposed a method to monitor the kinetics of 
decomposition of BDP, 17-BMP, and BOH which were characterized in whole human 
plasma (HP).  A reverse-phase HPLC assay was used for simultaneous separation 
and quantification of beclomethasone propionate esters and six degradation 
products, three of which were previously unidentified. Following incubation of BDP, a 
number of products were formed and a new metabolic pathway for BDP was 
proposed in an article in 1998.31          
 
        Daley-Yates, Price et al.32 worked to assess the absolute bioavailability, 
pharmacokinetics and metabolism of BDP in humans following intravenous, oral, 
intranasal and inhaled administration.32 Twelve healthy subjects participated in this 
study where BDP was administered via the following routes: intravenous infusion 
(1000 mg), oral (4000 mg, aqueous suspension), intranasal (1344 mg, aqueous 
nasal spray) and inhaled (1000 mg ex-valve, metered dose inhaler). Blood samples 
were collected for 24 hrs post dose for the measurement of BDP, 17-BMP and BOH 
in plasma by LC-MS. The chemical structures and relative receptor affinities for BDP 
and its main metabolites are shown in Fig. 7 below.   
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Figure 7: The chemical structures and relative receptor affinities for BDP and its main 
metabolites.32 
         BDP was not extensively distributed to the tissues but was eliminated rapidly 
with a high clearance and short half-life (0.5 hr). The disappearance of BDP was 
accompanied by the appearance of 17-BMP after a delay of approximately 1.5 hrs, 
which was in agreement with the fact that it was converted by esterases. Unchanged 
BDP has negligible oral and intranasal bioavailability with limited absorption following 
inhaled dosing. The oral and intranasal bioavailabilities of the active metabolite 17-
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BMP were high, but direct absorption in the nose was insignificant. The total inhaled 
bioavailability of 17-BMP (lung + oral) was also high (62%) of which approximately 
36% was due to pulmonary absorption.32,39  
           Nave and McCracken investigated the in vitro metabolism of BDP, 
budesonide (BUD), ciclesonide (CIC), and fluticasone propionate (FP) in human lung 
precision-cut tissue slices. In this study, differences in an in vitro metabolism of 
currently available ICS in human lung tissue slices were evaluated with respect to 
their local effect on pulmonary residence time. Lung tissue slices were incubated 
with BDP, BUD, CIC, and FP (initial target concentration of 25µM) for 2, 6, and 24 
hrs. Metabolites and remaining parent compounds in the tissue samples were 
analyzed by HPLC with UV detection. It was shown that BDP was hydrolyzed to 
active 17-BMP and to pharmacologically inactive BOH and 21-BMP. BMP was the 
major metabolite at 2 hrs and 6 hrs, whereas BOH was the major metabolite at 24 
hrs.  At 24 hr, BMP accounted for 26.6% and BOH for 64.9% of BDP-related 
material. These authors observed clear differences between the investigated ICS 
regarding the time of the drugs within the lung tissue slices.40 
 
1.1.11 Methods of detection and quantitation of corticosteroids 
       Steroid detection has been critical for the diagnosis of disorders of steroid 
hormone synthesis and metabolism since the 1960s. In addition, analytical methods 
are necessary since the therapeutic and doping use of corticosteroids has been 
widespread for several decades. A range of methodologies for detecting 
corticosteroids in biological fluids has previously been investigated. Unfortunately 
detection of corticosteroids in biological matrices has been problematic; traditional 
analytical techniques including gas chromatography coupled with mass spectroscopy 
(GC-MS), enzyme-linked immune sorbent assay (ELISA) or HPLC-UV show poor 
sensitivity or selectivity. Other analytical methods widely used to determine 
corticosteroids are based on radioimmunoassay (RIA) procedures; these are 
characterised by their high sensitivity. However, RIA is hazardous due to the use of 
radioactive materials. Also, modification of an assay procedure is difficult and time 
consuming. RIA requires approval and training to work with radioactive materials.41 
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         Methods for the detection and quantification of synthetic corticosteroids by GC-
MS have been reported. Although providing good sensitivity, these methods are not 
easy to use. The Atlanta Olympic Games in 1996 marked the first time every 
specimen was screened by GC-MS.42 Today, liquid chromatography coupled with 
mass spectroscopy (LC-MS) represents a powerful alternative combining rapidity, 
specificity and sensitivity. Several publications have proposed the detection of 
corticosteroids using LC with tandem mass spectroscopy (LC–MS–MS).42,45,48 
1.1.12 Specific methods for detection and quantitation of Beclomethasone 
dipropionate (BDP) 
        Investigation of a drug’s pharmacokinetic behaviour is a vital part of its 
development. Therefore, there are many methods in the literature for extraction and 
quantitation of BDP and its metabolites from a variety of sample types. In 
pharmaceutical preparations and biological matrices, multiple analytical procedures 
have been reported for the analysis of BDP using HPLC42,43,44,45,46,47, GC or capillary 
electrophoresis.30,43,48,49. Perhaps surprisingly, spectrophotometric techniques have 
scarcely been used.23,43 
       Jian-Jun Zou and colleagues developed a method for determining the 
pharmacokinetic profiles of BDP.33 It is believed that this paper is the first report of a 
simple and sensitive method to determine the two main active metabolites, BOH and 
17-BMP, in human plasma by liquid chromatography electrospray ionization tandem 
mass spectroscopy (LC–ESI (+/−)–MS–MS) using BDP as internal standard (IS) and 
to study the pharmacokinetics after intramuscular injection in healthy Chinese 
volunteers. Extraction was carried out on plasma with an ether-cyclohexane mixture 
and both metabolites were separated by HPLC on a Hanbon Lichrospher C18 column 
with a mobile phase of methanol–water (85:15, v/v) at a flow rate of 0.7 mL/min. 
Calibration curves were linear. The mean plasma extraction recoveries for BOH and 
17-BMP were in the ranges of 82.7–85.9% and 83.6–85.3%, respectively. The 
method was successfully applied to study the pharmacokinetics of a new formulation 
of BDP injection in healthy Chinese volunteers. The method achieved good 
sensitivity and specificity for the determination of BOH and 17-BMP in human 
plasma. No significant interference caused by endogenous compounds was 
observed. The alternate acquisitions of positive and negative ions in selected 
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reaction monitoring mode (SRM) also offered lower background and higher 
response. Plasma was not assayed for the minor and inactive metabolite 21-BMP. 
The method is simpler and faster than any other described in the literature. This 
method is suitable for pharmacokinetic studies in human subjects.        
         Guan, Uboh and colleagues presented a sensitive LC-MS-MS method for the 
detection, confirmation and quantification of BDP, 17-BMP, 21-BMP and BOH in 
equine plasma and urine. BDP contains two ester groups and 17-BMP and 21-BMP 
might be further hydrolyzed by plasma esterases to BOH. Therefore, it was 
necessary to evaluate the stability or decomposition of BDP, 17-BMP and 21-BMP in 
equine plasma at ambient temperature (25 °C). The concentration of BDP decreased 
by 36% over 2 hrs and that of 21-BMP by 86%, but the concentration of 17-BMP did 
not change over the 2 hrs period. The results showed that 17-BMP was stable in 
equine plasma at ambient temperature during the time period (2 hrs.). The method 
was evaluated with regard to the limit of detection, quantification range, precision 
and accuracy. The extraction efficiency was >89% for BDP and 17-BDP.36 
           The correlation coefficients of the calibration curves were >0.99. The limit of 
confirmation was 25 pg mL-1 for BDP and 17-BMP and 50 pg mL-1 for BOH in 
plasma. The quantification accuracy was within the range 78–116% for all the 
analytes in plasma and urine, which was satisfactory for quantification at very low 
concentrations. The intra-day relative standard deviation (RSD) was <16% for all the 
analytes and the inter-day RSD was <24%. The method was successfully applied to 
the analysis of equine plasma and urine samples for the analytes given to horses by 
inhalation. 17-BMP was the major analyte detected so it is the target analyte to 
detect the use of BDP in race horses.36 
1.2 Aim of the study 
      17-BMP is usually prepared using human lung homogenates. It is very difficult, 
both ethically and medically, to obtain a lung. Therefore, this project aims to develop 
a newer, rapid, ethically acceptable, robust method for conversion of BDP to its 
active metabolite, 17-BMP, in vitro, using pure esterase enzyme and hence 
removing the need to obtain lung tissue. The isolation and purification of 17-BMP 
should also be facilitated by this approach.  
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1.3 Experimental 
1.3.1 Materials  
Beclomethasone dipropionate (BDP, IUPAC: 9-chloro-11β,17,21trihydroxy-16β- 
methylpregna-1,4-diene-3,20-dione-17,21-dipropionate), was purchased from Fluka 
chemicals ( purity 99 %). 
Beclomethasone (BOH, IUPAC: 9α-chloro-16β-methyl-1,4-pregnadiene-11β,17α,21-
triol-3,20-dione) was purchased from Sigma Aldrich, U.K. 
Standard solutions (1 mg/mL) of beclomethasone dipropionate (BDP) and 
beclomethasone (BOH) were prepared in methanol. Working solutions were 
prepared by successive dilution with methanol and stored in the fridge at 4 °C. 
Esterase from porcine liver was purchased from Sigma Aldrich UK. 
Acetonitrile (MeCN), methanol (MeOH), ethanol (certified HPLC grade), cyclohexane 
dichloromethane (DCM) and tert-butyl methyl ether (TBME/MTBE) were purchased 
from Fisher Scientific (UK).  
Diethyl ether was purchased from Sigma Aldrich, U.K. 
A Mettler AT 261 Delta Range ® Fact analytical balance was used for weighing the 
solid forms of BDP and BOH. 
Eppendorf research-grade micropipettors were used for measuring out the required 
amount of solution (Fisher Scientific, UK).  
1.3.2 Instrumentation 
1.3.2.1 Liquid chromatography mass spectroscopy (LC-MS)  
 
        Chromatographic separation was developed on a Shimadzu Prominence UFLC 
system and Lab Solutions v. 5 software was used for the processing of the data 
(Schimadzu Corporation UK). It is an ultra-high-speed prominence LC-20AD XR that 
achieves both ultra-high-speed analysis and ultra-high separation, based on high 
analysis precision and reliability comprising of prominence System Controller, 
schimadzu Solvent Delivery Unit, prominence AutoSampler (SIL-20A XR), 
prominence Column Oven (CTO-20A), Schimadzu Fluorescence Detector (RF-10A 
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XL, prominence Diode Array Detector (SPD-M20A) and prominence Degasser (DGU-
20A3.  
         The column used was a Lichrospher 100, RP-18 (250 mm x 4.6 mm, 5 µm), 
column purchased from VWR (Merck, Germany). The mobile phase (A) was HPLC 
grade water and mobile phase (B) was acetonitrile. The flow rate was kept constant 
at 1.00 mL/min. The injection volume was 20 µL. The eluent UV absorbance was 
monitored using a diode array detector and monitored at a wavelength of 240 nm for 
the steroids.  
      The samples were analysed by a Bruker MicrOTOF-Q mass spectrometer 
coupled to the UFLC system to facilitate the study of BDP standards and metabolite 
formation. The mass spectrometer was a hybrid quadrupole/orthogonal accelerated 
Time-of-Flight equipped with an electrospray ionization (ESI) ion source. Positive ion 
ESI was chosen. Data acquisition and processing was carried out using Bruker’s 
proprietary DataAnalysis software.  
 
1.3.2.2 Chromatographic conditions  
 
Table 1 below briefly describes the instrumental parameters used for the analysis of 
BDP, BMP and BOH.  
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HPLC Shimadzu UFLC 
Mode Isocratic 
Analytical Column Lichrospher 100, RP-18 (250 mm x 4.6 mm, 5 µm), column no. 026023, Lot No. 497017 
Injection Port 
Type Manual 
Syringe Volume 50 µL 
Injection Volume 20 µL 
Column Flow 1.0 mL/min 
Detector Diode array, monitored at 240 nm 
Run Time 20 min 
 
Table 1: Instrumental parameters for the analysis of BDP, BMP and BOH 
 
The analytical column (C18) was selected on the basis of previous methodology 
which gave the required results. BDP and its metabolites were absorbed best at 240 
nm. 
1.4 Methodology 
1.4.1 Method development for the analysis of BDP  
 
         The challenge encountered in steroid analysis is to develop a specific 
technique for the analysis of an individual steroid in the presence of many 
structurally similar compounds. Often steroids and their metabolites differ by only the 
presence or absence of two hydrogen atoms or in the structure of the rings. 
 
1.4.1.1 Detection methods of BDP Analyte    
        To optimize the HPLC parameters, several mobile phase compositions were 
evaluated for the detection of BDP. Table 2 below summarises the methods used. 
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Table 2: Method development for the analysis of BDP 
 
1.4.1.2 Identification of BDP Analytes 
       To detect the peak of BDP, a 100 ppm solution was run in duplicate to 
determine the retention time. For this purpose 100 ppm, 10ppm and 1 ppm working 
solutions were prepared by serial dilution. The retention time was confirmed and it 
was decided to use the same method for further analysis.  
1.4.2 Method optimization and validation 
      Method optimization and validation was done according to the International 
Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH) guidelines. 
1.4.2.1 Experimental Protocol for Beclomethasone dipropionate (BDP) 
1.4.2.1.1 Stock solutions 
Standards 
         A stock solution of BDP was prepared in methanol at a concentration of 1000 
ppm. BDP (1.0 mg) was weighed and put into an eppendorf tube. The stock solution 
was made by dissolving the weighed amount in 1.0 mL of MeOH to achieve a clear 
solution with the final concentration of 1000 ppm (1.0 mg/1.0 mL). After preparation 
the stock solutions were labelled and stored in a fridge at 4 °C and allowed to 
equilibrate at room temperature for at least 15 min before use. The same method 
was used to prepare separate solutions of the metabolites. 
 
 
Sample 
No. 
Conc. of 
solution 
[mg/L] 
Mobile Phase 
A %      B %  
[HPLC H2O]    [MeCN] 
1 1000 40 60 
2 100 40 60 
3 100 25 75 
4 100 20 80 
5 100 50 50 
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Mixed standards of BDP and BOH 
      A stock solution of BDP and BOH was prepared as follows: BDP (1 mg) and 
BOH (1 mg) were weighed separately and dissolved in methanol separately. 
Working standard solutions were prepared by serial dilution of mixed aliquots of the 
stock solutions.   
1.4.2.1.2 Calibration standard solutions 
BDP  
      Standards were prepared by serial dilution of the stock solution with methanol to 
give concentrations of 100, 50, 25, 10, 5, 2.5, 1, 0.1 and 0.01 ppm. In order to get a 
calibration graph for BDP, the samples were run twice for each concentration. The 
calibration curves were constructed by plotting the average peak area of each 
analyte against the concentration. 
 
BOH 
       Standards were prepared by serial dilution of the stock solution with MeOH to 
give a concentration range from 0.01 - 10 ppm. 
 
Mixed solution of BDP and BOH 
       A working solution (100 ppm) was made prior to preparation of the calibration 
solutions of the mixed BDP and BOH sample. From the stock solution, an aliquot 
(0.1 mL) was pipetted out from both the stock solutions and 0.8 mL of MeOH was 
added to make a total volume of 1 mL. The working standards were made by serial 
dilution of the 100 ppm mixed solution within the concentration range from 0.01 - 1 
ppm, as depicted in Table 3 below. The standard solutions were prepared daily. 
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Conc. (ppm) Analyte Solution (ml) MeOH (ml) 
Total 
Volume(ml) 
100 0.1 + 0.1 from 1000 ppm solution 0.8 1 
10 0.1 from 100 ppm mix. solution 0.9 1 
1 0.1 from 10 ppm mix. solution 0.9 1 
0.75 0.75 from 1 ppm mix. solution 0.25 1 
0.5 0.5 from 1 ppm mix. solution 0.5 1 
0.25 0.5 from 0.5 ppm mix. solution 0.5 1 
0.1 0.1 from 10 ppm mix. solution 0.9 1 
0.01 0.1 from 0.1 ppm mix. solution 0.9 1 
 
Table 3: Preparation of working solutions for calibration 
 
         Calibration graphs for mixed runs of BDP and BOH were plotted by taking the 
average of two replicate values for 0.01, 0.1, 0.25, 0.5, 0.75, 1 and 10 ppm, as the 
samples were run twice for each concentration. In the MS experiments extracted ion 
chromatograms (EICs) were obtained for two ions, i.e. m/z 521 and 543 for BDP and 
m/z 409 and 431 for BOH corresponding to [M+H]+ and [M+Na]+ respectively. Graphs 
were plotted using the peak areas of the EICs.   
1.4.2.1.3 Standard solutions for Limit Of Detection (LOD) determination 
        For determination of the LOD, a previously prepared mixed standard solution of 
BDP and BOH was used. The solution was serially diluted each time i.e. 100 to 10 
ppm, 1.0, 0.5, 0.1, 0.01 and 0.001 ppm. Solutions were run in the HPLC system until 
no peak was observed. According to ICH guidelines, the limit of detection (LOD) is 
defined as the lowest concentration of an analyte in a sample that can be detected 
but not quantified. The limit of detection (LOD) was determined as the lowest 
concentration where the chromatographic peak had a signal-to-noise ratio of ≥ 3:1. 
1.4.2.1.4 Standard solutions for stability studies 
       To check the stability of the analytes, BDP (0.31 mg) was dissolved in ethanol 
(0.5 mL) and deionized water (4.5 mL). The solution was divided into two parts. One 
aliquot was stored in the freezer and the other under laboratory conditions (~ 20 °C). 
For the next four days, these solutions were run in the HPLC, in duplicate, at various 
time intervals.  
1.4.2.1.5 Standard solutions for Repeatability (Intra/ Same Day) 
      For the intra-day (same day) quality checks, working solutions of 2.5 ppm and 80 
ppm were analysed by HPLC at regular time intervals during the day, in duplicate.  
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1.4.2.1.6 Standard solutions for Reproducibility (Inter/Different Day) 
       For inter-day (different days) quality checks, working solutions of 2.5 ppm and 
80 ppm were analysed by HPLC for the next 4 days, at specific times, in duplicate.  
1.4.3 Enzyme hydrolysis of Beclomethasone dipropionate (BDP) using porcine 
esterase 
        The qualitative and quantitative analysis of synthetic corticosteroids is a major 
challenge. BDP contains two ester groups in its molecule and is a good candidate for 
hydrolysis to the monoesters 17-BMP and 21-BMP by plasma esterases, and 17-
BMP and 21-BMP might be further hydrolyzed by plasma esterases to BOH. So, 
enzyme hydrolysis of BDP was carried out to prepare 17-BMP as selectively as 
possible.  
1.4.3.1 Instrumentation  
       The hydrolysis reaction was carried out in a stirred thermostatic bath and 
circulator (Model GD100-S5) fitted with Optima™ digital thermostat (GD100) for 
precise temperature control from 0-100º C.  
        Removal of the enzyme from reaction mixtures was performed on an MSE 
Microcentaur centrifuge at 13,000 rpm.  
 
1.4.3.2 Reaction solution for enzyme hydrolysis of BDP using porcine esterase 
         BDP was hydrolysed enzymatically to prepare 17-BMP in in vitro conditions. 
BDP (0.31 mg) was dissolved in ethanol/water (1:4 v/v) and porcine liver esterase 
(2.0 mg) was added. The solution was incubated at 37 °C for 20 hrs in the dark. After 
incubation of BDP with esterase the enzyme was removed from the solution. The 
reaction mixture was placed into an Amicon cartridge (10,000 MWCO, Millipore, UK) 
which was placed into an ultra-centrifuge and spun at 13,000 rpm for 30 mins for the 
removal of the enzyme from the sample. The particles bigger than 10,000 MWCO 
are retained in the upper portion of the filter. The small molecules (including solvent) 
are collected in the lower portion. The liquid fraction containing the small molecules 
was diluted with deionised water to the desired concentration prior to analysis. 
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Sample Aliquots – 0 min, 30 min, 1 hr, 2 hr and 6 hr 
 
Sample Aliquots – 0 min, 5, 10, 20, 30, 45, 60, 75, 90 and 120 min 
 1.4.3.3 Enzyme hydrolysis protocol using porcine esterase 
        In the first timed experiment, several small aliquots equal to 0.5 mL were 
removed from the reaction mixture at t = 0 min, 30 min, 1 hr, 2 hr, 17.4 hr and 20 hr. 
The enzyme was removed from the solution as detailed in 1.4.3.2. Deionized water 
(0.5 mL) was added to each tube and the samples were analysed using LC-MS. The 
hydrolysis reaction was repeated and the method followed was the same as above 
except that the time for the collection of fractions was decreased from 20 hrs to 6 
hrs. The main purpose was to obtain more data points in fewer hrs.  
 
 
Next the aliquots were collected for 2 hrs only: 
 
 
 
      Enzyme hydrolysis was carried out using ethanol instead of methanol for 2 hrs. 
All the sample aliquots were analysed using LC-MS in the same way as before; 
extracted ion chromatograms of m/z 465 were used for data analysis.  
1.4.3.4 Enzyme hydrolysis of BDP (large scale) using porcine esterase 
       The results from the small scale experiments were very encouraging, so it was 
decided to try the reaction on a bigger (preparative) scale. For this purpose BDP 
(1.77 mg) was dissolved in ethanol (0.1 mL) to make a clear solution. Then, 
deionized water (9.9 mL) and esterase enzyme (1 mg) were added to make a 10 mL 
reaction solution. The reaction solution was incubated in a water bath at 37 °C in the 
dark for 20 hrs with subsequent analysis using LC-MS.  
1.5 Nuclear Magnetic Resonance (NMR) 
1.5.1 Instrumentation 
     All the hydrolysis reaction was carried out using either a Bruker Avance 500 
AV500 500.13 MHz NMR spectrum with Ultra ShieldTM magnet, at room temperature 
with 11.7 Tesla superconducting magnet or on a Bruker DPx400 400.13 MHZ 
unshielded magnet. NMR samples were prepared in deuterium oxide (D2O), d6-
DMSO, d6-ethanol and d3-CD3CN. The computer software used was Topspin 1.3. 
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1.5.2 Reaction solution to prepare 17-BMP using NMR 
      Firstly, enzyme hydrolysis was performed to prepare 17-BMP in in vitro 
conditions, using BDP (10.0 mg), dissolved in ethanol/water (1:4 v/v). The drug was 
incubated with porcine liver esterase (2.0 mg, 0.182 mL, 35.6 mg protein/mL, 154 
units/mg protein) at 37 °C for 2 hrs in the dark. An aliquot (0.5 mL) was removed 
from the reaction solution and the enzyme removed using an Amicon cartridge as 
before. The sample was then analysed using LC-MS to check that the reaction had 
proceeded to completion. The solution was then evaporated under N2 (to reduce the 
volume) and the remaining volume of the solution was transferred to a 250 mL round 
bottom flask, frozen under liquid nitrogen and freeze dried overnight using a Modulyo 
Edward’s Model RV 3 freeze dryer. The parameters used are tabulated below: 
 
 
 
 
 
Table 4: Instrumental parameters used for freeze dryer 
 
        The dried product was dissolved in d6-ethanol (650 µL) and its 1H NMR 
spectrum  was recorded using a Bruker Avance 500 MHz NMR spectrometer at 
room temperature with an 11.7 Tesla superconducting Ultra ShieldTM magnet. The 
computer software used for acquisition and processing was Topspin 1.3. 
1.6 Liquid-Liquid Extraction (LLE) of BDP and its 
metabolites from the reaction solution 
         A liquid-liquid extraction (LLE) procedure was developed to recover both BDP 
and its metabolites from the reaction solution. BDP and its metabolites are polar 
molecules and are extractable from acidic, neutral and basic solutions. In preliminary 
experiments, ether-cyclohexane, DCM, ether and TBME were compared for 
extraction of BDP and its metabolites using 5 mL of reaction mixture. Sequential 
Temperature 
-450 C 
Pressure 10-3 Torr 
Capacity of round-bottom flask 250 ml 
Sample volume 3-4 ml 
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extractions were carried out from the same water layer with the organic solvent (5 x 
5 mL), using the four different solvents as described above. 
1.6.1 Preparation of a reaction solution with porcine esterase enzyme and BDP 
[50:1 ] 
      The reaction solution was prepared and incubated with esterase enzyme as 
before for 2 hrs. The enzyme was removed from the reaction solution using an 
Amicon cartridge and the reaction solution was divided into two equal aliquots (2.5 
mL + 2.5 mL).  
1.6.2 Preparation of a reaction solution with porcine esterase enzyme and BDP 
[300:1] 
        In this method, a 300:1 ratio of BDP to enzyme was used. For this purpose, 
BDP (10 mg) and esterase enzyme (10 mg) were required in order to prepare and 
isolate a usable amount of product. Before trying this amount, it was decided to carry 
out a small trial run with the smallest concentration of BDP but using a lower ratio of 
esterase (300:1) in order to reduce the amount of enzyme used. BDP (0.31 mg) and 
esterase enzyme (0.31 mg) were dissolved in ethanol (0.5 mL) and deionized water 
(4.5 mL). Keeping the first steps the same as other methods, the reaction mixture 
was incubated for two hours. An aliquot (0.5 mL) was removed and analysed using 
LC-MS to check that the reaction had been successful. Cyclohexane (1 mL) and 
ether (4 mL) were added to the remaining reaction mixture of 4.5 mL. The organic 
layer was separated and set aside. To the same water layer, the same amounts of 
cyclohexane and ether mixture were added again. The organic layer was separated 
for the second time and set aside. The extraction was repeated for the third time and 
the fractions were combined and evaporated under nitrogen. MeCN (1 mL) was 
added to the sample which was then analysed using LC-MS in duplicate.  
1.6.3 Liquid liquid extraction of BDP and its metabolites (single extraction) 
         A water-immiscible organic solvent was added to the reaction solution in a 10 
mL conical flask. The addition was carried out in a fume cupboard. The mixture was 
swirled and then allowed to settle and the upper organic layer was separated by a 
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glass pipette and stored in a small labelled vial. Solvents used (in separate 
experiments) are listed below: 
• Cyclohexane/ether (1:4) 
• Ether 
• Dichloromethane 
• TBME 
        The organic layer was dried under nitrogen gas and acetonitrile (1 mL) was 
added prior to analysis using LC-MS, in duplicate. A further experiment was carried 
out to determine whether removal of the enzyme was necessary prior to LLE. After 
incubation for two hrs, the reaction mixture was divided into two parts. One aliquot 
was spun through a size-exclusion cartridge in order to remove enzyme and the 
other aliquot was extracted without further preparation. To both aliquots, a mixture of 
cyclohexane (0.5 mL) and ether (2.0 mL) was introduced, in separate 10 mL conical 
flasks. The addition was done in a fume cupboard. The mixture was swirled and then 
allowed to settle. It formed two layers, an upper organic layer and a lower aqueous 
layer. The upper organic layer was separated by a glass pipette for both portions. 
Both were stored in small labelled vials. The organic layers were evaporated under 
nitrogen, reconstituted with 1 mL of acetonitrile and analysed in duplicate using LC-
MS.  
1.6.4 Liquid liquid extraction of BDP and its metabolites (Multiple Extraction) 
        The hydrolysis reaction was carried out as before and the extracting solvent 
was added in a 10 mL conical flask. Extraction was repeated several times (n=5). 
The main aim was to extract all of the product from the solution. Solvents used (in 
separate experiments) are listed below: 
• Cyclohexane/ether (1:4) 
• Ether 
• Dichloromethane 
• TBME 
  After removal of the organic layer, the aqueous layer was extracted four more times 
and the organic layers were collected separately. The water layer was retained and 
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stored at -18 °C. All five organic fractions were evaporated separately under nitrogen 
then reconstituted in MeCN (1 mL) and the samples were analysed using LC-MS.  
1.7 Results and Discussion 
1.7.1 Method development for the analysis of BDP 
       Beclomethasone dipropionate is a potent pro-drug generating 17-BMP and is 
used in the treatment of chronic and acute respiratory disorders in humans. The 
therapeutic dose of BDP by inhalation results in very low plasma and urinary 
concentrations of BDP and its metabolites that pose a challenge to detection and 
confirmation by laboratories. To solve this problem, a method involving the use of 
LC-MS was developed for the detection, confirmation and quantification of the 
analytes. Different methods for identification of BDP were tried. The best method for 
elution of BDP compound was with 80 % MeCN with a low retention time and a 
sharp peak. 
     However, the research will be conducted on the metabolites of BDP, it is 
important to find a retention time with enough time lapse in between to be able to 
detect the metabolites which would elute before the parent drug due to their 
increased polarity. So, for this purpose method with 60 % MeCN as depicted in 
Table 5 below, was selected. 
 
 
 
 
 
Table 5: Retention times and peak areas for BDP with the selected method 
 
 
 
Conc. 
[mg/L] 
Mobile Phase 
RT/Min Peak area [AU] A % [HPLC H2O] 
B % 
[MeCN] 
0.1 40 60 8.948 2038 
0.5 40 60 8.937 13845 
1 40 60 8.985 28101 
10 40 60 8.933 272393 
100 40 60 9.263 3325540 
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1.7.2 Method optimization and validation  
      Method validation was, according to the guidelines given by ICH, performed by 
evaluating the calibration and linearity, LOD, stability, reproducibility and repeatability 
of the method. 
1.7.2.1 Calibration and Linearity 
       Calibration is the process of determining the relationship between response and 
known concentrations of an analyte under set conditions. The average of two values 
for 0.1, 1, 5, 10, 25, 50 and 100 ppm were used to plot the calibration curves as the 
samples were run in duplicate for each concentration. The calibration curve exhibited 
good linearity, as determined by linear regression analysis, with average correlation 
coefficients 0.9976 for UV data and 0.8847 for MS data.  
1.7.2.2 Calibration graphs for BDP       
  A typical chromatogram for a BDP standard is shown in Fig. 8, below. The analysis 
time was less than 20 min with BDP eluted at 9.29 min. 
                        
 
 
 
 
 
 
 
Figure 8: Chromatogram of a BDP standard (100 ppm) obtained at 240 nm (n=3) 
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         A nine-point calibration graph was constructed. A straight line was fitted to the 
data using linear regression. A representative plot describing the calibration data for 
BDP (UV detection) is shown in Fig. 9, with the data tabulated in Table 6 and for 
BDP (MS detection) in Table 6 and Fig. 10. 
 
 
 
 
 
                 
 
Table 6: A typical set of calibration data for BDP with UV detection 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Calibration graph for BDP (UV) (n=9) 
BDP Calibration [LC] 
Conc. 
[mg/L] 
Average 
Peak Area [AU] 
Standard 
Deviation 
[S.D] 
0.01 926.35 88.6 
0.1 3079.6 878.22 
1 31368.2 473.19 
2.5 92174.45 1279.65 
5 186434.2 1012.43 
10 337386.95 2973.87 
25 848969.15 11613.59 
50 2076176.5 41401.38 
100 3867942.4 90946 
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           A sample representative for BDP (MS) is shown in table 7 and Fig. 10. A 
straight line was fitted to the data using linear regression over the studied range of 
concentrations is shown by the equation y = 8981.4x+106102. It is clear from the 
calibration graph that the linearity was poor since the R2 value is 0.8847.  
 
 
 
 
  
 
 
 
    
Table 7: Typical calibration data for BDP with MS detection 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Calibration graph for BDP-MS at known concentration and peak areas (n=9) 
 
BDP Calibration [MS] 
Conc. 
[mg/L] 
Average  
Peak Area 
[AU] 
Standard 
Deviation 
[S.D] 
0.01 578.16 203.73 
0.1 7029.34 317.28 
1 56617 3719.38 
2.5 116701 7710.29 
5 177318 3517.15 
10 257107 10834.29 
25 478052 59389.89 
50 723735.5 4171.22 
100 876658.5 11202.69 
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1.7.2.3 Calibration graphs for BOH  
        The graphs were plotted by taking the average of two peak area values for 
0.01, 0.1, 1, 2.5, 5 and 10 ppm standards, as the samples were run twice for each 
concentration. Each calibration curve exhibited good linearity, as determined by 
linear regression analysis, with correlation coefficients 0.9995 for LC data and 
0.9985 for MS data. Table 8 and Fig. 11 represent the calibration data and graph for 
BOH, below.  
      
 
 
 
 
  
Table 8: Typical calibration data for BOH-UV 
 
 
                    
 
 
 
 
 
 
 
 
 
Figure 11: Calibration graph for BOH-UV with known concentration and peak areas (n=2) 
BOH Calibration [LC] 
Conc. [mg/L] Average Peak Area [AU] 
Standard 
Deviation [S.D] 
0.01 170.7 62.08 
0.1 2666.4 56 
1 36280.3 66.39 
2.5 105125.75 593.05 
5 213749.3 2834.5 
10 413868.3 4011.84 
y = 41760x - 883.28
R² = 0.9995
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         The above graph showed excellent linearity with R2 value 0.9995. Fig. 12 shows 
a typical chromatogram for BOH at 100 ppm. 
 
 
              
 
 
 
 
 
 
Figure 12: Typical chromatogram for analysis of BOH (n=2) 
 
                
    
 
 
 
 
 
 
Table 9: A typical set of calibration data for BOH (MS) 
                     
 
 
 
BOH Calibration [MS] 
Conc. 
[mg/L] 
Average Peak Area 
[AU] 
Standard 
Deviation 
[S.D] 
0.01 767.59 271.67 
0.1 1374.26 520.12 
1 3222.29 613.25 
2.5 8241.65 453.64 
5 13631.5 1952.32 
10 22168.5 891.66 
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Figure 13: Calibration graph for BOH-MS 
The above MS graph for BOH showed good linearity with a R2 value of 0.9849 (n=2)  
 
1.7.2.4 Calibration graphs for mixture run of BOH and BDP  
 
       Calibration graphs were plotted by taking the average of two values for 0.01, 
0.1, 0.25, 0.5, 0.75 and 1 ppm standards. A sample of the calibration data for a 
mixed run of BOH and BDP is shown in Table 10 and Fig. 14 and 15. Fig. 16 shows 
a typical chromatogram. 
 
 
 
 
 
 
Table 10: Typical calibration data for a mixed run of BDP and BOH 
BOH Calibration [LC] BDP Calibration [LC] 
Conc. 
[mg/L] 
Ave. 
Peak  Area 
[AU] 
Standard 
Deviation 
[S.D] 
Ave. 
Peak Area 
[AU] 
Standard 
Deviation 
[S.D] 
0.01 4582.1 957.28 3571.4 476.87 
0.1 40619.65 3860.31 32199.75 248.55 
0.25 8620.3 72.12 8106.75 31.61 
0.5 19622.35 253.21 16335.5 146.37 
0.75 30945.3 388.2 26839.1 322.16 
1 40270.35 123.96 34089.1 155.28 
y = 2154.3x + 1552.5
R² = 0.9849
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Figure 14: Calibration graph for mixture run for BOH-UV (n=2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Calibration graph for a mixture run for BDP-UV (n=2) 
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Figure 16: A typical chromatogram showing the mixed run of BDP and BOH at 100 ppm 
concentration (n=2) 
 
       Each calibration curve, as determined by linear regression analysis, exhibited 
linearity for LC data with correlation coefficients of 0.9833 for BOH and 0.9873 for 
BDP. For MS data correlation coefficients for BOH and BDP were 0.9233 and 
0.9899. A curve was observed in the graphs for BOH and BDP, possibly because 
BDP and BOH existed as multiple adducts with different masses. EICs were used to 
plot graphs for BOH (Table 11, Fig. 17) and for BDP (Table 15, Fig. 19) below.        
 
 
 
 
 
 
 
Table 11: A sample calibration data for BOH with m/z 409+431 
 
BOH Calibration [MS(409+431)] 
Conc. 
[mg/L] 
Average  
Peak Area 
[AU] 
Standard 
Deviation 
[S.D] 
0.01 737.61 189.19 
0.1 4038.13 715.68 
0.25 1955.27 300.87 
0.5 2550.56 859.27 
0.75 2722.49 145.48 
1 4460.86 378.97 
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Figure 17: Calibration graph for BOH (MS) (409+431) (n=2) 
        The above graphs showed that by plotting graphs with two adducts with 
different masses (409 and 431), R2 was improved. So, it was decided to perform 
calibration by considering six possible adducts with different masses, summarized in 
Tables 12 and 13 for BOH. Again, EICs were used to plot graphs for BOH (Table 14, 
Fig. 18) below. 
 
                               
 
 
 
 
 
 
Table 12: Adducts of BOH used to plot revised calibration curves 
. 
 
                        
Masses 
Mol. Wt. 
BOH 
(408) 
[M+H]+ 409 
[M+Na]+ 431 
[2M+H]+ 817 
[2M+Na]+ 839 
[3M+H]+ 1225 
[3M+Na]+ 1247 
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Table 13: m/z Data for BOH 
                       
 BOH-409 BOH-431 BOH-817 BOH-839 BOH-1225 BOH-1247 
C
o
n
c
.
 
Injectio
n
 
Reten. 
Time 
Peak  
Area 
Reten. 
Time 
Peak  
Area 
Reten. 
Time 
Peak  
Area 
Reten. 
Time 
Peak  
Area 
Reten. 
Time 
Peak  
Area 
Reten. 
Time 
Peak  
Area 
0.01 1 3.6 807.2 3.5 869.26 3.6 497.14 3.6 756.85 3.5 253.92 3.6 238.13 
  2 3.7 400.46 3.6 873.52 3.4 262.54 3.6 789.71 3.8 225.5 3.6 268.31 
  Ave 3.65 603.83 3.55 871.39 3.5 379.84 3.6 773.28 3.65 239.71 3.6 253.22 
  S.D 0.07 287.61 0.07 3.01 0.14 165.89 0 23.24 0.21 20.10 0 21.34 
  Preci 1.94 47.63 1.99 0.35 4.04 43.67 0 3.00 5.81 8.38 0 8.43 
            
                
0.1 1 3.6 3207.59 3.6 4746.05 3.6 349.39 3.6 441.82 3.7 219.56 3.6 113.81 
  2 3.6 3856.53 3.7 4342.32 3.6 150.19 3.7 682.42 3.6 268.03 3.8 139.76 
  Ave 3.60 3532.06 3.65 4544.19 3.6 249.79 3.65 562.12 3.65 243.80 3.7 126.79 
  S.D 0.00 458.87 0.07 285.48 0 140.86 0.07 170.13 0.07 34.27 0.14 18.35 
  Preci 0.00 12.99 1.94 6.28 0 56.39 1.94 30.27 1.94 14.06 3.82 14.47 
            
                
0.25 1 3.5 2779.8 3.7 2090.34 3.7 210.46 3.3 175.74 3.6 180.08 3.6 142.75 
  2 3.6 1556.23 3.7 1394.7 3.8 372.59 3.5 375.36 3.5 133.37 3.6 129.58 
  Ave 3.55 2168.02 3.70 1742.52 3.75 291.53 3.4 275.55 3.55 156.73 3.6 136.17 
  S.D 0.07 865.19 0.00 491.89 0.07 114.64 0.14 141.15 0.07 33.03 0 9.31 
  Preci 1.99 39.91 0.00 28.23 1.89 39.33 4.16 51.23 1.99 21.07 0 6.84 
  
                          
0.5 1 3.6 3960.46 3.6 2436.79 3.6 398.42 3.7 892.71 3.6 86.75 3.7 322.63 
  2 3.7 2355.83 3.7 1449.13 3.5 185.87 3.7 780.9 3.6 267.04 3.9 316.96 
  Ave 3.65 3158.15 3.65 1942.96 3.55 292.15 3.7 836.81 3.6 176.90 3.8 319.80 
  S.D 0.07 1134.64 0.07 698.38 0.07 150.30 0 79.06 0 127.48 0.14 4.01 
  Preci 1.94 35.93 1.94 35.94 1.99 51.45 0 9.45 0 72.07 3.72 1.25 
        
                    
0.75 1 3.6 3095.54 3.6 2446.06 3.6 1315.53 3.6 200.39 3.7 215.82 3.6 418.44 
  2 3.6 2555.17 3.6 2793.18 3.5 1563.41 3.6 695.09 3.6 78.291 3.7 746.63 
  Ave 3.60 2825.36 3.60 2619.62 3.55 1439.47 3.6 447.74 3.65 147.06 3.65 582.54 
  S.D 0.00 382.10 0.00 245.45 0.07 175.28 0 349.81 0.07 97.25 0.07 232.07 
  Preci 0.00 13.52 0.00 9.37 1.99 12.18 0 78.13 1.94 66.13 1.94 39.84 
        
                    
1 1 3.6 3958.13 3.6 4559.99 3.8 268.25 3.6 472.93 3.6 268.55 3.5 175.21 
  2 3.5 4427.65 3.6 4897.66 3.8 716.47 3.6 550.39 3.6 277.64 3.6 159.92 
  Ave 3.55 4192.89 3.60 4728.83 3.8 492.36 3.6 511.66 3.6 273.10 3.55 167.57 
  S.D 0.07 332.00 0.00 238.77 0 316.94 0 54.77 0 6.43 0.07 10.81 
  Preci 1.99 7.92 0.00 5.05 0 64.37 0 10.70 0 2.35 1.99 6.45 
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Table 14: A typical set of calibration data for BOH (MS) (overall) 
 
 
 
                        
 
 
 
 
 
 
 
Figure 18: Calibration graph for BOH-MS (overall) (n=2) 
      After plotting peak areas for all adducts with different masses, an excellent 
linearity was achieved i.e. R2 = 0.9949 which confirms that BOH existed as multiple 
adducts with different masses, especially at higher concentrations. 
      For BDP graphs were plotted with two adducts (+Na) (521+543) (Table 15 and 
Fig. 19) and then with all the possible adducts with different masses, summarized in 
Tables 16 and 17. Again, EICs were used to plot the graph for BDP (Table 18, Fig. 
20). In the calibration graphs it was observed that the intercepts were not at zero. It 
is possibly due to the response of the mobile phase from both LC as well as the 
mass spectrometer. 
Conc. 
[mg/L] 
Ave.  
Peak Area 
[AU] 
Standard 
Deviation 
[S.D] 
0.01 520.212 269.83 
0.25 795.09 910.8 
0.5 1121.13 1193.87 
0.75 1343.63 1152.95 
1 1727.74 2127.85 
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Table 15: Sample calibration data for BDP with m/z 521+543 
 
                       
                             
 
 
 
 
 
 
Figure 19: Calibration graph for BDP (MS) (m/z 521+543) (n=2) 
            
 
 
 
 
 
 
Table 16: Adducts of BDP used to plot calibration curves 
BDP Calibration [MS(521+543)] 
Conc. 
[mg/L] 
Average  
Peak Area 
[AU] 
Standard 
Deviation 
[S.D] 
0.01 3141.38 4023.85 
0.1 21024.35 12121.44 
0.25 6444.49 4882.3 
0.5 11649.68 8185.92 
0.75 18010.5 12537.71 
1 21482.05 14830.08 
Masses Mol Wt. BDP 
 
520 
[M+H]+ 521 
[M+Na]+ 543 
[2M+H]+ 1041 
[2M+Na]+ 1063 
[3M+H]+ 1561 
[3M+Na]+ 1583 
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 BDP-521 BDP-543 BDP-1041 BDP-1063 BDP-1561 BDP-1583 
C
o
nc
.
 
Inject
.
 
Reten. 
Time 
Peak  
Area 
Reten. 
Time 
Peak  
Area 
Reten. 
Time 
Peak  
Area 
Reten. 
Time 
Peak  
Area 
Reten. 
Time 
Peak  
Area 
Reten. 
Time 
Peak  
Area 
0.01 1 9.3 316.51 9.5 5283.97 9.5 218.25 9.5 251.67 9.4 794.66 9.4 157.37 
  
2 9.3 275.66 9.5 6689.36 9.3 340.57 9.5 121.26 6.5 678.6 9.4 128.57 
  
Ave 9.30 296.09 9.50 5986.67 9.4 279.41 9.5 186.47 7.95 736.63 9.4 142.97 
  
S.D 0.00 20.42 0.00 702.70 0.14 86.49 0 92.21 2.05 82.07 0 20.36 
  
Preci 0.00 6.90 0.00 11.74 1.50 30.96 0 49.45 25.79 11.14 0 14.24 
  
          
                
0.1 1 9.5 13307.9 9.5 32708 9.5 390.37 9.5 1234.64 9.5 337.88 9.5 105.52 
  
2 9.5 11598.5 9.5 26483 9.4 282.1 9.5 1231.5 9.5 436.35 9.5 151.41 
  
Ave 9.50 12453.2 9.50 29595.5 9.45 336.24 9.5 1233.07 9.5 387.12 9.5 128.47 
  
S.D 0.00 854.70 0.00 3112.50 0.07 76.56 0 2.22 0 69.63 0 32.45 
  
Preci 0.00 6.86 0.00 10.52 0.75 22.77 0 0.18 0 17.99 0 25.26 
  
          
                
0.25 1 9.5 2137.17 9.5 9796.9 9.7 303.45 9.6 150.66 9.5 186.2 9.8 337.34 
  
2 9.5 3847.18 9.4 9996.7 9.6 304.57 9.6 252.69 9.4 130.27 9.3 348.23 
  
Ave 9.50 2992.18 9.45 9896.8 9.65 304.01 9.6 201.68 9.45 158.24 9.55 342.79 
  
S.D 0.00 855.00 0.07 99.90 0.07 0.79 0 72.15 0.07 39.55 0.35 7.70 
  
Preci 0.00 28.57 0.75 1.01 0.73 0.26 0 35.77 0.75 24.99 3.70 2.25 
                            
0.5 1 9.5 8074.9 9.5 19199 9.6 110.44 9.5 591.84 9.5 109.41 9.6 163.71 
  
2 9.4 3647.81 9.5 15677 9.3 468.04 9.5 274.38 9.4 195.45 9.3 415.16 
  
Ave 9.45 5861.36 9.50 17438 9.45 289.24 9.5 433.11 9.45 152.43 9.45 289.44 
  
S.D 0.07 2213.55 0.00 1761.00 0.21 252.86 0 224.48 0.07 60.84 0.21 177.80 
  
Preci 0.75 37.77 0.00 10.10 2.24 87.42 0 51.83 0.75 39.91 2.24 61.43 
  
      
                    
0.75 1 9.4 8391.7 9.4 26071 9.4 359.11 9.5 230.97 9.7 186.57 9.5 299.63 
  
2 9.5 9898.3 9.4 27681 9.5 254.67 9.5 213.043 9.5 189.13 9.6 73.65 
  
Ave 9.45 9145 9.40 26876 9.45 306.89 9.5 222.01 9.6 187.85 9.55 186.64 
  
S.D 0.07 753.30 0.00 805.00 0.07 73.85 0 12.68 0.14 1.81 0.07 159.79 
  
Preci 0.75 8.24 0.00 3.00 0.75 24.06 0 5.71 1.47 0.96 0.74 85.62 
  
      
                    
1 1 9.5 10938 9.4 30613 9.5 246.44 9.5 744.18 9.6 113.07 9.5 81.99 
  
2 9.5 11053.1 9.4 33324 9.5 249.32 9.4 503.52 9.4 335.34 9.4 201.15 
  
Ave 9.50 10995.6 9.40 31968.5 9.5 247.88 9.45 623.85 9.5 224.21 9.45 141.57 
  
S.D 0.00 57.55 0.00 1355.50 0 2.04 0.07 170.17 0.14 157.17 0.07 84.26 
  
Preci 0.00 0.52 0.00 4.24 0 0.82 0.75 27.28 1.49 70.10 0.75 59.52 
 
Table 17: m/z Data for BDP 
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Conc. 
[mg/L] 
Ave.  
Peak Area 
[AU] 
Standard 
Deviation [S.D] 
0.01 1271.37 2319.72 
0.25 2315.95 3872.82 
0.5 4077.26 6914.81 
0.75 6154.07 10760.83 
1 7366.94 12788.89 
 
Table 18: A typical set of calibration data of BDP (MS) (overall) 
 
 
 
                          
 
 
 
 
 
 
 
 
Figure 20: Calibration graph for BDP (MS) (overall) (n=2) 
                              
As before, the linearity was greatly improved by taking multiple adducts into account. 
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1.7.2.5 Limit Of Detection (LOD) of BDP and BOH 
       For determination of the LOD, a previously prepared stock solution of the two 
analytes was used. The solution was serially diluted each time i.e. 100 to 0.001 ppm. 
The limit of detection (LOD) was found to be 0.01 ppm both for BDP (Fig. 21) and 
BOH (Fig. 22).  
 
    
 
                                                 
 
 
 
 
 
 
 
Figure 21: Chromatogram shows LOD for BDP at 0.01 ppm (n=2) 
             
 
                
 
 
 
 
 
 
 
 
 
Figure 22: Chromatogram shows LOD for BOH at 0.01 ppm (n=2) 
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1.7.2.6 Stability - BDP 
       Two standard solutions of 2.5 and 80 ppm were analysed using HPLC with the 
same method used to identify the peak. Stability was expressed as the ratio of 
measured concentration against days. The results showed that both analytes were 
quite stable under normal room temperature.  
 
 
 
 
 
 
 
 
Figure 23: Stability graph for BDP at two different concentrations (2.5 and 80 ppm) (n=4) 
 
Both analytes were found to be stable in solution at both concentrations over 4 days 
as shown in Fig. 23. 
1.7.2.7 Repeatability - BDP 
        The precision of the work was determined by injecting two concentrations of 
BDP (low 2.5 ppm and high 80 ppm) which were analysed using HPLC four times at 
regular time intervals over the course of the day to determine the intra-day variation. 
The intra-day variations, expressed as the coefficient of variation in peak area ratios, 
were calculated by dividing the standard deviation of the calculated concentrations 
by the mean concentration and multiplying by 100.     
        For intra-day (same day) quality check, the working solutions of 2.5 ppm and 80 
ppm were analysed at regular time intervals; Table 18 shows peak areas and RSD 
% values over the course of the day. The resulting RSD percentages were less than 
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1%. The intra-day variability, determined for the two standard concentrations of BDP 
on four occasions, is shown in Table 19, below.  
 
Table 19: Intra-day repeatability-peak areas for BDP (n=4) 
 
1.7.2.8 Reproducibility - BDP 
 
        Any analytical method must give reliable data. Reproducibility of the repeated 
identical measurements (replicates) for the 2.5 ppm and 80 ppm solutions was 
calculated on four different days, in order to find out any differences between the 
repeats. The present method has very good reproducibility. The inter-day variability 
determined at the same two concentrations and repeated on four different days is 
illustrated in Table 20 showing the average peak areas for BDP along with S.D and 
RSD%. 
    
Table 20: Inter-day reproducibility-peak areas for BDP (n=4) 
1.7.3 Enzyme hydrolysis and Size exclusion chromatography  
      BDP is a widely used inhaled corticosteroid for the inhalation therapy of asthma 
in both adults and children. Owing to the presence of the dipropionate ester 
functional group in its side chain, it is easily hydrolysed via esterases in the human 
lung, liver and other parts of the body to the more polar products 17-BMP, 21-BMP 
Time 
Conc.[mg/L] 
 
11:00 AM 1300 pm 15 pm 17 pm Mean STDEV RSD % 
2.5 77746 77573 77428 77376 77530.75 165.95 0.21 
80 2829645 2836445 2855501 2855568 2844290 13277.8 0.46 
Days   → 
Conc. [mg/L] 
↓ 
1 2 3 4 Mean STDEV RSD % 
2.5 76806 77426 77489 77426 77286.8 321.87 0.41 
80 2565999 2637022 2636011 2613011 2613011 33244.8 1.27 
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and BOH. 17-BMP is the active metabolite, whereas both 21-BMP and BOH have 
very low binding affinity to the glucocorticoid receptor. In this experiment, in-vitro 
hydrolysis of BDP using esterase enzyme as well as the isolation and 
characterisation of its degradation product was reported. Enzyme hydrolysis was 
performed for 20 hrs. The results were encouraging as product formation was 
observed (Table 21). 
 
 
    
 
 
Table 21: Enzyme hydrolysis [50:1ratio] time analysis for 20 hrs with RT and peak areas 
        The retention time of the major product 17-BMP was not constant. So, it was 
decided to perform enzyme hydrolysis again and this time data would be collected 
from the LC (Fig. 24 and 25). 
          
 
 
 
 
 
 
 
 
Figure 24: Chromatogram at 0 min, BDP is seen at 8.04 min 
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Peak Area 
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Figure 25: Chromatogram at 120 min, BMP is shown at 5 min 
                          
The above chromatograms showed the clear conversion of BDP to BMP. Then it was 
decided to monitor the reaction for 6 hrs only. Again the conversion of BDP to BMP 
was seen. Next it was decided to monitor the reaction for 2 hrs only, in order to 
obtain more data points, as summarized in Table 22, below. 
 
 
 
 
 
 
 
Table 22: Enzyme hydrolysis [50:1ratio] time analysis for 2 hrs with RT and peak areas 
        All the samples were run on the LC-MS in the same way as before. Results 
were not encouraging as new peaks were seen in the chromatogram. After 
Time/Min Retention Time 
Peak 
Area 
[AU] 
0 6.386 3985.3 
5 6.345 3447.4 
10 6.496 3224.9 
20 6.277 3538.1 
30 6.28 3656.5 
45 6.251 6577 
60 6.265 5097.7 
75 6.262 6859.2 
90 6.255 5153 
120 6.259 7050.3 
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discussion it was decided to repeat the enzyme hydrolysis reaction with a ratio of  
50: 1 (enzyme : BDP). The results are shown in Table 23 and Fig. 26, below. 
 
 
 
 
  
Table 23: Enzyme hydrolysis [50:1ratio] time analysis for 2 hrs with peak intensities 
 
 
                
 
 
 
 
 
 
Figure 26: Enzyme hydrolysis [50:1 ratio], timed analysis for 2 hrs 
                     
      The above LC-MS results showed the formation of the required product i.e. BMP. 
The graph was plotted with time versus peak intensity. As expected the graph 
showed a gradual and steady rise with no reappearance of the parent product. Fig. 
27 shows the chromatogram at 0 min and its mass spectrum is shown in Fig. 28. 
Figs 29 and 30 show the chromatograms and mass spectra for the product. 
However, it still needs to be determined whether the product is 17-BMP or 21-BMP.   
  
Time/min Peak intensity (465.2) 
0 23 
5 5 
10 15 
20 62 
45 405 
60 446 
75 565 
120 618 
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Figure 27: Chromatogram at 0 min, BDP is seen at 9.06 min 
 
                        
 
 
 
 
 
 
 
 
Figure 28: MS of the peak at 9.06 min, BDP is seen at m/z 521 
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Figure 29: Chromatogram at 120 min, BMP is shown at 4.87 min 
              
 
 
 
 
 
 
 
 
Figure 30: Mass spectrum of the peak at 4.87 min, BMP is seen at m/z 465 
      Enzyme hydrolysis was conducted in the same way as the above method but this 
time the amount of enzyme was decreased to half, i.e. 1.0 mg, in order to see the 
effect of decreasing the amount of the enzyme (300: 1; enzyme: BDP ratio). The 
reaction was monitored for 6 hrs and the results are summarized below in Table 24 
and Fig. 31. 
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Table 24: Enzyme hydrolysis [300:1ratio] timed analysis for 6 hrs with peak areas 
 
 
 
 
 
 
 
 
 
 
 
Figure 31: Enzyme hydrolysis [300:1 ratio], timed analysis for 6 hrs 
       The above graph shows that there was no prominent or drastic change in the 
reaction as expected. By comparing both the graphs (50:1 and 300:1 ratio), it 
becomes obvious that after 120 min there was no significant change in the reaction 
observed. So, if the amount of enzyme was decreased in this specific reaction it 
would not affect the reaction on a big scale. The method was not only developed but 
it was also cost effective. Results showed the presence of BDP and this was 
confirmed with the EIC of BDP at m/z 521(Fig. 32) and the mass spectrum (Fig. 33).                                      
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Figure 32: EIC of m/z 521 corresponding to BDP 
 
 
 
 
 
 
 
 
 
 
Figure 33: Mass spectrum of the reaction at 0 min, BDP is seen at m/z 521 
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      After 120 min the reaction solution was analysed using LC-MS and the results 
showed the formation of BMP. Formation of the BMP product was confirmed with the 
EIC of BMP at m/z 465 (Fig. 34) and the mass spectrum (Fig. 35).                                                
                                      
 
 
 
 
 
                       
 
Figure 34: EIC of m/z 465, BMP is seen at RT=5.8 min 
 
 
 
               
 
 
 
 
 
 
 
Figure 35: Mass spectrum of the peak at 5.8 min, BMP is seen at m/z 465 
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      BDP is a di-ester compound and both possible mono-ester hydrolysis products 
may be expected to co-elute. So, the next step was to confirm the formation of the 
required product (17-BMP).To obtain a usable amount of product for detailed 
analysis, the reaction was repeated on a large scale. 
1.7.3.1 Enzyme hydrolysis of BDP (large scale) using porcine esterase  
       The reaction was carried on a large scale and was analysed using LC-MS. BMP 
formation was observed which was shown in the LC chromatogram (Fig. 36).  BMP 
was observed at RT 6.30 min. 
 
 
                       
 
 
 
 
  
 
Figure 36: Chromatogram (UV), 180 min, BMP is seen at 6.3 min 
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Figure 37: MS chromatogram of the reaction after 180 min (top) and MS of the peak at 6.8 
min (bottom). BMP is seen at m/z 465 
        The results clearly showed formation of BMP, but still some solid was seen in 
the reaction which may have contained BDP. It was therefore decided to leave the 
reaction mixture solution for incubation for 5 more hrs. Again, the reaction solution 
(0.5 mL) was then spun through an Amicon cartridge and analysed using LC-MS.                        
 
 
 
 
 
 
 
 
 
 
 
Figure 38: Chromatogram (UV) of the reaction mixture after 8 hrs. BMP is seen at 6.05 min 
(n=3) 
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      The chromatogram shown in Fig. 38 showed that further conversion of the 
reactants to product had occurred as the peak area had increased, however some 
solid was still present in the reaction tube. The reaction was therefore left overnight. 
After 26 hrs, the reaction solution was analysed using LC-MS and the results 
showed the formation of BMP at 6.3 min, shown in Fig. 39. This was confirmed with 
the EIC of BMP at m/z 465 (Fig. 40 top) and the mass spectrum (Fig. 40 bottom). 
 
 
                                                          
 
 
 
 
 
 
 
 
 
  
Figure 39: Chromatogram (LC) of the reaction mixture at 26 hrs, BMP is seen at 6.3 min 
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Figure 40: EIC of m/z 465 (top), mass spectrum of the peak at 6.8 min (bottom) 
 
1.7.4 Formation of BMP and BOH using NMR 
        Over the past fifty years nuclear magnetic resonance spectroscopy has become 
the well-known technique for determining the structure of organic compounds. Of all 
the spectroscopic methods, it is the only one for which a complete analysis and 
interpretation of the entire spectrum is normally expected. 
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      The reaction mixture was filtered under vacuum and then LLE was conducted on 
the filtrate, with ether (five sequential extractions). The fractions were mixed 
together, evaporated and dissolved in d6-ethanol (650 µL) and the sample was 
analysed using NMR.                                                                          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41: Selected regions of the 1H NMR spectra of BDP (a) and the reaction mixture 
filtrate after extraction (b) 
 
        The reaction showed that the product had been formed and was fairly pure. The 
1H NMR spectrum (Fig. 41b) was compared with the spectrum of standard BDP (Fig. 
41a). The highlighted portion of Fig. 41 above showed clearly that the signals 
between 4.4 and 4.5 ppm and between 4.8 and 4.9 ppm, corresponding to the 
propionate group, has disappeared and new peaks have appeared between 4.5 and 
4.6 ppm. However, it was not clear whether the product is 17-BMP or 21-BMP. For 
further confirmation whether the product is 17-BMP, the above 1H NMR spectrum 
was compared, at the selected regions, with the spectra from standards of BOH,   
17-BMP and 21-BMP and it further confirmed that signals between 4.2 and 5.6 ppm 
in 17-BMP (2), highlighted in pink, correspond to a steroidal product (Fig. 43). 
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Figure 42: Comparison of selected regions of 1H NMR spectra of BOH (1), 17-BMP (2), 21-
BMP (3) and the reaction product (4) 
 
 
       There was some solid residue left on the filter paper which was dissolved in d6- 
ethanol (650 µL) and analysed using 1H NMR spectrometry. The spectrum (Fig. 43) 
showed the presence of BMP, providing evidence that BMP was present both in the 
liquid sample and the solid.    
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Figure 43: Selected region of the 1H NMR of the residue dissolved in d6-ethanol from the 
reaction 
   
The residue was dissolved in ethanol (1-2 mL) and analysed using LC-MS; the 
resulting chromatogram is shown in Fig. 44.   
  
     
       
 
 
 
 
 
 
 
 
 
Figure 44: Chromatogram from LC-UV analysis of the residue dissolved in d6-ethanol 
Peaks corresponding to 17-BMP and BDP appeared at 6.24 and 9.24 min., 
respectively, as expected. 
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1.7.4.1 Further confirmation of formation of BMP by Nuclear Magnetic 
Resonance (NMR) 
 
        As it was clear that BMP had been formed but not whether it was 17-BMP or 
21-BMP, further analysis was carried out using NMR to identify the product.           
 
 
 
 
 
 
 
 
 
 
 
 
Figure 45: Selected regions of the 1H NMR spectra of BDP standard (a) and the reaction 
product (b) 
 
      Fig. 45 (a) shows the 1H NMR spectrum of the BDP standard and Fig. 45 (b) 
shows the 1H NMR spectrum of the reaction product. It can be seen that it was not a 
pure product, but contains many extra peaks; however, the spectrum clearly shows 
numerous signals corresponding to a steroidal product.   
       In order to have a clear image, the previous spectrum was expanded from 0.6 
ppm to 2.9 ppm, Fig. 46 (a, b). In the spectrum of BDP between 1.1 and 1.2 ppm 
propionate CH3- groups are observed. In the reaction mixture those groups were 
seen at the same shift but are somewhat overlapped by an impurity signal.  
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Figure 46: Expansion of the 1H NMR spectra for the BDP standard (a) and the reaction 
product (b) 
 
       However, the signals corresponding to the protons in the 17- and 21-propionate 
groups of BDP appeared at 2.4 ppm and 1.12 ppm a signal corresponding to 2 x CH2 
groups is present in the spectrum of BDP but in the reaction mixture those signals 
were decreased (integration = 2H). Inspection of the integrals shows that two protons 
have been lost from the signal at 2.43 ppm and three from signal at 1.12 ppm, which 
clearly confirmed that one of the –CH2 - groups has been cleaved away. 
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Figure 47: Expansion of the 1H NMR spectra for the BDP standard (a) and the reaction 
product (b)       
      Evidence for the formation of 17-BMP (as opposed to 21-BMP) is provided by 
inpection of the signals for the protons at position 21 in Fig 48 a, where the signals 
appear as doublets at 4.81 and 4.42 ppm. In the above spectra, Fig. 47 (a, b) it can 
be seen that the proton signals from H21 and H21’ have changed dramatically after 
the hydrolysis reaction.  
      In the spectrum of the reaction mixture (Fig. 47b), the protons at position H21 and 
H21’ were shifted from 4.5 ppm to almost 4.04 ppm (2H) and appeared as a single 
signal. This is indicative of cleavage of the 21-propionate group from the molecule. In 
the spectrum of BDP (Fig. 47a) the two protons at 21 and 21’are diastereotopic and 
their signals appear as doublets with markedly different shift. This is further evidence 
that the bulky propionate group has been lost, allowing free rotation of the CH2 
protons at C21.31 
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        The above results confirms previous findings by Foe et al that showed the rapid 
hydrolysis of BDP via esterase enzyme to 17-BMP which was the major metabolite 
detected.  
1.7.5 Liquid Liquid Extraction (LLE) of BDP and its metabolites  
       A range of solvents were accessed to see which would be the most efficient for 
the extraction of BDP metabolites from the reaction solution. Five sequential 
extractions were carried out with each solvent to attempt complete recovery of the 
analyte.                     
1.7.5.1 Liquid Liquid Extraction (LLE) of BDP and its metabolites from 
aqueous solution with Ether and Cyclohexane  
 
S.No. BMP BDP Ratio 
Relative 
recovery 
(BMP) (%) 
Relative 
recovery 
(BDP) (%) 
1 4673754 14726 317.38 100 100 
2 3402770 30893 110.15 73 210 
3 1704314 9552 178.42 36 65 
4 572930 18991 30.17 12 129 
5 246849 16890 14.62 5 115 
  
Table 25: Peak areas from LC analysis after LLE with a cyclohexane-ether mixture, five 
sequential extractions 
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Figure 48: LLE with cyclohexane-ether mixture, five sequential extractions 
 
        The above graph shows that almost all BMP was extracted since the amount 
present in each subsequent extraction decreased until only a small amount was 
recovered in fraction 5 (5% of the amount in fraction 1). Interestingly, the amount of 
BDP extracted in each fraction remained broadly constant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ether-Cyclohexane 
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1.7.5.2 Liquid Liquid Extraction (LLE) of BDP and its metabolites from 
aqueous solution with Ether  
 
S.No. BMP BDP Ratio 
Relative 
recovery 
(BMP) (%) 
Relative 
recovery 
(BDP) (%) 
1 8333942 3158 2638.66 100 100 
2 4724445 67915 69.56 57 2151 
3 2064252 94538 21.84 25 2994 
4 420671 87027 4.83 5 2756 
5 127579 88337 1.44 2 2797 
 
Table 26: LLE with ether, five sequential extractions 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 49: LLE with ether, five sequential extractions 
 
Extraction of the final product was excellent with ether, as can be seen from table 25 
and Fig. 49 above. The majority of the product was extracted in fractions 1-3 and by 
fraction 5 only a small amount of product was still present in the reaction mixture. 
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1.7.5.3 Liquid Liquid Extraction (LLE) of BDP and its metabolites from 
aqueous solution with Dichloromethane (DCM) 
 
S.No. BMP BDP Ratio 
Relative 
recovery 
(BMP) (%) 
Relative 
recovery 
(BDP) (%) 
1 2941309 9649 304.84 100 100 
2 2606147 22264 117.06 89 231 
3 1082870 13070 82.85 37 135 
4 323208 3582 90.23 11 37 
5 300781 3531 85.19 10 37 
 
Table 27: LLE with dichloromethane, five sequential extractions 
 
 
 
 
 
 
 
 
 
 
 
Figure 50: LLE with dichloromethane (DCM), five sequential extractions 
     The above graph (Fig. 50) shows that after five extractions still some product was 
left in the reaction mixture; the results were not as good as with the cyclohexane-
ether mixture and with ether. 
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1.7.5.4 Liquid Liquid Extraction (LLE) of BDP and its metabolites from 
aqueous solution with Tert-butyl methyl ether (TBME) 
 
 
 
 
 
 
 
Table 28: LLE with tert-butyl-methyl ether, five sequential extractions 
 
 
Figure 51:  LLE with tert-butyl-methyl ether (TBME), five sequential extractions 
 
Figure 52: LLE with tert-butyl-methyl ether (TBME), five sequential extractions 
 
 Figure 531: LLE with tert-butyl-methyl ether (TBME), five sequential extractions 
      Extraction of the final product was excellent with TBME as shown in the graph 
above (Fig. 51). However, a significant amount of the parent compound, BDP, was 
observed. It was concluded that, from all the solvents used, the best extraction was 
observed with ether. 
 
S.No. BMP BDP Ratio 
Relative 
recovery 
(BMP) (%) 
Relative 
recovery 
(BDP) (%) 
1 4714836 180245 26.16 100 100 
2 1985542 380755 5.21 42 211 
3 593007 411464 1.44 13 228 
4 158062 375253 0.42 3 208 
5 66259 483891 0.14 1 268 
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1.8 Conclusion 
             Beclometasone dipropionate (BDP) was the first available inhaled 
corticosteroid used for the treatment of asthma. BDP is a prodrug that is metabolized 
by esterases in the human lung, liver and other parts of the body to three different 
metabolites, beclometasone-17-monopropionate (17-BMP), beclometasone-21-
monopropionate (21-BMP) and beclometasone (BOH).  
There are few reports in the literature in which pulmonary hydrolysis of esters has 
been investigated in vitro. The method reported here involved in vitro metabolism of 
BDP but using lyophilised porcine esterase instead of lung tissue. Samples of 17-
BMP were successfully prepared using selective enzymatic hydrolysis which was in 
accordance with the literature, for example the investigation conducted by Nave and 
McCracken41 in which BDP was hydrolysed to its active metabolite 17-BMP in 2-6 
hours using human lung tissue slices. Therefore, the method presented in this 
chapter was advantageous as the rate of enzyme hydrolysis in this report was faster 
(the reaction was complete in 2-4 hours) and the requirement for use of lung tissues 
was removed.  
 
 A quick, simple, reproducible and specific LC-MS method for the quantitation of 
BDP and its metabolites 17-BMP and BOH has been developed and validated in 
accordance with the ICH guidelines. The accuracy, recovery and precision recovery 
of the method were within acceptable limits (accuracy and recovery ~100% while 
precision <10%) and has been successfully used to analyse samples from this study. 
The calibration curves obtained with this LC-MS method were linear over the 
concentration range used, 0.001-100 mg/L for BDP and 0.01-10 mg/L for BOH.  
The hydrolysis reaction was successfully monitored using LC-MS and further 
confirmed by recording NMR spectra. The NMR experiments showed evidence for 
the rapid hydrolysis of BDP to 17-BMP (the major metabolite) via the esterase 
enzyme as expected from previously published studies using lung 
homogenates.31,38,39  In addition, it has been found that if the ratio of enzyme to BDP 
is decreased it does not affect the rate of reaction. 
Liquid liquid extraction (LLE) was carried out in an attempt to isolate pure 
samples of the metabolites of BDP. Four different solvents were compared and the 
best extraction results were obtained with ether with the recoveries within the 
Chapter: 1                                In-vitro metabolism of a corticosteroid 
 
69 
 
acceptable limits. The recovery of the required products was more than 95%. 
Previous studies have reported that optimal extraction was achieved with an ether-
cyclohexane mixture.33  
The results of stability tests showed that the three analytes were stable under 
the conditions investigated in this study.   
In conclusion, this work showed that the proposed method has the advantage 
of rapidity and simplicity over those described in the literature, without using lung 
tissues. 
1.9 Future Work 
      After development and validation of the LC-MS method for BDP and BMP the 
next step will be to scale-down these methods, e.g. using nano-LC, nano-LC-MS. 
Additional sensitivity is required to detect drugs at biological concentrations (typically 
ng/mL); usually samples are concentrated using an off-line SPE step but this can 
lead to sample losses.  
        Direct sampling using nano-LC could lead to improved quantitation methods. 
Furthermore, the applications of the methods to quantify BDP and its metabolites in 
very low volumes of urine and blood should be investigated. When analysing 
samples from adult test subjects, it is possible to obtain relatively large volumes of 
urine and blood for testing. However, in paediatric cases, sample availability is much 
more limited.  
       Future studies will aim to develop methods of quantifying BDP and its 
metabolites in very small volumes of biological fluids and to extend this methodology 
to analysis of dried blood spots so that finger prick blood testing for these analytes is 
feasible.  
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Electronic vs. steric effects in the synthesis 
of a rhenium complex of progesterone
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2.0 Electronic vs. steric effects in the synthesis of a 
rhenium complex of progesterone 
2.1 Introduction             
2.1.1 Biomolecules  
         A biomolecule, also called a biogenic substance, is any molecule that is 
produced by a living organism. This class of molecules includes both large 
macromolecules such as proteins, polysaccharides, lipids, and nucleic acids, and 
small molecules such as primary metabolites, secondary metabolites, and natural 
products.50 Biomolecules are involved in metabolic processes and maintenance of 
living organisms, therefore methods for their detection and quantitation are essential. 
One such method involves “tagging” the biomolecule with a fluorescent label, 
enabling sensitive and specific detection.51 
        Recent advancements in analytical methods relating to organic chemistry, 
molecular biology, spectroscopy, engineering, and chemical biology have provided 
powerful tools to apply different fluorescent labelling techniques for analyzing 
molecular events in cells.52 Fluorescence methods involve several unique 
experimental parameters, for instance excitation and emission wavelength, intensity 
and fluorescence lifetime.53 
2.1.2 Luminescence 
     The word luminescence comes from the Latin lumen, meaning light, and was first 
introduced as “luminescenz” by the physicist and science historian Eilhardt 
Wiedemann in 1888, to describe ‘all those phenomena of light which are not solely 
conditioned by the rise in temperature’, as opposed to incandescence. Many 
important applications based on photoluminescence have been developed. 
Fluorescence microscopy, fluorescent tubes and lamps, optical brighteners, plasma 
screens, fluorescent and phosphorescent paints, phosphorescent labels, safety 
signs, and counterfeit detection (security documents, bank notes, art works) are a 
few examples of this.  Luminescence occurs when a molecule absorbs energy and 
an electron is promoted into an excited state. The electron then decays to the ground  
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state. In any light-emitting process, the sample must absorb an appropriate amount 
of energy from a suitable source prior to emission of light.54 
Luminescence is subdivided into a number of categories according to the origin of 
this energy. Examples include:  
• Bioluminescence (emission of light by living animals and plants) 
• Chemiluminescence (which may occur during the course of a chemical 
reaction and consecutive to absorption of energy by the reactant molecules) & 
• Electroluminescence (light accompanying an electric discharge, for example 
in a rarefied gas, or after bombardment by electrons sometimes referred to as 
cathodoluminescence).  
 
The various types of luminescence are classified according to the mode of emission, 
including:  
• Fluorescence  
• Phosphorescence, and  
• Delayed fluorescence54,55  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 54: Jablonski diagram showing the electronic states of a molecule and transitions 
between them.55  
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        A Jablonski diagram (Fig. 53) provides a good basic overview of the potential 
transitions within simple luminescent systems. Light energy is absorbed in order to 
excite an electron in to one of the singlet excited states from which point relaxation 
can occur. These principles are used in techniques such as fluorescence 
spectroscopy which has wide ranges of application in various disciplines of 
scientific/medical research.55,56 
       Tracking biomolecules (proteins, antibodies, amino acids, and peptides) often 
requires labelling with a “reporter group”, which gives a response in the chosen 
analytical technique. At present, several labelling methods such as isotope markers, 
radioactive tracers, colorimetric biosensors, photochromic compounds, 
electrochemical sensors, and fluorescent labels are available for this purpose.52 
Fluorescence is now used extensively in biotechnology, flow cytometry, medical 
diagnostics, DNA sequencing, forensic science, and genetic analysis. Fluorescence 
detection is highly sensitive, and there is no longer the need for the expense and 
difficulties of handling radioactive tracers for most biochemical measurements. There 
has been dramatic growth in the use of fluorescence for cellular and molecular 
imaging. Among the labelling methods, fluorescent labelling has the upper hand due 
to its non-destructive nature; enhanced performance and simplicity.57 Two types of 
fluorescent compounds are often used for bioconjugation: small organic fluorescent 
compounds, such as fluorescein, and fluorescent proteins that contain a covalently 
bound chromophore, such as phycobilliprotein. Both types can be used to label 
antibodies, proteins, and other biomolecules for detection purposes. Most of the 
common fluorescent compounds are very hydrophobic and not very stable.58,59 
2.1.3 Luminescent Biological Labels and Probes 
        A biological label (or a labelling reagent) is a small molecule that can be 
covalently connected to a biomolecule such as an amino acid, protein or DNA. It 
contains a signalling group which offers detectable properties and a reactive portion 
which reacts with a specific functional group of a biomolecule. Luminescent labels 
and probes can be divided into several types.  
Fluorescent organic molecules are the most commonly used. They are designed 
as chemical and biological probes due to their excellent absorptivity and emission 
quantum yields which provide remarkable detectability.  
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Various lanthanide chelates have also been employed as luminescent labels due to 
their extraordinarily long lifetimes and sharp emission bands. 
Additionally, luminescent transition metal complexes have been widely developed 
as labelling reagents and probes, because of their intense and long-lived emission; 
also their emission energy can be tuned by using different ligands.59,60,61,62 
2.1.4 Labelling of biomolecules with fluorescent compounds  
         Much work has been done on the labelling of biomolecules with fluorescent 
groups. Labelling is one of the most common methodologies used for bio-analytical 
purposes. The use of organic molecules in non-fluorescent labelling, in the ultraviolet 
and visible regions, is important in several applications. However, in recent years, 
detection based on fluorescence techniques has received special attention and 
notable progress has been made in both fluorescence instrumentation and synthesis 
of new compounds.63  
          The use of metal complexes in therapy and diagnostic imaging is increasing. 
Throughout history metals and metal compounds have been used in medicine to 
treat a variety of ailments. In the last century, metal complexes were used to treat 
diseases ranging from syphilis (organoarsenic compounds) to cancer (platinum anti-
tumour drugs) to arthritis (gold compounds). The use of metal complexes as 
diagnostic agents is a relatively new area of medical research, and has flourished 
during the last 40 years. An even more recent development is the use of 
paramagnetic metal complexes for enhancing contrast of magnetic resonance 
imaging (MRI). In particular, luminescent transition metal complexes of Re(I) and 
Ru(II) have been recognized as good potential candidates.64  
2.1.5 Luminescent rhenium(I) polypyridine complexes  
       Since the first systematic studies of the excited-state properties of luminescent 
Re(I) polypyridine complexes, their spectroscopic, photophysical, and photochemical 
properties have been attracting much interest for more than thirty years.65,66 Re(I) 
complexes have attracted much attention due to their applications in luminescent 
biological molecular probes and photocatalysis. For example, Re(I) tricarbonyl 
polypyridine complexes have been used for luminescent bio-labelling, DNA probes 
and luminescent materials.67  The isotopes of rhenium are primarily used as 
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therapeutic agents that results in the development of therapeutic 186Re and 188Re 
drugs based on 99mTc imaging agents. Bone metastasis treatment has been the 
major use of rhenium complexes to date.64       
          Among the transition metal complexes, rhenium(I) tricarbonyl complexes with 
a d6 configuration have interesting photophysical and photochemical behaviour such 
as high stability and fairly strong emission in the visible region.68 The advantages of 
using rhenium(I) complexes over other d6 transition metal complexes are their ease 
of emission colour-tuning and longer-lived excited states, which are useful in the 
development of multicolour probes for time resolved applications such as 
fluorescence lifetime imaging microscopy (FLIM). Therefore, luminescent labelling 
reagents are an important addition to the family of Re(I)-based biological probes as 
they will enable the labelled biomolecules to possess luminescence properties, 
which could be applied in the design of new bioassays and imaging experiments.69   
          The aim of this project was to investigate new methods of labelling steroids 
with rhenium-containing luminescent labels, including progesterone and 
testosterone.  
2.1.6 Progesterone 
       Progesterone (pregn-4-ene-3,20-dione, Fig. 54) is a 21-carbon steroid hormone 
which possesses ketone groups at carbons 3 and 20. It is synthesized in the ovaries, 
placenta and adrenal glands and prepares the body for conception and pregnancy 
and regulates the menstrual cycle. Although progesterone is thought to be a sex 
hormone of women, it is also synthesized in men.70 
 
                            
 
 
 
 
Figure 55: The structure of progesterone                                  
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        Apart from the primary role of progesterone in women, progesterone derivatives 
find therapeutic application in men for the treatment of benign prostatic hypertrophy 
(BPH) and prostate carcinoma. The newer endogenous actions of progesterone in 
the CNS, including in traumatic brain injury, peripheral nerve injury, Alzheimer’s 
disease and diabetic neuropathy, provide exciting therapeutic opportunities.70  
2.1.7 Testosterone 
          Testosterone (4-androsten-17β-ol-3-one, Fig. 55) is one of the important sex 
hormones produced by the body. It is part of a class of male hormones called 
androgens. In men, testosterone is produced mainly in the Leydig cells of the testes 
and production is controlled by the brain's hypothalamus, and also the pituitary 
gland.72  
 
 
 
 
 
 
 
Figure 56: The structure of testosterone 
 
Testosterone is responsible for: 
1. promoting male secondary characteristics (e.g. increased muscle, hair and 
bone growth).73,74 
2. a deep voice and a beard.73,75  
3. growth of reproductive organs (e.g. testes and prostate) and sperm.  
4. health and wellbeing as well as the prevention of osteoporosis.71,72 
5. the maintenance of male reproductive organs and of spermatogenesis. 
        Testosterone is also metabolised into dihydrotestosterone which regulates the 
secretion of luteinising hormone and follicle stimulating hormone.76,77 Circulating 
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concentrations of testosterone are approximately 15–25 times higher in adult men 
compared to women. Maintenance of these levels is necessary for development and 
maintenance of all secondary sexual characteristics described above.78  
2.2 Steroids and co-ordination chemistry 
      The Harding group is interested in different areas of research including steroid 
quantitation and co-ordination chemistry. It was decided to combine both areas for 
this research project. Tagging of biologically important compounds is done mostly 
with organic fluorescence, which is mostly short lived and decays very quickly. Also, 
there are fluorescent compounds present naturally in the body which often exhibit 
auto-fluorescence. One of the challenges, however, is to differentiate the auto-
fluorescence from that of the tagged compound which is applied specifically for 
study. The possible solution to this problem is perhaps the use of metal-based 
fluorescence. Luminescent metal complexes tend to exhibit longer-lived emission 
than organic fluorophores. Therefore, using metal-based fluorescence may enable 
use of time-gated luminescence measurements, which can discriminate fluorescence 
emissions at certain times. The time-gated luminescence technique has become a 
useful tool in life science and microbial ecology in recent years. The main advantage 
of this technique is that it can provide a method for eliminating short-lived, auto-
fluorescence if the fluorescence lifetime of the metal-based fluorescent is much 
longer than the short-lived auto-fluorescence (typically a few ns) and hence the 
specific long-lived signal can be selected and measured (Fig. 56).79   
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Figure 57: Time-gated fluorescence spectroscopy 
    
2.3 Previous work 
 
         Work reported by Harding and co-workers have previously used the rhenium 
complex of 3,3’-diamino-2,2’-bipyridine (complex 1) as a fluorescent label for various 
biomolecules.80  The two amine groups of the complex can react with aldehydes or 
ketones to form a cyclic aminal product (Fig. 57). 
 
 
               
 
 
 
 
 
 
Figure 58: The general reaction of complex 1 with ketones          
 
Previous work includes reaction of complex 1 with dihydrotestosterone (DHT) (Fig. 
58).  
H+
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Figure 59: Dihydrotestosterone 
 
          DHT is a metabolite of testosterone; the only structural difference is that the 
double bond between positions 4 and 5 of testosterone (Fig. 57) is absent in DHT. 
Complex 1 was successfully reacted with DHT, forming two isomers (Fig. 59). 
 
 
 
 
 
 
 
 
 
 
 
Figure 60 (a): Isomer 180                                                (b): Isomer 380 
 
 
 
 
 
 
 
 
CO 
Cl 
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2.4 Literature Review 
       The current widespread interest in the coordination chemistry of rhenium is 
mainly due to the potential therapeutic applications of the radioisotopes 186Re and 
188Re in radiopharmacy. Technetium-based radiopharmaceuticals are already well 
established in diagnostic nuclear medicine. The chemistry of rhenium is 
characterized by the easily accessible oxidation states from -I to +VII, which readily 
interconvert under mild conditions. The most easily accessible oxidation state is 
Re(VII) and it is obtained by the mild oxidation of the metal and its complexes in the 
presence of oxidizing agents like nitric acid.81 In recent years the use of complexes 
containing luminescent transition metal ions for biological interest has gained much 
attention. Lo et al. have reported a range of Re(I)- and Ru(II)-containing complexes 
which act as biomolecular probes, including biotin-transition metal conjugates as 
non-covalent probes.82,83,84,85 
        These authors focussed their work on the structural design of the metal 
complexes, the labelling and photophysical properties of the complexes and the 
biomolecules, biomolecular interactions, cellular uptake, and intracellular localization 
properties of luminescent transition metal complexes. The rich photophysical 
properties of luminescent inorganic and organometallic transition metal complexes 
made them excellent candidates for biological and cellular studies. They discussed 
some selected examples of the cellular up-take characteristics and cytotoxicity which 
can be used in the development of biological probes. The main challenge was the 
design of probes that were capable of sensing intracellular analytes such as oxygen, 
proton, ions, and small molecules. The cytotoxicity of transition metal complexes can 
be substantially reduced by introducing a biocompatible PEG pendant that protects 
the complexes from interacting non-specifically with extracellular biomolecules. Thus 
the results showed that the luminescent transition metal–PEG complexes had a 
strong potential to be applied as non-cytotoxic intracellular probes for various 
analytes.  The formation of covalent adducts with nucleic acids and proteins and the 
possible inhibition of enzymes by metal complexes have been extensively studied. 
The possibility of using these complexes as photodynamic therapeutics has received 
much attention recently. They concluded that with the right choice of metal centres 
and ligands, as well as a selection of biologically-relevant substrates and reactive 
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functional groups, luminescent inorganic and organometallic transition metal 
complexes will continue to contribute to a wide range of biological applications.86  
        L. K. Kam-Wing, C. A. Wing-Tat and L. W. Ho-Tin in 2011 published a micro-
review in which they describe the fundamental emission characteristics of 
luminescent rhenium(I) tricarbonyl  polypyridine complexes. They discussed the 
basic photophysical properties of luminescent rhenium(I) tricarbonyl polypyridine 
complexes that are used as luminescent probes. They also included and discussed 
recent reports on the use of these complexes as labels and luminescent probes 
targeting biomolecules. Great importance was given to the rhenium(I)-labelled 
biomolecules which gave long-lived emission originating from the metal complexes. 
Also, the use of various ligands can vary the emission properties of these 
complexes. This enables them to function as cellular probes and imaging reagents. 
Furthermore, the addition of various groups and biologically relevant substrates into 
these complexes has also resulted in the development of new cellular probes for 
processes with an emphasis on studies of their structure–property relationships, 
bioconjugation, biomolecular binding, cellular uptake, cytotoxicity, and bioimaging 
applications.87  
         Harding and colleagues worked mainly upon luminescence from d-block metal 
ions. Fluorescent labelling of steroids is required for many applications, including 
immunoassays, receptor binding studies and fluorescence detection (e.g. in HPLC). 
They had discussed many fluorescent labelling reagents in use for derivatisation of 
steroids but they were mostly organic fluorescents which possessed a short lifetime. 
In this article a new route to simple, one-step functionalisation of dihydrotestosterone 
containing a ketone group in the 3- or 17-position has been developed, with a 
rhenium fac-tricarbonyl bipyridyl complex containing a diamino unit. Some examples 
of rhenium-containing androgen derivatives have also been reported.80 
        D. E. Reichert and colleagues presented a review which summarizes some of 
the developments of metal complexes and metal-complex bio-conjugates for the 
diagnosis of disease that have occurred over the past 10 years. They highlighted 
metal complexes that have been synthesized and evaluated in vivo over the last 10 
years. This review gave insight to the significant progress made in the field of 
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coordination chemistry especially metal based radiopharmaceuticals. Radiometals 
used as labels for biomolecules were used for diseases such as neurological 
disorders88 and diagnosing cancer.89 the discovery of attaching metal complexes to 
smaller and larger biological molecules90-92 revolutionized research in the field of bio 
conjugates. Metal complexes attached to biomolecules allow even more specific 
biological processes to be studied, including the formation of thrombi93, the imaging 
of brain and renal infection94,95, and the understanding of antigens and receptors 
found in certain types of cancer.96 The radiolabeling of antibodies for the detection of 
cancer in the early 1970s97,98 marked the beginning of the use of radiolabeled 
proteins and peptides for targeting antigens and receptors that are up regulated in 
tumours. Metals and metal compounds were in use in medicine to treat a variety of 
ailments. In the last century, metal complexes were used to treat diseases ranging 
from syphilis to cancer to arthritis. The first isotope used in medicine was iodine-131, 
which in 1946 was used to treat thyroid cancer. Today, there are a wide variety of 
radiometals and radiometal complexes used in medical practices. An even more 
recent development was the use of paramagnetic metal complexes for enhancing 
contrast of MRI. Designing metal complex-based imaging agents require 
consideration of their redox properties, stability, stereochemistry, charge and 
lipophilicity of the metal complex. The isotopes of rhenium are primarily used as 
therapeutic agents, and this has led to the development of therapeutic 186Re and 
188Re drugs based on imaging agents.99  
2.5 Experimental 
2.5.1 Materials  
The rhenium complex of 3-3’-diamino-2,2’-bipyridine (complex 1) was prepared by 
other group members according to literature methods.80 
Progesterone and testosterone were purchased from Fluka chemicals (purity 99 %). 
Camphorsulfonic acid (CSA), was purchased from Sigma. 
Solvents 
 
Acetonitrile, methanol, ethanol (certified HPLC grade), cyclohexanone, hexane, 
dichloromethane (DCM), dimethylsulfoxide (DMSO) and diisopropyl ether (DIPE) 
were purchased from Fisher Scientific (UK). 
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Deuterated solvents were purchased from Goss Scientific.  
Ultrapure water was either purchased from VWR or produced in-house using a 
Barnstead NanoPure (Thermo scientific).  
Stock solutions and working solutions were prepared by successive dilution with 
MeCN. 
2.5.2 Instrumentation 
2.5.2.1 Liquid Chromatography Mass Spectroscopy (LC-MS) 
        Chromatographic separation was developed on a Shimadzu Prominence UFLC 
system and Lab Solutions v. 5 software was used for the processing of the data 
(Schimadzu Corporation UK). It is an ultra-high-speed prominence LC-20AD XR that 
achieves both ultra-high-speed analysis and ultra-high separation, based on high 
analysis precision and reliability comprising of prominence System Controller, 
schimadzu Solvent Delivery Unit, prominence AutoSampler (SIL-20A XR), 
prominence Column Oven (CTO-20A), Schimadzu Fluorescence Detector (RF-10A 
XL, prominence Diode Array Detector (SPD-M20A) and prominence Degasser (DGU-
20A3.  
         The column used was a Lichrospher 100, RP-18 (250 mm x 4.6 mm, 5 µm), 
column purchased from VWR (Merck, Germany). The mobile phase (A) was HPLC 
grade water and mobile phase (B) was acetonitrile. The flow rate was kept constant 
at 1.00 mL/min. The injection volume was 20 µL. The eluent UV absorbance was 
monitored using a diode array detector and monitored at a wavelength of 240 nm for 
the steroids. 
      The samples were analysed by a Bruker MicrOTOF-Q mass spectrometer 
coupled to the UFLC system to facilitate the study of BDP standards and metabolite 
formation. The mass spectrometer was a hybrid quadrupole/orthogonal accelerated 
Time-of-Flight equipped with an electrospray ionization (ESI) ion source. Positive ion 
ESI was chosen. Data acquisition and processing was carried out using Bruker’s 
proprietary DataAnalysis software.  
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        For the analysis of complex 1 and its derivatives the mobile phase (A) was 
HPLC water and mobile phase (B) was MeCN. The flow rate was kept constant at 
1.00 mL/min. The injection volume was 20 µL. The eluate UV absorbance was 
recorded using a diode array detector and monitored at wavelengths of 275 nm and 
379 nm (Table 29).  
 
HPLC Shimadzu UFLC 
Mode Isocratic 
Analytical Column 
Lichrosphere 100, 
RP-18 (250 mm x 4.6 mm, 5 µm), 
column no. 026023 
Lot No. 497017 
Injection Port 
Type Manual 
Syringe Volume 50 µL 
Injection Volume 20 µL 
Mobile Phase A 
(HPLC water) 40 % 
Mobile Phase B 
(MeCN) 60 % 
Column Flow 1.0 mL/min 
Detector UV at 275 and 379 nm 
Run Time 30 minutes 
 
Table 29: Instrumental parameters for the analysis of complex 1 and its derivatives 
   
      The samples were also analysed by a Bruker MicrOTOF-q mass spectrometer 
(Bruker daltonics Corporation, Germany) coupled to the UFLC system to facilitate 
the study. Positive mode electrospray ionisation was chosen. Data acquisition and 
processing was carried out using Bruker’s proprietary DataAnalysis software.  
 2.5.2.2 Preparative High Performance Liquid Chromatography (HPLC)  
 
          Preparative separations were carried out on a Gilson preparative HPLC 
system Model-803C mono-metric module, using Gilson Piston Pumps Model 303 
and 305. The column used was a Dynamax, pre-packed C18 column module, 21.4 
mm I.D x 250 mm, serial No. B910924. The detector was a Gilson HM Holochrome 
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UV-VIS using 286 nm wavelength. The data was collected on a chart recorder (Kipp 
and Zonen BD 40) and integrator. The mobile phase (A) was MeCN, 65 % and 
mobile phase (B) was HPLC water, 35 %. The flow rate was kept constant at 10.00 
mL/min. The run time was 60 min (Table 30). 
   
HPLC Gilson model 303 & 305 pump, 
 
UV Detector Gilson HM Holochrome UV/VIS 
Chart Recorder Kipp & Zonen BD 40 (5 mm/min) 
Mode Isocratic 
Prep - Column Dynamax – 60 A 
Injection Port Type Manual 
Syringe Volume 1.5 ml  
Injection Volume 20 µL 
Mobile Phase A 
(MeCN)  65 % 
Mobile Phase B 
(HPLC water)  35 % 
Flow Rate 10 mL/min 
Run Time 60 min 
 
 
Table 30: Instrumental parameters for preparative separations 
2.5.2.3 Nuclear Magnetic Resonance (NMR) 
 
        NMR spectra were acquired on a Bruker Avance 400 MHz or Bruker Avance 
500 MHz NMR spectrometer using Bruker Topspin software. Spectra were recorded 
at room temperature. Thin-layer chromatography (TLC) was performed on Merek 
Silica gel 60 F254 TLC cards and Aluminium oxide/TLC cards by Fluka (Sigma 
Aldrich). The samples were dried using a Savant DNA 120 Speed vac Concentrator. 
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2.5.2.3 X-ray Chrystallography    
          For this analysis Single crystal X-ray diffraction data was collected on a Bruker 
APEX II DUO (3-and 4-axis configurations) equipped with a graphite 
monochromated Mo(Kα) radiation source and a cold stream of N2 gas and refined 
using APEX 2 software.  
2.6 Methodology 
2.6.1 Method development for  complex1-cyclohexanone 
2.6.1.1 A. complex 1-cyclohexanone, as a method development model 
           To develop a LC method with cyclohexanone, as a model compound for the 
steroids, various conditions were tried. A reaction (on small scale) was performed 
with complex 1 and cyclohexanone to obtain the aminal product. To set a method 
protocol for the cyclohexanone standards of complex-1 and cyclohexanone was run. 
It was followed by mixed run of both the compounds at different mobile phase 
concentrations and flow rates to obtain well separated peaks. Reaction mixture was 
prepared by dissolving complex 1 (1 mg) in MeCN (1 mL) and to this was added 
cyclohexanone (1 µL) and few grains of camphor sulfonic acid (CSA) as a catalyst. 
The mixture was left heating for 2 hrs. 
2.6.1.2 B. Reaction of complex 1 with cyclohexanone, as a method development 
model 
        To develop a method for the reaction of complex 1 with cyclohexanone, various 
conditions were optimised to conduct an investigation on large scale. 
        Reaction mixture was prepared by dissolving complex 1 (20 mg) in MeCN (2 
mL) and to this was added cyclohexanone (20 µL) and few grains of camphor 
sulfonic acid (CSA) as a catalyst. The mixture was left heating for 6 hrs at 60° C in 
the dark. TLC (5% MeOH in DCM) was done on alumina plate. Separation and 
collection of the fractions were done on preparative HPLC, dried in DCM and 
analysed by using NMR and crystallography.  
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2.6.1.3 Detection Methods (Identification of Analytes)      
       Firstly, standards of complex 1 and cyclohexanone were run separately to find 
their retention times. Then, a 100 ppm mixed solution of complex 1 and 
cyclohexanone was run at different percentages of mobile phase (MeCN) and 
different flow rates to obtain sharp and well-separated peaks of both the analytes. 
Table 31 below summarises the methods used.  
 
 
 
                  
 
 
 
 
 
Table 31: Method development for the analysis of complex 1 and cyclohexanone 
Method 9 was found to give optimum separation. It was decided to use this method 
for further analysis.  
2.6.2 Method optimization and validation for complex1-cyclohexanone 
2.6.2.1 Stock solutions 
Complex 1 
         A stock solution of complex 1 was prepared in MeCN at a concentration of 500 
ppm equivalent to 1.0 mL of stock solution. Complex 1 (0.5 mg) was weighed on a 
Mettler analytical balance and put into an eppendorf tube.                
         The stock solution was made by dissolving the weighed amount in MeCN (1.0 
mL) to achieve a clear solution with the final concentration of 500 ppm (0.5 mg/1.0 
mL). After preparation the stock solutions were covered in aluminium foil, labelled 
and stored in the dark for future use.  
Cyclohexanone 
         A stock solution was prepared by dissolving 10 µL cyclohexanone in 1 mL of 
MeCN to make a 9470 ppm stock solution.  
S.No 
Conc. of 
Solution  
[mg/L] 
B %  
[HPLC] 
Flow Rate  
[ml/min] 
1 100 60 1 
2 100 60 1.5 
3 100 40 1 
4 100 40 2 
5 100 70 0.5 
6 100 30 2 
7 100 40 0.5 
8 100 30 0.5 
9 100 30 1 
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2.6.2.2 Working solutions 
Cyclohexanone 
         From the stock solution, 0.01 mL was measured and added to MeCN (0.99 mL) 
to give a solution of 94.7 ppm (1.0 mL). 
Mixed run of complex 1 and cyclohexanone 
          A mixed solution of complex 1 and cyclohexanone was prepared as follows; 
an aliquot (0.2 mL) was pipetted from the 500 ppm stock solution of complex 1. To 
this solution was added cyclohexanone (0.01 mL) and MeCN (0.79 mL) was added 
to make the final volume 1.0 mL. 
2.6.2.3 Experimental protocol (small scale) of complex 1 and cyclohexanone 
(small scale)  
 
         A reaction solution was made on a small scale to check the method and the 
data was collected using LC-MS. 
2.6.2.3.1 A.Reaction mixture of complex 1 and cyclohexanone 
         A reaction was performed with complex 1 and cyclohexanone to obtain the 
aminal product. Complex 1 (1 mg) was dissolved in MeCN (1 mL) and to this was 
added cyclohexanone (1 µL) and few grains of camphor sulfonic acid (CSA) as a 
catalyst. The mixture was left heating for 2 hrs and aliquots were removed and 
analysed after every 20 minutes.  
 
2.6.2.3.2 B. Reaction mixture of Complex 1 and progesterone 
Peak identification – Progesterone              
         To detect the peak of progesterone, a small amount of the steroid (standard) 
was dissolved in MeCN (1 mL) and analysed using HPLC at 240 nm wavelengths to 
determine the retention time.                                          
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Experimental protocol of progesterone (small scale) 
   
        Four experiments were performed with different amount of (equivalence) 
progesterone in order to obtain the required results.  
Experiment - 1 
     For this reaction, the mixture was prepared as follows: Complex 1 (1 mg) and 
progesterone (1.28 mg, 2 eq.) were dissolved in MeCN (1 mL) and few grains of 
CSA were added. The reaction tube was secured with parafilm, incubated in a water 
bath at 60 °C and incubated for several hrs in the dark; after every 30 min to one 
hour an aliquot was removed and was analysed using LC-MS. 
Experiment – 2 
      The experiment was repeated and the method followed was the same as 
Experiment 1 above except that the amount of progesterone was increased to 2.56 
mg (4 eq.). 
Experiment – 3 
 
       In this experiment the method followed was same as Experiment 1 above except 
for the amount of progesterone which was increased to 3.84 mg (6 eq.).  
Experiment – 4 
       The amount of progesterone was increased to 6.4 mg (10 eq.); other parameters 
were the same as in previous experiments.  
 
2.6.2.3.2.2 Timed NMR experiment for progesterone 
        The NMR reaction was performed on small scale first using complex 1 (2 mg) 
and progesterone (12.8 mg) dissolved in d3-MeCN (650 µL) with a few grains of CSA 
in an NMR tube. The tube was incubated in a water bath at 60 °C for 2 hrs. in the 
dark. The reaction mixture was analysed using NMR as shown in Fig. 58. 
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Figure 58: General experimental protocol of  
NMR timed reaction 
Preparative High Performance Liquid Chromatography (HPLC) (large scale) 
        Complex 1 (50 mg) and progesterone (320 mg) were dissolved in d3-MeCN (3 
mL) and a few grains of CSA were added. The reaction tube was incubated in a 
water bath for 6 hrs, in the dark, at 60 °C. After every hr, the 1H NMR spectrum was 
recorded to observe the changes in the starting materials. That was carried on for six 
hrs. After 6 hrs heating, another 1H NMR was taken and compared with the 1H NMR 
of starting material (complex 1). An aliquot (25 µL) was removed from this reaction 
mixture and MeCN (0.50 mL) was added, the solution mixed thoroughly and then 
analysed using LC-MS.  
          The next step was to isolate the pure product. It was decided to use 
preparative HPLC to collect a workable amount of pure compound and to try to 
crystallize the product. The sample (in 1 mL aliquots) was run on the preparative 
HPLC which recorded the graph on a chart recorder. In order to get the pure form, 
fractions were collected after every 30 sec. from the onset of the progesterone peak, 
for approximately 24 min in total.  
For isomer 1, fractions 99 – 112 were collected, combined, extracted into DCM after 
removal of MeCN on the rotary evaporator and dried. For isomer 2, fractions 125 – 
140 were collected. The same steps were repeated for these fractions. The proton 
NMR spectra were acquired in d3-MeCN. After NMR analysis, fraction 2 was purified 
using column chromatography (SiO2, 10 % MeOH in DCM). The column showed 
three bands, one of the bands contained more material than the other two and was 
1H NMR after 2 hrs 
1H NMR after 6 hrs 
Sample run in LC-MS   
65% B and 0.5 % 
Sample run in prep-HPLC 
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analysed using 1H NMR. The NMR spectrum showed that it was a mixture but it 
contained more product compared to fraction 1.  
           Yellow crystals of X-ray quality were obtained by slow evaporation of MeCN. 
These were analysed on a Bruker APEX II DUO (3-and 4-axis configurations)   and 
refined using APEX 2 software. 
           Crystal data for {1-Progesterone} (C34H38ClN4O4Re1): M = 788.33; Monoclinic, 
P21, a = 8.2794(4), b = 14.2628(7), c = 13.7207(6) Å, β = 104.9290(10) °; V = 
1565.55(13) Å3, Z = 2; ρcalc = 1.672 Mg m-3, F(000) = 788; dimensions 
0.40×0.15×0.01 mm; µ(MoKα) = 4.012 mm-1, T = 150 (2) K. A total of 23647 
reflections were measured in the range 1.54 ≤ θ ≤ 33.14 ˚ (hkl range indices: -
12≤h≤12, -21≤k≤18, -21≤l≤20), 10735 unique reflections (Rint = 0.0369). The 
structure was refined on F2 to Rw = 0.0567, R = 0.0305 (9501 reflections with I > 
2σ(I)) and GOF = 0.872 on F2 for 400 refined parameters, 1 restraint. Largest peak 
and hole 1.466 and -0.858 eÅ-3. 
2.6.2.3.3 C. Reaction mixture of complex 1 and testosterone  
2.6.2.3.3.1 Experimental protocol (small scale) 
         Complex 1 (2 mg) and testosterone (11.71 mg, 10 eq.) were dissolved in       
d3-MeCN (0.650 mL) and a few grains of camphor sulfonic acid (CSA) were added. 
The solution was heated for 1 hr in a water bath at 60 °C and analysed using 1H 
NMR. Four experiments were performed according to the general experimental 
protocol as described below in Fig. 60. 
 
 
 
 
 
 
 
 
Figure 61: General experimental protocol of complex 1 with testosterone 
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        The reaction mixture was heated for 1 hr in a water bath at 60 °C and then 
analysed using 1H NMR. The sample was heated for further 1 hr period and 
analysed by NMR until it had been heated for a total of 11 hrs. This was continued 
the following day when it was heated for 2 hrs period before acquisition of the proton 
NMR spectrum, to a total of 25 hrs of heating.  
2.6.2.3.3.2 Experimental protocol  of complex 1 and testosterone (large scale)     
       The reaction mixture was prepared by dissolving complex 1 (30 mg), and 
testosterone (176 mg, 10 eq.) in MeCN (3 mL) and adding a few grains of CSA. The 
reaction tube was heated at 60 °C in a water bath for 18 hrs in the dark. The reaction 
was monitored by TLC (SiO2, 5 % MeOH in DCM) until all of the starting material had 
been consumed. To confirm the presence of the product, an aliquot of the reaction 
mixture (25 µL) was mixed with MeCN (0.5 mL) and this sample was analysed using 
LC-MS at 65% B and 0.5 mL/min flow rate. Also testosterone (0.5 mg) was dissolved 
in MeCN (0.5 mL) and analysed as a standard to facilitate peak identification. The 
remaining sample was dried in a Savant DNA 120 Speed vac Concentrator (20 min) 
and the remaining reaction mixture was put in a freezer. 
        The purification of the crude product via column chromatography (Al2O3, MeOH 
in DCM) gave yellow coloured product. Fractions containing the product were 
combined, dried, and dissolved in MeCN (1.0 mL); this sample was then diluted 
approximately. From the above sample, an aliquot (0.25 mL) was removed and 
mixed with MeCN (0.75 mL - 1.0 mL) and analysed using HPLC at 65% MeCN and 
0.5 mL/min flow rate.  
Preparative High Performance Liquid Chromatography (HPLC)         
         It was decided to use preparative HPLC to collect a workable amount of pure 
compound to try to crystallize the product. The sample (in 1 mL aliquots) was 
separated on the preparative HPLC. In order to get the optimum separation, fractions 
were collected after every 30 seconds from the start, i.e. T=0. The conditions used 
on the preparative HPLC were as shown in Table 32. 
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Table 32: Instrumental parameters for preparative separations 
       The sample was dissolved in MeCN (3 mL), at which point a small amount of 
yellow precipitate formed which was removed using vacuum filtration.  The filtrate (in 
0.5 mL aliquots) was then separated using the preparative HPLC using the 
conditions shown above. Samples were collected every 30 sec in labelled vials. 
However, in the initial experiment the peaks recorded were quite small, so it was 
decided to change the range from 1.0 to 0.5 AUFS. 
        Two isomers were identified from the chromatogram and selected fractions of 
each isomer were combined. The acetonitrile was removed by rotary evaporation 
and the remaining aqueous solution for each isomer was extracted into DCM, dried 
(MgSO4) and evaporated to dryness under vacuum. The 1H NMR spectra of both 
isomers were acquired in CD3CN. The NMR spectra showed that isomer 2 contained 
more products. Crystallisation of isomer 2 was attempted in two ways: 
(a) By solvent diffusion of DIPE into an acetonitrile solution of isomer 2  
(b) A small amount of the sample was dissolved in MeCN and placed in the 
fridge.   
Unfortunately, attempts to crystallise this sample have so far been unsuccessful. 
 
 
 
 
 
 
 
Method No. 2 
Range 1.0 AUFS 
Frequency 286 nm 
Pressure 88 bar 
MeCN (A%) 65% 
H2O (B%) 35% 
Flow rate 10 mL/min 
Run time 60 min 
Chapter: 2             Synthesis of a rhenium complex of progesterone 
 
94 
 
2.7 Results and Discussion 
          Liquid chromatography is a fundamental separation technique in the life 
sciences that combines the resolving power of liquid chromatography with the 
detection specificity of mass spectrometry. Liquid chromatography (LC) separates 
the sample components and then introduces them to the mass spectrometer (MS). 
The MS creates and detects charged ions. LC-MS systems facilitate the analysis of 
samples that traditionally have been difficult to analyze.  
        Cyclohexanone was used as a method development model for the reaction 
between complex 1 and steroids (Fig. 61, Scheme 1), and their subsequent analysis 
by liquid chromatography coupled with mass spectrometry (LC-MS), since it 
replicates the “A” ring of the steroid but is cheaper and available in larger quantities. 
 
 
 
 
 
 
Figure 62: Scheme 1: Reaction between complex 1 and cyclohexanone to form the 1-
cyclohexanone product 
 
 
2.7.1 Determination of retention times of the starting materials 
Complex-1 
        A 100 ppm solution of complex 1 was analysed using LC-UV and the peak from 
the compound appeared at RT 5.57 min. at 60% B MeCN and 1.0 mL/min flow rate 
using 379 nm wavelengths (Fig. 62). 
 
H+ 
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Figure 63: LC-UV chromatogram showing complex1, (100 ppm), 60 % MeCN, 1.0 mL/min 
flow rate, 379 nm 
 
Cyclohexanone 
      A 100 ppm solution of cyclohexanone was analysed using LC-UV giving a 
retention time of 11.26 min. at 60% B MeCN and 1.0 mL/min flow rate using 286nm 
wavelength (Fig. 63). 
 
 
 
 
 
 
 
 
Figure 64: LC-UV chromatogram showing cyclohexanone, (100 ppm), 60 % MeCN, 1.0 
mL/min flow rate, 286 nm 
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Mixture of complex 1 and cyclohexanone 
        A mixture of complex 1 and cyclohexanone was analysed to optimise 
separation of the starting materials. Many methods were tried to get the best 
separation. The best method for separation of complex 1 and cyclohexanone was 
found to be method 9 (30 % MeCN and 1.0 mL/min flow rate), which gave excellent 
detection, separation and retention time. It was therefore decided to use this method 
for further analysis.  
2.7.2 A.  Method development of complex 1 & cyclohexanone 
A timed reaction of complex 1 with cyclohexanone was carried out using the newly 
developed chromatographic method (30 % MeCN, 1.0 mL/min). A solution of 
complex 1 (1 mg) and cyclohexanone (1 µL) in MeCN (1mL) with a few grains of 
CSA was heated in the dark. The reaction was monitored for 2 hrs. Aliquots were 
removed and analysed using HPLC at 0 min, 20, 60, 90 and 120 min. 
 
 
 
 
 
 
 
 
 
 
Figure 65: LC-UV chromatogram of the complex 1 and cyclohexanone reaction (100 ppm), 
30 % B and 1.0 mL/min flow rate (t=0 min) 
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Figure 66: LC-UV chromatogram of the complex 1 and cyclohexanone reaction (100 ppm), 
30 % B and 1.0 mL/min flow rate (t=60 min) 
 
 
 
 
 
 
 
 
 
 
Figure 67: LC-UV chromatogram of the complex 1 and cyclohexanone reaction (100 ppm), 
30 % B and 1.0 mL/min flow rate (t=120 min) 
 
    The results in Figs. 64, 65 and 66 show that complex 1 reacted well with the 
cyclohexanone. It seemed that the two expected isomers of the product were 
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overlapping at around 21 min. However, the retention time of the two peaks was 
excessively long (more than 15 min). It was therefore decided to reduce the retention 
time by using different percentages of mobile phase (MeCN) and different flow rates 
to obtain a shorter analysis time, as shown in Table 33 below. 
  
 
                
 
 
 
Table 33: MeCN compositions and flow-rates of the selected methods 
 
 
 
 
 
 
 
 
 
 
Figure 68: LC-UV chromatogram of the complex 1 and cyclohexanone reaction, 55 % B and 
0.5 mL/min flow rate (t=180 min) 
 
       Excellent separation of the analytes was observed in the chromatogram (Fig. 
67) and the retention time of the product was also reasonable (12.56 min). So within 
20 min the reaction can be monitored easily.  
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2.7.3 B. Method development of complex 1 & Progesterone 
2.7.3.1 Timed liquid chromatography mass spectroscopy (LC-MS) experiment 
         As the reaction of complex 1 with cyclohexanone was successful it was 
decided to proceed with the steroid of our interest, i.e. progesterone. The timed 
reaction of complex 1 with progesterone was run using the newly developed 
chromatographic method (55 % MeCN, 0.5 mL/min) (Fig. 68, Scheme 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 69: Scheme 2: Reaction between complex 1 and progesterone to form the 1-
progesterone product 
 
Initially, a solution of progesterone was prepared in MeCN (1 mL) and analysed 
using LC to locate its peak and retention time. The chromatogram below, Fig. 69, 
showed that the peak appeared at RT 25.83 min. 
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Figure 70: LC-UV chromatogram showing progesterone (100 ppm) in MeCN, 55 % MeCN, 
0.5 mL/min flow rate, 240 nm 
       A solution of complex 1 (1 mg) and progesterone (6.4 mg, 10 eq.) in MeCN (1 
mL) and a few grains of CSA was heated in the dark. The reaction was monitored for 
3 hours. Aliquots were removed and analysed using LC at 0, 30, 60, 90 and 120 min. 
Reference chromatograms are shown below (Figs 70-73). 
 
 
 
 
 
 
 
 
 
Figure 71: LC-UV chromatogram of the complex 1 and progesterone reaction at 100 ppm, 
55 % B and 0.5 mL/min flow rate (t=0 min) 
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Figure 72: LC-UV chromatogram of the complex 1 and progesterone reaction at 100 ppm, 
55 % B and 0.5 mL/min flow rate (t=30 min) 
 
 
. 
 
 
 
 
 
 
 
 
Figure 73: LC-UV chromatogram of the complex 1 and progesterone reaction at 100 ppm, 
55 % B and 0.5 mL/min flow rate (t=90 min) 
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Figure 74: LC-UV chromatogram of the complex 1 and progesterone reaction, 55 % B and 
0.5 mL/min flow rate (t=180 min) 
  
         Fig. 73 above shows the result at 180 minutes. Two peaks were observed 
corresponding to two isomers of the product between 53 and 56 min, which was 
considered to be an excessive retention time. In order to reduce the retention times 
of the analytes, the mobile phase composition was changed; the amount of 
acetonitrile in the mobile phase was increased to 65 %, keeping the flow rate the 
same at 0.5 mL/min. 
 
        The results were quite encouraging as the retention time for the products was 
decreased from 55 minutes to 22.5 min. Fig. 74, below, shows that increasing the 
acetonitrile concentration from 55% to 65% brought the two isomers and other peaks 
to reasonable retention times: complex 1 (5.25 min), progesterone (14.62 min) and 
for the two product peaks isomer 1 appeared at 20.39 min and isomer 2 appeared at 
22.71 min. These chromatographic conditions were used for subsequent 
experiments. 
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Figure 75: Chromatogram of the complex 1 and progesterone reaction at 100 ppm, 65 % B 
and 0.5 mL/min flow rate (t=300 min) 
 
     Another analysis was carried out after 360 min and it was observed that a 
significant amount of product had been formed (Fig. 75). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 76: Chromatogram of the complex 1 and progesterone reaction at 100 ppm, 65 % B 
and 0.5 mL/min flow rate (t=360 min) 
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2.7.3.2 Timed NMR experiment for progesterone (large scale) 
      To gain more insight into the reaction between complex 1 and progesterone, a 
timed NMR experiment was carried out. Complex 1 (2 mg) and progesterone (12.8 
mg, 20 eq.) were dissolved in CD3CN (650 µL) and a few grains of CSA were added 
at t = 0. At t = 2 hrs, the 1H NMR spectrum of the reaction was acquired; some 
signals from the product were observed (Fig. 76). Since the steroid region of the 
spectrum is complex and non-first order, only the aromatic regions of the spectra are 
shown here.  
 
 
 
 
 
 
 
Figure 77: Selected region of the 1H NMR spectrum of the reaction of complex 1 and 
progesterone (t=2 hr) 
 
Represents the starting material                      
        Represents the formation of products 
       Since the reaction had not gone to completion, the reaction mixture was heated 
for 4 more hours. The 1H NMR spectrum was re-recorded (Fig. 77) and showed that 
all the starting material had been converted to the product. 
 
      
 
 
 
 
 
Figure 78: Selected region of the 1H NMR spectrum of the reaction of complex 1 and 
progesterone (t=6 hr) 
 
                  Represents the formation of products  
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The reaction was repeated, recording 1H NMR spectra every hr; the results are 
shown in Fig. 78. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 79: Stacked 1H NMR spectra showing progress of the reaction from 1 hr to 6 hr 
 
 Key:                 Represents the starting material       
                         Represents the formation of products 
 
      The above stacked plot shows the aromatic regions of the 1H NMR spectra. In 
the first spectrum (t=1 hr), the starting materials are indicated by blue arrows. These 
three signals came from the protons on the bipyridine rings in the starting material 
i.e. complex 1. The above figure shows clearly that the starting material gradually 
decreased and there was an increase in product formation after every hr. 
     Comparison of the spectra for complex 1 and the product (1-progesterone) shows 
that two isomers have been formed (Fig. 79). In the spectrum of the starting material 
(top) signals from the bipyridyl groups were present between 7.3 and 8.6 ppm.  
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        The spectrum of the reaction mixture after 6 hrs of heating (bottom) showed 
that these signals shifted upon reaction of complex 1 with progesterone and also 
became more complicated; in fact, there are two sets of bipyridyl signals, confirming 
the formation of the two isomers. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 80: Selected regions of the 1H NMR spectra of complex 1 (top) and the 1-
progesterone product (bottom) 
 
2.7.3.3 Preparative Chromatography to produce the metabolites of BDP 
         Beclometasone dipropionate is a widely used inhaled corticosteroid for the 
inhalation therapy of asthma in both adults and children. Owing to the presence of 
the dipropionate ester functional group in its side chain, it is easily hydrolysed via 
esterases in the human lung, liver and other parts of the body to the more polar 
products 17-beclometasone monopropionate (17-BMP), 21-beclometasone 
monopropionate (21-BMP) and beclometasone (BOH). 17-beclometasone 
monopropionate is the active metabolite, whereas both 21-BMP and BOH have very 
low binding affinity to the glucocorticoid receptor. In this experiment, we reported the 
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in-vitro hydrolysis of BDP using esterase enzyme as well as the isolation and 
characterisation of its degradation product. 
 
          The reaction mixture was prepared by dissolving complex 1 (50 mg) and 
progesterone (320 mg, 10 eq.) in MeCN (3 mL) with addition of a few grains of CSA. 
The solution was heated at 60 ºC for 6 hrs before analysis using LC-UV to develop a 
method suitable for a preparative separation (Fig. 80).  
 
 
 
 
 
 
 
 
 
Figure 81: LC-UV chromatogram for the complex 1/progesterone reaction, after 6 hrs of 
heating 
 
          The sample (in 1 mL aliquots) was separated using the preparative HPLC. The 
chromatogram showed some side products, a prominent peak due to progesterone 
at 24 min and two unresolved peaks for the product isomers (since the resolution of 
preparative HPLC was not as high as analytical scale HPLC). The chromatogram 
obtained is shown in Fig. 81 below.  
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Figure 82: Preparative HPLC chromatogram of the complex 1/progesterone product (65 % 
MeCN, 10 mL/min, run time 60 min) 
      For each isomer, fractions were collected (Fig. 82), combined and the acetonitrile 
removed in vacuo. The remaining aqueous sample was extracted into DCM and 
dried (MgSO4), giving a yellow solid. 
 
 
 
 
 
 
 
 
 
 
Figure 83: A preparative HPLC chromatogram showing collection of fractions for the two 
isomers of 1-progesterone 
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2.7.3.4 Solid state characterisation for 1-progesterone 
 
        Single crystal X-ray Diffractometer can determine crystal structure with detailed 
information about bond lengths and bond angles, of small molecules and 
macromolecules, and also provides accurate and precise measurements of 
molecular dimensions. 
       Yellow crystals of 1-progesterone were formed by slow evaporation of MeCN. 
These were analysed using single-crystal X-ray diffraction, and the structure is 
shown below in Fig. 83.    
  
 
           
 
 
 
 
 
 
 
 
 
Figure 84: Single-crystal X-ray structure of 1-progesterone 
 
      The rhenium centre adopts a distorted octahedral geometry and is coordinated 
by two pyridyl nitrogen atoms and two carbon monoxide ligands in the equatorial 
positions, with another carbon monoxide ligand and a chloride ion occupying the 
axial coordination sites. 
        Fig. 84 shows that complex 1 reacted with the carbonyl group at carbon 3, 
which was not expected; it had been thought that as this is a conjugated ketone the 
rhenium complex would be more likely to react at the acetyl carbonyl at position 20. 
Examination of the space-filling model for this molecule, however, shows that C20 is 
sterically hindered by the methyl group at position 18.  
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Figure 85: Single-crystal X-ray structure of 1-progesterone as a space-filling model, showing 
the steric hindrance around C20 
 
        Selected bond lengths were measured using Mercury software and showed a 
surprising result - a rearrangement of the double bond between C4 and C5 had 
occurred at the conjugated end of the progesterone; interestingly, the double bond 
was now found between C5 and C6 (Fig. 85).  
 
 
 
 
 
 
 
 
 
  
 
 
Figure 86: Single-crystal X-ray structure of 1-progesterne with bond length (Å) 
 
The structure of the progesterone standard with bond measurements is shown below 
in Fig. 86. 
C20 
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Figure 87: Single-crystal X-ray structure of the progesterone standard with bond lengths (Å) 
       
           The measurements of the relevant bond lengths are shown in Table 34 below, 
along with the analogous measurements for the progesterone standard. 
 
 
1-Progesterone Progesterone 
C3-4 1.533 1.461 
C4-5 1.508 1.348 
C5-6 1.338 1.502 
C6-7 1.494 1.529 
 
Table 34: Selected bond lengths for 1-progesterone and progesterone (Å) 
          To obtain further evidence for the shift in the double bond, the structure was 
refined without modelling the hydrogen atoms on the alkene and methylene groups 
in question. The software located three Q peaks (i.e. unassigned peaks of electron 
density of ~ 1 eÅ-3); two Q peaks were located on C4 and one Q peak was found on 
C6. This confirmed the shifting of the double bond (Fig. 87). 
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Figure 88: Partial structure of 1-progesterone showing the location of the Q peaks 
 
         A similar bond rearrangement is seen on formation of ketals from ∆4-3-
ketosteroids with ethylene glycol, in which ∆5-steroids are formed (Fig. 88).  
 
 
 
 
 
 
 
 
Figure 89: Ketal formation with 3-ketosteroids 
 
         This has been demonstrated with a number of steroids100,101  including 
progesterone.102 In this latter paper ketal moieties were formed at both C3 and C20 
of progesterone; however this was not observed in the work reported here, probably 
because progesterone was used in large excess in the aminal formation.  
2.7.4 C. Reaction of complex 1 and testosterone 
2.7.4.1 Analysis using NMR        
         Having successfully prepared 1-progesterone, it was decided to investigate 
whether a similar product could be prepared with testosterone, an androgenic steroid 
which contains the same conjugated ketone moiety in the A ring (Fig. 89 and 90 
Scheme 3). 
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Figure 90: Testosterone                                           
 
 
 
 
 
 
 
 
 
 
 
  
       
Figure 91: Scheme 3: Reaction between complex 1 and testosterone to form the 1-
testosterone product 
        Firstly, an experiment was carried out in an NMR tube to see whether a product 
could be formed on a small scale. Complex 1 (2 mg) and testosterone (11.7 mg, 10 
eq.) were dissolved in CD3CN. A small amount of camphor sulfonic acid was added 
and the solution was heated at 60 ºC in a water bath. The reaction was monitored 
using 1H NMR. By looking at the results (Fig. 91) it becomes clear that the reactants 
were converted to products after 10 hrs as no obvious changes were observed after 
that. Therefore, the experiment was repeated on a larger scale to enable isolation 
and characterisation of the product.                                                                                    
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Figure 92: Selected regions of the 1H NMR spectra of the reaction between complex 1 and 
testosterone (CD3CN) after 1, 5, 10 and 13 hrs 
 
    Key:                 Represents the starting material       
                              Represents the formation of products 
 
2.7.4.2 Reaction of testosterone and complex 1 (large scale)  
     
       Complex 1 (30 mg) and testosterone (176 mg, 10 eq.) were dissolved in MeCN 
(3 mL) and a few grains of camphor sulfonic acid were added. The reaction was 
stirred for 3 hrs at 60 ºC and monitored using TLC (Al2O3, 5% MeOH in DCM) until 
all of the starting material had been consumed (after approximately 24 hr).  An 
aliquot (0.25 mL) was removed from the reaction solution and diluted with MeCN (0.5 
mL) and analysed using HPLC. Fig. 92 shows the chromatogram obtained at 286 
nm. A sample of testosterone was analysed under the same conditions for 
comparison (Fig. 93). 
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Figure 93: LC chromatogram of the reaction mixture after 24 hrs, at 65 % B, 1.0 mL/min flow 
rate and 286 nm 
 
 
                 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 94: Chromatogram of testosterone at 65 % B and 1.0 mL/min flow rate 
 
       The chromatogram (Fig. 92) showed some side products, a very small peak of 
the starting material testosterone at 8.61 min and two peaks from the two product 
isomers (RT=12.20 and 13.99) for isomer I and 2 respectively. Once it was 
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confirmed that the product isomers were formed, it was decided to separate them 
using preparative HPLC. The reaction solution was then separated (in 1 mL aliquots) 
by preparative HPLC; the chromatogram is shown in Fig. 94 below. The 
chromatogram showed a very small peak due to testosterone and unresolved peaks 
for the product isomers (since the resolution of preparative HPLC was not as high as 
analytical scale HPLC). 
 
 
 
 
 
 
 
 
 
Figure 95: Preparative HPLC chromatogram showing collection of fractions for the two 
isomers of 1-testosterone 
 
 
           For each isomer, fractions were collected (Fig. 95), (isomer 1: 21-23, 110-
113, 175-178, 241-242 and for isomer 2: 27-30,116-122, 181-188, 245-251) 
combined and the MeCN was removed under vacuum. The fractions were extracted 
into DCM, dried (MgSO4), filtered and evaporated in vacuo. The proton NMR 
spectrum of each fraction was acquired in CD3CN (Fig. 96).  
 
 
 
 
 
Testosterone 
Products  
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Figure 96: Preparative HPLC chromatogram showing collection of fractions for the two 
isomers of 1-testosterone 
 
 
                                                                
 
                        
 
 
 
 
 
 
 
 
Figure 97: Selected regions of the 1H NMR spectra of 1-testosterone fraction 1 (top) and 
fraction 2 (bottom) 
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        Examination of the aromatic region of the spectrum of isomer 1 (Fig. 96) 
showed many signals and the sample was clearly impure. However, the spectrum of 
isomer 2 shows a clean sample of the product has been isolated.  
        Attempts were made to crystallise the product both by solvent diffusion and by 
refrigeration of an acetonitrile solution of fraction 2. Unfortunately to date these 
attempts have been unsuccessful.  
2.8 Conclusion 
     The main aim of the work presented here was to attach a steroid, progesterone, 
to a rhenium-containing fluorescent group (the rhenium complex of 3,3’-diamino-2,2’-
bipyridine, complex 1, section 2.3); this aim was achieved with formation of the 
desired product and full characterisation obtained. Much of the work reported 
previously in the literature on metal complexes of steroids uses androgens but few 
studies have used female hormones such as progesterone. This is one of the first 
examples of a luminescent metal complex of this steroid.  
The method was developed using the model compound cyclohexanone which 
mimics the A-ring of progesterone (section 2.6.1.1). The product 1-progesterone was 
successfully characterized by using a HPLC method (which was developed for this 
research), preparative HPLC, column chromatography, 1D-NMR and X-ray 
crystallography. The co-ordination chemistry of 1-progesterone revealed some 
interesting results. After reaction between complex 1 and progesterone 
rearrangement of the double bond from positions 4-5 to 5-6 was observed from the 
single-crystal X-ray structure which, as far as we can tell, has not previously been 
reported for diamine derivatives of ketosteroids, although is well-precedented during 
derivatisation of ketosteroids using diols.91,92  
        After successful reaction of progesterone with complex 1, the same method 
was applied for the synthesis of the 1-testosterone product which was characterised 
using the LC method, preparative HPLC, column chromatography, and 1D-NMR. 
The formation of 1-testosterone was confirmed using 1D-NMR. Despite meticulous 
attempts to grow crystals under different conditions both by solvent diffusion and by 
refrigeration of an acetonitrile solution unfortunately production of crystals for X-ray 
analysis has so far been unsuccessful due to the limited amount of the product 
obtained after column chromatography.  
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2.9 Future Work 
      This project and the results displayed in this thesis could be developed in various 
ways, for example by attaching other metals which possess fluorescent properties, 
such as ruthenium, or by exploring the addition of steroid groups in the axial position 
of the Re(CO)3Cl(L2) core with the aim of enhancing the luminescence lifetime of the 
metals. The methods developed could also be used with other steroidal compounds 
such as corticosteroids.  
      Further work is required to complete the structural determination of 1-
testosterone produced by X-ray crystallography. Detailed 2D-NMR experiments are 
required. 
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3.0 Enzymatic oxidation of galactose 
3.1 Introduction 
The four major classes of organic molecules in living systems are:  
• proteins; 
• lipids; 
• nucleic acids and;  
• carbohydrates. 
         Carbohydrates are the most abundant organic molecules found in nature.103 
Nearly all organisms synthesize and metabolize carbohydrates. Plants and animals 
combine numerous glucose molecules to form large energy-storing molecules such 
as starch and glycogen and a variety of other macromolecules.104,105 
Carbohydrates are always challenging targets for analytical chemists as there are 
difficulties in both their separation and detection. Due to the chirality, branching 
structures and cross-linking the number of isomers of carbohydrates is huge.106 For 
over a century, nucleic acids, proteins and lipids have been extensively studied 
worldwide. Carbohydrates have only more recently received close attention through 
the expanding field of glycobiology. Glycobiology is advancing at increasing rates 
due to advanced developments in new technologies and in genomics.  Glycobiology 
is the study of the roles of carbohydrates in cellular life. Carbohydrates are the 
primary products of plant photosynthesis and the metabolic precursors of all other 
organic compounds. Often they are covalently bound to proteins (glycoproteins) and 
lipids (glycolipids) to form glycoconjugates.107 
 
         Carbohydrates are composed of polyhydroxyl units known as 
monosaccharides, of which some of the more common monosaccharides are 
glucose, galactose, mannose, fucose and N-acetylgalactosamine. These units are 
joined together by a glycosidic bond between the hydroxyl group of one 
monosaccharide and the hydroxyl functions of the second monosaccharide, with loss 
of a molecule of water. Oligosaccharides and polysaccharides are composed of the 
different monosaccharide unit repeated over and over such as in cellulose and 
starch. Complex carbohydrates act as receptors for binding proteins, typically lectins 
(carbohydrate-binding proteins). Carbohydrate–protein interactions occur through 
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glycoproteins, glycolipids, or polysaccharides present on cell surfaces.108-110 
Carbohydrates interact with lectins through hydrogen bonds, metal coordination, van 
der Waals and hydrophobic interactions.111,112  
 
So, it is incomplete to discuss carbohydrates without discussing lectins.  
3.1.1 Lectins 
        Lectins, derived from the Latin word legers meaning ‘‘to choose ’’or ‘‘select’’, 
are defined as proteins that preferentially recognize and bind carbohydrate 
complexes protruding from glycolipids and glycoproteins.113-117  
         Lectins are a class of proteins that bind mono- and oligosaccharides of 
eukaryote glycoconjugates reversibly, do not possess catalytic activity104, agglutinate 
cells and precipitate complex carbohydrates or polysaccharides. Their interaction 
with polysaccharides resembles the antibody–antigen and enzyme–substrate 
reactions. In contrast to antibodies, lectins are not the products of the immune 
system, their structures are diverse, and their specificity is restricted to binding to 
carbohydrates.97,98,99 Lectins interact with carbohydrates through binding sites to 
create complexes. Such complex formation is dependent on the particular lectin and 
its specificity for certain carbohydrate structures.118-120  
        High resolution X-ray crystallography of lectins in complex with their ligands 
showed the types of bonds formed and identified the chemical groups on the protein 
and the carbohydrate that interact with each other.120,121 Multiple lectins were 
isolated from microorganisms and also from animals.122 Hydrophobicity is the main 
force of binding lectins with carbohydrates.120  
             Carbohydrate-binding sites are often shallow depressions on the surface of the 
protein.123 The carbohydrate-binding sites of lectins recognise and fit to the ligand 
carbohydrate through a lock and key-type mechanism, involving complex networks 
of hydrogen bonds which result in the displacement of water molecules with the 
establishment of new hydrogen bonds. These hydrogen bonds and van der Waals 
contacts are the dominant forces in binding stability.120,124 
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Applications of lectins 
The availability of lectins with distinct and different carbohydrate specificities has 
resulted in the use of these proteins: 
 as tools in medical and biological research;  
 for red blood cell typing, structural studies of blood group substances and 
identification of new blood groups; 
 for investigation of complex carbohydrate functions on surfaces of animal 
cells, bacteria and viruses; 
 for isolation, purification and structural studies of carbohydrate-containing 
polymers.125 
 Lectins have applications in many fields, including cancer research, 
immunology and cell identification.126  
3.1.2 Galactose Oxidase (GO) 
         In recent years use of galactose oxidase (GO) has gained much attention. The 
enzyme GO contains a metalloradical complex consisting of a type 2 copper site and 
a protein derived cofactor covalently attached to the sulphur of a cystein,126 which 
permit the oxidation of primary alcohols to the corresponding aldehyde with reduction 
of dioxygen to hydrogen peroxide (Fig. 97). 
 
 
 
 
 
Figure 98: Oxidation of alcohols to aldehyde using galactose oxidase (GO) 
     
         GO was first reported in the growth medium of Polyporus circinatus127 although 
the organism was later identified as the filamentous fungus Dactylium dendroides128 
and then Fusarium.129 It catalyses a wide range of primary alcohols (RCH2OH), 
including sugars and polysaccharides, to the corresponding aldehydes under aerobic 
conditions while reducing oxygen to hydrogen peroxide,124,130,131 as shown in 
Equation 3.1 and Fig. 98.132 
GO
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                                      RCH2 OH+O2         RCHO+H2O2    (3.1) 
 
 
 
 
 
 
 
               
Figure 99: A reaction catalysed by galactose oxidase (GO).130,131 
 
           It is thought that hydrogen peroxide produced is then used for either antibiotic 
defence or for use by peroxidases in lignin degradation. GO is strictly regioselective, 
and no secondary alcohol or other reducing group is oxidized. However, the enzyme 
exhibits a broad substrate spectrum ranging from monosaccharides and 
polysaccharides to aliphatic and aromatic alcohols and polyalcohols.131,133,134 
3.1.2.1 Structure of GO 
The enzyme is monomeric, made up of 639 amino acids136 and has a relative 
molecular mass of 68.5 kDa.135  
Substrate specificity and binding 
GO displays broad substrate specificity with activity towards a wide range of primary 
alcohols. This is a desirable trait in an industrial biocatalyst.136 GO activity has also 
been reported towards polysaccharides where D-galactose occurs on the non-
reducing end.137,138  
Applications of Galactose Oxidase (GO) 
GO is used for various biomedical applications, including clinical assays for 
galactose in blood and other fluids, histochemical studies and early detection of 
cancer. GO is a promising enzyme for the production of biosensors because of its 
ability for direct electron transfer (DET) to the electrode and could thus be attractive 
for applications in biofuel cells, especially if the substrate specificity of GO could be 
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broadened to other sugars, especially glucose.131,133,134 There are numerous 
examples of the use of GO in biotechnological applications:  
• Detection and quantification of D-galactose is important in a number of 
different situations. For example, the condition galactosaemia, where one of 
the enzymes required for D-galactose metabolism is absent, requires the 
patient to closely monitor their D-galactose intake and blood and urine 
levels.139 It is necessary to monitor the levels of D-galactose and other GO 
substrates in the food industry, for example in processing of sugar beet140  
and in the dairy industry141,142  
• Labelling of D-galactose-terminating glycans on cell surfaces has been used 
by several groups in characterising and quantifying different cell types, such 
as in brain tissue.143 GO is also used in characterising changes upon virus 
infection of fibroblasts.144  
• Labelling of cell surface glycans is also used in cancer diagnosis as the 
disaccharide D-galactose-β-(1-3)-N-acetyl-D-galactosamine (Gal-GalNAc) is 
expressed on the surface of colon cells in the early stages of 
carcinogenesis.145-148 The same method has also been used for detection of 
breast carcinoma.148  
• Modification of polysaccharides by GO provides access to oxidation of the 
natural plant-based polymer guar which has uses in paper strengthening.149 
Derivatives of galactoxyloglucan have potential uses in abrasion resistant 
clothing or diagnostic strips.150  
• Generation of chemicals such as unnatural sugars,151 sugar-based polymers 
used in hydrogels, adsorbents and biorecognition agents152 and 5-C-
(hydroxymethyl hexoses), a potential group of artificial sweeteners153 can all 
be carried out using GO as a catalyst.  
       Parikka and Tenkanen studied GO catalyzed oxidation.154 Their main aim was to 
control the degree of reaction, optimizing aldehyde (methyl-α-D-galacto-hexodialdo-
1,5-pyranoside) production, and minimizing the formation of side products from the 
reactive aldehydes. The reaction conditions chosen for preliminary experiments were 
combined as reported earlier. GO, produced in transgenic Pichia pastoris carrying 
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the galactose oxidase gene from Fusarium spp. was used as a catalyst, methyl-α-D-
galactopyranoside as substrate, reaction temperatures were between 4 and 40 °C, 
combinations of galactose oxidase, catalase, and horseradish peroxidase were 
varied. Phosphate buffer (pH 6 to pH 7.3), and H2O have been used as reaction 
media in GO-catalyzed reactions. The reactions were first followed with thin-layer 
chromatography (TLC) and then analysed by 1H NMR spectroscopy and GC-MS and 
the main products were isolated, characterized, and identified. The preliminary 
experiments showed one main product and several secondary products in the 
reaction mixture. The three most stable products were isolated by preparative TLC, 
and characterized by NMR and mass spectrometry. The main product of GO-
catalyzed oxidation of methyl-α-D-galactopyranoside 1 was an aldehyde 2, shown 
below in Fig. 99.154 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 100: Oxidation of methyl-α-D-galactopyranoside and the formation of secondary 
products.154 
 
        The product 2 existed as a hydrate in D2O, Fig 99, 2b above with an 
intermediate 2a, and NMR analysis confirmed the structure. The main side products 
were found to be uronic acid 3 and α, β unsaturated aldehyde 4. An optimal 
combination of all the three enzymes gave aldehyde (methyl-α-D-galacto-
(2 a) 
(2 b) 
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hexodialdo-1,5-pyranoside) in approximately 90% yield. The main secondary 
product, uronic acid (3), and an unsaturated aldehyde (4), were observed for the first 
time to form in parallel. 1H and 13C NMR data of the products were reported for the α, 
β unsaturated aldehyde for the first time.154         
 
          The reaction conditions in oxidations of other galactose derivatives were 
optimised with a trisaccharide, D-raffinose, and the reaction was followed by NMR 
spectrometry. Substrate 6, D-raffinose, was converted to the corresponding 
aldehyde 7, using all the three enzymes and water as a solvent (Fig. 100). Oxidation 
of D-raffinose resulted in approximately 90% yield of the corresponding aldehyde. 
 
 
 
 
 
 
 
 
Figure 101: Oxidation of D-raffinose using three types of enzymes.156 
                             
         Parikka, Tenkanen and colleagues published further work in which they used 
GO as a catalyst to oxidize selectively the C-6 hydroxyls of terminal galactose to 
carbonyl groups.155 The polysaccharides studied included spruce 
galactoglucomannan (GGM), guar galactomannan (guar gum, GM), larch 
arabinogalactan (AG), corn fibre arabinoxylan (corn fibre gum, AX), and tamarind 
seed xyloglucan (XG) with terminal galactose contents varying from 6% to 40%. A 
combination of two enzymes was used to enhance the action of galactose oxidase. 
The oxidation conditions optimized earlier with methyl-α-D-galactopyranoside and 
raffinose were applied here for the oxidation of the polysaccharides (Fig. 101) and 
spruce galactoglucomannan was used in the preliminary experiments to confirm the 
reaction conditions and enzyme dosages suitable for the polymers. An analysis 
technique was developed for the quantification of the reactive aldehydes with GC-
MS, utilizing reduction with NaBD4 and acidic methanolysis. Results were varied 
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between the polysaccharides. The best degrees of oxidation of terminal galactosyls 
were obtained with xyloglucan (85%) and spruce galactoglucomannan (65%). The 
highest oxidation degree based on total carbohydrates was achieved with guar gum 
(28%), which had the highest galactose content. Some other alcohols with a primary 
hydroxyl group, such as glycerol, salicyl alcohol, and xylitol, are reported to be 
substrates for GO.155  
 
 
 
 
 
 
  
Figure 102: GO-Catalysed oxidation of the galactose units of polysaccharides.155 
                     
          Leppanen, Parikka, Eklund et al. presented the first ever report on the 
utilization of MALDI-TOF-MS in the analysis of enzymatically and chemically 
modified GGM, and GM derivatives.156 Galactose units of spruce GGM, guar GM 
and tamarind (XG) were selectively allylated. Aldehyde groups formed enzymatically 
in the above-mentioned galactose-containing polysaccharides were chemically 
derivatized by indium mediated allylation. Aldehyde functionalities were formed at 
the C-6 position via enzymatic oxidation by galactose oxidase along with catalase 
and horse radish peroxidase (HRP). Polysaccharides that were selectively oxidized 
by GO were spruce O-acetyl GGM, guar GM, and (galacto) XG. They were modified 
in a one-pot reaction as all reaction steps were done in water. The formation of the 
allylated or propargylated product was identified by MALDI-TOF–MS. All 
polysaccharide products were isolated and further characterized by GC–MS or NMR 
spectroscopy on Bruker AV 600 instrument. As a solvent a mixture of d6-DMSO and 
D2O (1:2) was used. These experiments were successful in adding allyl 
functionalities onto different polysaccharides.156  
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         Siebum and colleagues investigated the utility of both galactose oxidase and 
alcohol oxidase for use in alcohol-to-aldehyde oxidations. Alcohol oxidase has been 
successfully used in combination with the aldolase DERA in a two-step, one-pot 
reaction.157 These authors investigated the preparative scope and limitations of the 
enzymes on the basis of 30 different alcohol substrates. Galactose oxidase (D. 
dendroides) and alcohol oxidase (P. pastoris) were used as biocatalysts. Both 
enzymes were oxidases that use molecular oxygen as an electron acceptor in the 
oxidation of alcohols to aldehydes (Fig. 102). It was discovered that the reaction 
does not require a cofactor like NADPH which makes oxidases more suitable for 
biocatalytic oxidations than the cofactor-dependent dehydrogenases.  To test the 
synthetic utility of the oxidizing enzymes, 30 different (highly) functionalized primary 
alcohols were treated with GO and AO. Overall conversions were determined by 
NMR after 48 hrs of reaction. GO remained largely selective to galactose-derived 
substrates. AO had a clear preference for unbranched, aliphatic, primary alcohols. 
They had proved that both GO and AO can be used for the preparation of 
functionalized aldehydes, under mild aqueous conditions, on a synthetically useful 
scale.157 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 103: The galactose oxidase (GO) and alcohol oxidase (AO) catalytic systems.157 
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       Kinoshita, Inagake and co-workers carried out fluorimetric determination of 
mucin-type glycoproteins using galactose oxidase and peroxidase.160 Galactose 
oxidase oxidizes galactose and/or N-acetylgalactosamine in solution (Fig. 103) and 
produces hydrogen peroxide which reacts with the fluorogenic substrate, 3-(p-
hydroxyphenyl) propionic acid (HPPA), in the presence of HRP; the oxidized 
substrate emits fluorescence at 405 nm after excitation at 320 nm. 
 
 
 
 
 
 
 
 
         
Figure 104: The galactose oxidase (GO) and alcohol oxidase (AO) catalytic systems.158 
          Although the fluorimetric determination of carbohydrates using glucose 
oxidase and galactose oxidase has been reported, the optimal conditions for 
quantitative determination were not described before. Using acid-hydrolysates of 
bovine submaxillary mucin (BSM, 50 mg) as a model, conditions for fluorimetric 
determination by the galactose oxidase-HRP method were optimized. Tris-HCl buffer 
(0.1 M, pH 8.0) was employed for the enzyme reaction and both enzyme reactions 
proceeded sufficiently at pH 8.0. With the change in concentration of galactose 
oxidase and peroxidase, the fluorescent yields became constant. Galactose oxidase 
(D-galactose: oxygen 6-oxidoreductase) specifically oxidizes the C-6 hydroxymethyl 
group of galactose and N-acetylgalactosamine. Previous studies evaluated 
fluorogenic substrates for the fluorometric assay of hydrogen peroxide based on the 
HRP-catalyzed reaction and demonstrated that 3-(p-hydroxyphenyl propionic acid) 
(HPPA) was one of the best substrates. They described a specific method for the 
determination of galactose/N-acetylgalactosamine in some glycoprotein samples.158 
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3.2 Aim of research 
This project aims are;  
• To evaluate different methods for enzyme oxidation of galactose to produce 
galactose with an aldehyde group on.  
• To react that compound with complex-1 (as mentioned in section 2.3 at page 
76) to make a luminescent sugar complex. 
3.3 Experimental 
Materials  
Galactose, methyl-β-D-galactopyranoside and horse radish peroxidase were 
purchased from Fluka chemicals (purity 99 %). 
Galactose oxidase, camphorsulfonic acid (CSA), catalase (solid) and catalase 
suspension were purchased from Sigma (purity 99 %). 
 
Solvents 
Acetonitrile (99.6 +%) certified HPLC grade, methanol (99.8 +%) certified HPLC 
grade and phosphate buffer (potassium dihydrogen phosphate 50 mM) were 
purchased from Fisher Scientific (UK). 
DCM, DMSO, DIPE, glacial acetic acid, potassium permanganate, acetic acid, 
petroleum ether and 2-propanol were all purchased from Fisher Scientific (UK).  
Chloroform-d and D2O were purchased from Goss Scientific Ltd. 
Stock solutions and working solutions were prepared by successive dilution with 
acetonitrile or DMSO. 
Instrumentation  
 
• Chromatographic separation was developed on a Shimadzu Prominence UFLC 
system running LabSolutions software (v. 5). The column used was a 
Lichrospher 100, RP-18 (250 mm x 4.6 mm, 5 µm), column no. 026023, Lot. No. 
497017 purchased from VWR (Merck, Germany).  
• Samples were analysed on a Bruker MicrOToF-q mass spectrometer coupled to 
the Shimadzu UFLC system. Positive mode electrospray ionisation was chosen. 
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MS data acquisition and processing were carried out using Bruker’s proprietary 
software, DataAnalysis.                                                                    
• Sample purification was carried out using a Gilson prep-HPLC, Model-803C 
mono-metric module, using Gilson Piston Pumps Model 303 and 305. The column 
used was a Dynamax, pre-packed C18 column module, 21.4 mm I.D x 250 mm, 
serial No. B910924. The detector was a Gilson HM Holochrome UV-VIS using 286 
nm wavelength. The data was collected on a chart recorder (Kipp and Zonen BD 
40) and integrator. The mobile phase (A) was MeCN, 65 % and mobile phase (B) 
was HPLC water, 35 %. The flow rate was kept constant at 10.00 mL/min. The run 
time was 60 mins. 
• NMR experiments were carried out using a Bruker Avance 500 MHz NMR 
spectrometer at room temperature. The software used was Topspin 1.3. 
• Removal of the enzyme from reaction mixtures was performed using Amicon 
cartridges (Millipore) and an MSE Microcentaur centrifuge at 13,000 rpm.  
 
• TLC was performed on silica and alumina plates, as appropriate.  
 
• Where samples required drying they were frozen under liquid nitrogen and freeze-
dried overnight using a Modulyo Edwards Model RV 3 freeze dryer. The 
parameters used are tabulated below: 
 
 
 
                  
 
                   
Table 35: Instrumental parameters used for the freeze dryer 
 
 
 
Temperature -450 C 
Pressure 10-3 Torr 
Capacity of round-bottom flask 250 ml 
Sample volume 3-4 ml 
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3.4 Methodology      
3.4.1 NMR Timed experiment for oxidation reaction 
       Galactose powder (2 mg) and galactose oxidase enzyme (2.56 mg) were 
dissolved in D2O (0.650 mL). 
Experimental protocol  - On small scale          
Experiment – 1  
      Galactose powder (2 mg) was dissolved in D2O (0.650 mL) and the 1H NMR 
spectrum was recorded. Galactose oxidase (2.56 mg) was then added and the 
solution heated for 4 hrs in a water bath at 37 °C. The 1H NMR spectrum was then 
re-recorded. 
Experiment – 2                                
      Experiment 1 was repeated keeping all the conditions constant. Galactose 
powder (2 mg) was dissolved in D2O (0.650 mL) and the 1H NMR spectrum was 
recorded. The reaction mixture was heated for 1 hr only, instead of 4 hrs, in a water 
bath at   37 °C and the 1H NMR spectrum was re-recorded. 
3.4.2 Comparison of Methodologies for oxidation reaction 
       Four different methodologies were tested, and compared to see which one was 
the best one for the enzyme oxidation of galactose and that method can be used to 
attach complex 1 to obtain a luminescent sugar complex.  
3.4.2.1 Method  1        
       The first experimental protocol followed was the enzymatic assay of galactose 
oxidase.159               
NMR Timed experiment for oxidation reaction 
       Galactose powder (99.3 mg) was dissolved in D2O (1.0 mL) and galactose 
oxidase enzyme (0.135 mg) was added. The reaction mixture was incubated for 2 
hrs in a water bath at 37 °C. An aliquot (0.650 mL) was removed and analysed by 1H 
NMR spectrometry.             
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3.4.2.2 Method  2        
        Next method of enzymatic oxidation was used according to the paper of Parikka 
and Tenkanan .154 The reaction mixture was prepared as follows: 
 
Experiment (1)          
Enzymatic assay of galactose oxidase              
        Galactose oxidase (1.41 mg), horse radish peroxidase (0.39 mg), methyl-β-D-
galactopyranoside (100 mg) and catalase (56 mg) were combined and dissolved in 
deionized water (7.5 mL) in a large vial, without a lid. The reaction was stirred for 24 
hrs at 4 ºC. After 4.5 hrs an aliquot (0.5 mL) of the reaction mixture was removed and 
spun through an Amicon filter (10,000 MWCO) for 30 min. to remove the enzymes. 
The filtrate containing the small molecules was collected, dried in a speed dryer for 1 
hour then reconstituted with D2O (0.650 mL) and the 1H NMR spectrum was 
recorded. Then, after 24 hrs the reaction was stopped, another aliquot (0.5 mL) was 
removed, the enzymes were removed and the sample was dried and reconstituted 
with D2O (0.650 mL) and its 1H NMR spectrum was recorded. 
 
Experiment (2)                         
With catalase suspension 
        Galactose oxidase (1.41 mg), horse radish peroxidase (0.39 mg), methyl-β-D-
galactopyranoside (100 mg) and catalase suspension (0.03 mL) were dissolved in 
deionised water (7.5 mL). An aliquot (0.5 mL) was removed, spun through an 
Amicon filter (10,000 MWCO) to remove the enzymes and set aside for subsequent 
analysis (t = 0). The reaction solution was transferred into a large vial, without a lid, 
which was stirred for 24 hrs at 4 ºC. Aliquots were removed after 1, 2, 3, 4 and 24 hrs 
and processed as the t = 0 sample. All samples were dried, reconstituted with D2O 
(0.650 mL) and their 1H NMR spectra recorded. An additional sample was removed 
at t = 24 hrs and processed as before except that the 1H NMR spectrum was 
recorded in d6-DMSO rather than D2O.                                    
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Experiment (3)                          
         The above experiment was repeated. Galactose oxidase (1.41 mg), horse 
radish peroxidase (0.23 mg), methyl-β-D-galactopyranoside (100 mg) and catalase 
suspension (0.03 mL) were dissolved in deionised water (7.5 mL). A small portion of 
the reaction mixture (0.5 mL) was removed, spun down through an Amicon filter to 
remove the enzymes and set aside (t = 0). Further aliquots were removed over 4 hrs 
and the    1H NMR spectra of all aliquots were recorded. The reaction mixture was 
left overnight. After 24 hrs a further aliquot (0.5 mL) was removed, the enzyme 
removed, the sample dried and d6-DMSO added (0.650 mL). The 1H NMR spectrum 
was recorded.  
3.4.2.3 Method  3              
         Another method of enzymatic oxidation was used according to the paper of 
Siebum et al.157 The reaction mixture was prepared as follows: 
Experiment (1) 
TLC                                                
        Methyl-β–D-galactopyranoside (30 mg) was dissolved in deionised water (1 mL) 
and the solution was analysed using TLC (SiO2, MeOH, chloroform, acetic acid and 
deionized water (30:60:4:4 v/v). The TLC plate was dipped in potassium 
permanganate to allow visualisation of the spots. 
Experiment (2)                         
         To a conical flask (20 mL capacity) was added phosphate buffer (5.0 mL, 50 
mM, pH 7.0). Methyl-β–D-galactopyranoside (194 mg), galactose oxidase (8.1 mg, 
30 units), and catalase (14.4 µL, 4880 units) were dissolved in deionised water (7.5 
mL). The aqueous solution was then added to the buffer. This reaction mixture was 
placed under an oxygen atmosphere and stirred at 4 ºC for six days, during which 
time the reaction was monitored by TLC (SiO2, MeOH, chloroform, acetic acid and 
deionised water (30:60:4:4 v/v).  The TLC plate was dipped in either potassium 
permanganate or DNP to aid visualisation of the spots. The sample was separated 
using column chromatography using the same mobile phase used for TLC. The 
fractions were collected, combined and freeze dried in a round bottom flask, 
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separately, overnight. Then a small part of the sample was removed and its 1H NMR 
spectrum was recorded in d6- DMSO.                         
3.4.2.4 Method  4           
 
         A different method of enzymatic oxidation was used according to the paper of 
Osuga et al.160 The reaction mixture was prepared as follows: 
Methyl-β-D-galactospyranoside (40 mg), galactose oxidase (122 mg, 450 U) and 
catalase (4 mg) were dissolved in phosphate buffer (1 mL, pH 6.0). The mixture was 
stirred on a hot plate at 25 ºC for 24 hrs and the reaction was monitored by TLC 
(SiO2, n-propanol/ethanol/water (3:2:1 v/v). The aldehyde product was visualised 
using 0.4 % DNP in HCl (2 N). After 24 hrs the reaction mixture was heated to 95 ºC 
for 5 min (to denature the enzyme) and the protein precipitated was removed by 
centrifugation. The product obtained was freeze dried. Two samples of the product 
were scratched from the side and the base of the flask. The 1H NMR spectra of both 
samples were recorded in d6- DMSO and D2O. 
3.4.2.5 Best oxidation method to use with rhenium complex          
        Four different methodologies were investigated for the oxidation of methyl-β-D-
galactopyranoside using galactose oxidase and the best results were achieved using 
method 2. The aldehyde product of methyl-β-D-galactopyranoside obtained in 
method 2, was then reacted with complex 1 (as mentioned in section 2.3 at page 
76). 
A) Reaction of oxidation product with rhenium complex (Complex 1) experiment 
using Method 2 
TLC analysis of the reaction mixture (without complex-1) 
        The mobile phase for TLC was made by mixing MeOH (10 mL), DCM (20 mL), 
glacial acetic acid (1 mL) and deionised water (1 mL). The reaction mixture was 
spotted onto the silica plate and the plate was eluted. The plate was dried and 
dipped in a solution of potassium permanganate, (KMnO4, in 5% NaOH) dried and 
observed under a UV lamp. 
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Column chromatography of the reaction mixture  
         The reaction mixture was separated on a silica column using the same mobile 
phase as the TLC separation and fractions were collected. Fractions 1-23, 24-45 and 
46-70 were combined (separately) and dried. The 1H NMR spectra of the samples 
were acquired in DMSO-d6 which showed that fractions 24-45 contained more 
material than other two fractions 1-23 and 46-70. 
 
Reaction mixture (with complex-1) 
         Next, MeCN (5 mL) was added to a flask containing fractions 24-45. Complex 
1(10 mg) and few grains of CSA were added to it. The reaction mixture was left 
overnight. An aliquot (1.0 mL) was removed after 24 hrs, dried under vacuum and 
the 1H NMR spectrum of the sample was acquired in d6- DMSO.  
 
TLC of fraction 24-45                                                 
         TLC separation of the reaction mixture was attempted using a silica plate and 
1% MeOH in DCM as the mobile phase. This experiment was then repeated using 3 
%, 5 % and 10 % MeOH in separate experiments to find out which percentage 
separated the reaction mixture best. The result showed that 10 % MeOH in DCM 
separated the reaction mixture best. 
Column chromatography of the reaction mixture  
         After optimisation of the separation conditions, the sample was then separated 
by column chromatography using 10% MeOH solution in DCM as the mobile phase. 
Two prominent bands were visible. Any yellow fractions were collected as these 
would correspond to rhenium-containing species. Fractions 1 (18-23) and fractions 2 
(26-39) were combined, dried under vacuum and dissolved in d3-MeCN and 
analysed using 1H NMR spectrometry.   
Liquid chromatography                                       
        Fraction 1 was dissolved in MeCN (1 mL) and analysed using LC at 65% MeCN 
and 0.5 mL/min flow rate. The separation achieved was insufficient so the 
experiment was repeated using different percentages of MeCN (50%, 45% and 35%) 
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to obtain adequate separation. Separation with 35% MeCN, 0.5 mL/min gave 
optimum separation. Fraction 2 was then analysed using this method.  
Preparative  high performance liquid chromatography (HPLC)                                    
         It was decided to use preparative HPLC to collect a workable amount of pure 
compound for subsequent analysis. The remainder of the LC-MS sample was 
divided into two aliquots (2 x 0.45 mL) and run through the preparative HPLC. In 
order to get the pure product, fractions were collected after every 30 sec from the 
start, i.e. t = 0, for both aliquots. The fractions were collected and stored in labelled 
vials. The conditions used on prep-HPLC were as shown in Table 36. 
 
 
 
 
 
 
 
 
 
Table 36: Conditions used for preparative HPLC separation of fractions 
         Two isomers were observed which were designated isomer 1 and isomer 2 in 
order of elution. For isomer 1, fractions 32-36 and 125-129 were collected, combined 
and the MeCN removed under vacuum. The remaining aqueous solution was 
extracted into DCM, dried (MgSO4) and the solvent removed under vacuum. The 1H 
NMR spectrum was acquired in CD3CN. For isomer 2, fractions 43-48 and 137-142 
were collected, combined and isolated as described above.  
B) Reaction of oxidation product with rhenium complex (Complex 1) using 
Method 3 
It was decided to separate the sample (section 3.4.2.3, method 3 and experiment 2) 
using column chromatography prior to analysis. 
Method No. 2 
Range 1.0, 0.2 AUFS 
Frequency 286 nm 
Pressure 116 bars 
ACN (A%) 65% 
H2O (B%) 35% 
Flow rate 10 mL/min 
Run time 50 min 
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Column chromatography       
         The reaction mixture was separated on a silica column using the same mobile 
phase as the TLC separation (SiO2, MeOH, chloroform, acetic acid and deionised 
water (30:60:4:4 v/v) Fractions 21-24 and 28-33 were collected, after column 
chromatography, and combined to give two samples for further analysis. The 1H 
NMR spectra of the samples were acquired in d6- DMSO and the fractions were 
freeze dried.  
         Next, MeCN (5 mL) was added to a flask containing fractions 28-33. Complex 
1(10 mg) and few grains of CSA were added to it. The reaction mixture was left 
overnight. An aliquot (1.0 mL) was removed after 24 hrs, dried under vacuum and 
the 1H NMR spectrum of the sample was acquired in d6-DMSO.  
3.5 Results and discussion 
3.5.1 NMR Timed experiment for oxidation reaction 
        To determine whether the desired product had been formed in the reaction 
mixture a series of 1D NMR experiments were carried out.  
Experimental protocol - On a small scale          
Experiment – 1  
          Galactose powder (2 mg) was weighed and dissolved in D2O (0.650 mL) and 
the 1H NMR spectrum was recorded as a reference. Galactose oxidase (2.56 mg) 
was then added and the solution was heated for 4 hours in a water bath at 37 °C. 
The 1H NMR spectrum was then re-recorded. Fig.104 shows the 1H NMR spectrum 
of the reaction mixture at t=4 hrs (In the spectra, below, α-s and β-s represents the 
peaks for starting materials and α-p and β-p represents the peaks for the product/s). 
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Figure 105: Comparison of selected regions of the 1H NMR spectra of the reaction mixture 
with the galactose standard over time (t=0, 1 and 4 hr) 
 
         Comparison of a reaction mixture, run for up to 4 hrs with the standard of 
galactose suggested that subtle changes were observed between 3-4 ppm. A new 
signal arose at 1.0 ppm (1) and it persists there throughout the reaction run time. 
From the starting material (galactose) in Fig. 104, a reduction in the peak size was 
observed between 3.6 ppm to 4.0 ppm. There was an increase in the signals 
between 3.3-3.5 ppm. Signals become complex after 4 hrs in the reaction mixture. A 
doublet was seen to increase from minimal value as seen in the starting material 
between 4.4-4.5 ppm (2) which suggested that α-galactose was converted to β-
galactose whose anomeric proton signal appeared between 4.4-4.5 ppm. 
Experiment – 2  
         A spectrum was recorded for the galactose reaction mixture after 1 hr (Fig. 
105, B) (B) compared with the standard (A) under identical conditions as above.  
 
 
1 hr. 
Galactose 
Standard 
4 hr. 
1.52.02.53.03.54.04.55.0 ppm
Scale: 0.2119 ppm/cm, 84.77 Hz/cm
0 hr. 
1 2 3 
α-s 
β-s 
β-p 
α-p 
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Figure 106: Selected regions of the 1H NMR spectrum of the galactose reaction mixture 
after 1 hr (B) compared with the standard (A) 
 
        When the spectrum of the galactose standard (Fig. 105, A) was compared with 
the reaction mixture after 1 hr of heating in the water bath changes in the spectrum 
were seen between 4.4 and 4.5 ppm. Many changes were also observed when the 
part of the spectra between 3.30 – 4.06 ppm was expanded. 
 
 
 
 
 
 
 
 
 
Figure 107: Selected regions of the 1H NMR spectra of the galactose reaction mixture 
(bottom) compared with galactose (above) 
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        Regions 1 and 3, above, showed that new signals appeared between these 
parts of the spectra, while in region 2 the signals became much complex.                   
3.5.2 Comparison of Methodologies for oxidation reaction 
         Four different methodologies were tested, and compared to see which one was 
the best one for the enzyme oxidation of methyl-β-D-galactopyranoside. 
3.5.2.1 Method  1        
         The first experimental protocol followed was the enzymatic assay of galactose 
oxidase.159The basic principle is given below:             
 
                  D-Galactose + O2                           D-Galacto-hexodialdose + H2O2 
NMR Timed experiment for oxidation reaction 
         Two 1H NMR experiments were performed. For experiment A the reaction 
mixture was prepared with galactose powder (99.3 mg) in D2O (1.0 mL) and 
galactose oxidase enzyme (0.135 mg) was added and incubated for 2 hrs. An aliquot 
(0.650 mL) was removed and analysed by 1H NMR spectrometry. For experiment B 
the reaction mixture was prepared with methyl-β-D-galactopyranoside (99.3 mg) 
keeping all other conditions the same as experiment A.      
 
                                            
 
 
 
 
 
 
  
Figure 108: Selected regions of the 1H NMR spectra of the galactose reaction mixture 
showing progress in the reaction (after 2 hrs) 
 
(A) 
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Chapter: 3                                         Enzymatic oxidation of galactose 
 
143 
 
          The galactose reaction mixture was run for two hrs and when the 1H NMR 
spectra of the selected regions (Fig. 107) were compared with the standard of 
galactose no significant change in the reaction mixture was observed (Fig. 108). 
 
 
 
 
 
 
 
 
 
 
 
Figure 109: Selected regions of the 1H NMR spectra of the methyl-β-D-galactopyranoside 
reaction mixture showing progress in the reaction (after 2 hrs) 
 
3.5.2.2 Method  2     
The experimental protocol followed was the oxidation of methyl-α-galactopyranoside 
by galactose oxidase described by Parrikka et al.154 The main secondary products, a 
uronic acid (methyl-β-D-galactopyranosiduronic acid) and an unsaturated aldehyde, 
were observed for the first time to form in parallel. 
 
 
 
 
 
Figure 110: Conversion of methyl--D-galactopyranoside in to its oxidation products.154 
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Experiment (1)   
Enzymatic assay of galactose oxidase  
         The reaction mixture was prepared with three types of enzymes: galactose 
oxidase (1.41 mg), horse radish peroxidase (0.39 mg) and catalase (56 mg). Methyl-
β-D- galactopyranoside (100 mg) was used as a substrate and was dissolved in 
deionized water (7.5 mL). The reaction was stirred for 24 hrs at 4 ºC. After 4.5 hrs an 
aliquot (0.5 mL) was removed and the enzymes removed using an Amicon filter 
(10,000 MWCO). The filtrate was collected, dried in vacuo then reconstituted with 
D2O (0.650 mL) and the 1H NMR spectrum was recorded. 
 
 
 
 
 
 
 
 
 
 
 
Figure 111: Selected regions of the 1H NMR spectrum of the galactose oxidase reaction 
mixture (in D2O) showing progress in the reaction after 5 hrs (B) compared with the 
reference 1H NMR spectrum from K. Parikka and M. Tenkanen.154 
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             The 1H NMR spectrum (Fig. 110) shown in inset (A) was obtained by Parikka 
and co-workers after 5 hrs of reaction. It was clear from the above figure (B) that 
after 5 hrs changes were observed in the reaction mixture, especially at 3.6 ppm 
which shows that second product was formed. Between 3.9-4.0 ppm a very small 
peak showed that the first product was there but less abundant than was depicted in 
the literature.  
          After 24 hrs the reaction was stopped, another aliquot (0.5 mL) was removed, 
dried and reconstituted with D2O (0.650 mL) and its 1H NMR spectrum was recorded 
(Fig. 111, A) and compared with the reference spectrum from the literature (Fig. 111, 
B, inset). Some changes were observed in the spectrum; Fig. 112 shows the 
comparison of the 1H NMR spectra after 5 and 24 hrs. A new signal was observed at 
9.0 ppm (Fig. 113).  
 
 
 
 
 
 
 
 
 
 
 
Figure 112: Selected regions of the 1H NMR spectrum of the galactose reaction mixture (in 
D2O) showing progress in the reaction after 24 hrs.154 
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Figure 113: Selected regions of the 1H NMR spectra of the galactose oxidase reaction 
mixture showing progress in the reaction after 5 hr and 24 hrs 
 
 
 
 
 
 
Figure 114: Expansion of the 1H NMR spectra of the galactose oxidase reaction mixture 
showing formation of the aldehyde product after 5 hr and 24 hrs 
 
Experiment (2)  
With catalase suspension 
          The same reaction mixture was repeated but with the catalase suspension 
instead of the solid enzyme, to see whether it will give the products of our choice. 
The reaction mixture was prepared as follows: galactose oxidase (1.41 mg), horse 
radish peroxidase (0.39 mg), methyl-β-D-galactopyranoside (100 mg) and catalase 
suspension (0.03 mL) were dissolved in deionized water (7.5 mL). An aliquot (0.5 
3.23.33.43.53.63.73.83.94.04.14.24.34.44.54.64.74.84.95.05.15.25.3 ppm
Scale: 0.1074 ppm/cm, 42.98 Hz/cm
5 hrs 
24 hrs 
5 hrs 
24 hrs 
6.06.57.07.58.08.59.09.510.0 ppm
Scale: 0.21 ppm/cm, 84.01 Hz/cm
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mL) was removed, ultrafiltered through an Amicon cartridge (10,000 MWCO) to 
remove the enzymes and set aside for subsequent analysis (t = 0). 
          The reaction solution was stirred for 24 hrs at 4 ºC. Aliquots were removed 
after 1, 2, 3, 4 and 24 hrs and processed as the t = 0 sample. All samples were 
dried, reconstituted with D2O (0.650 mL) and their 1H NMR spectra recorded (Fig. 
114). An additional sample was removed at t = 24 hrs and processed as before 
except that the 1H NMR spectrum was recorded in d6- DMSO rather than D2O.  
 
 
 
 
 
 
 
  
 
 
Figure 115: Stacked 1H NMR spectra of above reaction (t=2 hr and 4 hr) compared with t=0 
         
       After comparing results, at different time intervals, it was found out that the 
results were encouraging but not as clear. The 1H NMR spectra of the reaction 
mixture (t=0 and t=4 hrs) were compared with the reference 1H NMR spectrum from 
Parikka et al154 which indicated that a number of peaks were in accordance with the 
reference spectrum showing that partial oxidation had occurred. The signals for the 
formation of the product were present between 3.5 ppm and 3.6 ppm (Fig. 115). The 
signals present between 3.8-3.9 ppm clearly showed that the proton signals from 
product 1, which were expected and a peak appeared at 9.1-9.2 ppm (Fig. 116, 
below) corresponding to formation of an aldehyde although there was also a new 
signal at 9.5 ppm which could not be identified. 
O hr 
4 hr 
3 hr 
2 hr 
3.43.53.63.73.83.94.04.14.24.34.44.54.64.74.84.95.05.1 ppm
Scale: 0.08945 ppm/cm, 44.74 Hz/cm
β-p 
Chapter: 3                                         Enzymatic oxidation of galactose 
 
148 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 116: 1H NMR spectra of the reaction mixture (t=0) and after (t=4 hr) along with the 
reference 1H NMR spectrum from Parikka et al.154 
 
 
 
 
 
 
 
 
  
Figure 117: Selected regions of the 1H NMR of the reaction (t=2 hr to 4 hr) compared with 
t=0 showing formation of the aldehyde product 
6.57.07.58.08.59.09.5 ppm
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           The reaction mixture was allowed to run for 24 hrs. After that, the 1H NMR 
spectra were run in d6-DMSO and D2O and the result with D2O showed that the 
oxidation reaction brought changes in the proton NMR as the signals become quite 
complex in the region between 3.6-4.1 ppm (Fig. 117).  
 
 
 
 
 
 
 
 
 
 
Figure 118: Selected regions of the 1H NMR spectra of the galactose oxidase reaction 
mixture showing progress in the reaction after 24 hr in D2O and d6-DMSO 
 
 
           When the selected regions of the reaction mixture after t=24 hrs (D2O) were 
compared with t=0, the spectra clearly indicated that oxidation had occurred and this 
brought changes in the spectrum after 24 hrs (Fig. 118). However, when the 
spectrum of t=24 hrs (D2O) was compared with the reference spectrum t=0 (Fig. 117) 
it was concluded that reaction did occur but was not as efficient as had been 
expected. 
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Figure 119: Selected regions of the 1H NMR spectrum of the galactose oxidase reaction 
mixture showing progress in the reaction after 24 hrs in D2O and compared with t=0 
 
         The above proton NMR clearly showed that after 24 hrs most of the features 
not observed at t=0 in Fig. 118 appeared in the post reaction, especially in the region 
labelled as A. New signals appeared in two regions of the proton NMR spectrum, 
between 3.8-4.1 ppm and 4.7-5.2 ppm. The peaks corresponding to the reaction 
mixture became complex (B).   
 
Experiment (3)                          
With all fresh compounds 
          Galactose oxidase (1.41 mg), horse radish peroxidase (0.23 mg), methyl-β-D 
galactopyranoside (100 mg) and catalase suspension (0.03 mL) were dissolved in 
deionised water (7.5 mL) and the reaction was followed for 4 hrs. An aliquot (0.5 mL) 
was removed (t=0), ultra filtered to remove the enzymes and set aside for 
subsequent analysis (t = 0). Further aliquots were removed over 4 hrs and the 1H 
NMR spectra (in D2O) were recorded.    
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Figure 120: 1H NMR spectra (in D2O) of the enzyme assay reaction (t=0 and 4 hr) 
 
 
           Comparing the spectra of t=0 hr and 4 hrs, it was found that after 4 hrs (Fig. 
119) there was an increase of the signals seen in the reaction mixture as compared 
to t=0. Also two additional signals appeared between 3.9-4.0 ppm, and at 4.1-4.2 
ppm which could indicate the presence of oxidation products or degradation of the 
product before NMR. From the literature reference154 (Fig. 121), it was indicated that 
the reactants were converted to the products of interest. When the region between 
4.8– 5.3 ppm was expanded further, it showed that new signals had appeared in this 
region. 
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Figure 121: Selected regions of the 1H NMR spectra (in D2O) of the enzyme assay reaction 
(t=0 and 4 hr) 
 
 
 
 
 
 
 
 
 
 
 
Figure 122: 1H NMR spectra (B, in D2O) of the enzyme assay reaction (t=4 hr) compared 
with the reference 1H NMR spectrum (A) from the literature.134 
 
New signals had appeared in the downfield region of the proton NMR at 6.0, 9.1 and 
9.4 ppm (Fig. 122).  
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Figure 123: 1H NMR spectrum of the enzyme assay reaction (t=4 hr) highlighting the 
formation of an aldehyde product 
 
         The reaction mixture was left overnight. After 24 hrs a further aliquot (0.5 mL) 
was removed, the enzymes removed, the sample dried and reconstituted in d6-
DMSO (0.650 mL). The 1H NMR spectrum was recorded (Fig.124).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 124: 1H NMR spectrum (in d6-DMSO) of the enzyme assay reaction (t=4 hr) 
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Figure 125: Expanded anomeric region of 1H NMR spectra (B, in d6-DMSO) of the enzyme 
assay reaction (t=24 hr) compared with the reference NMR spectrum (A) from the 
literature.134 
 
         The proton NMR spectrum clearly showed that the signals became more 
abundant after 24 hrs. It was therefore decided to analyse the sample using thin 
layer chromatography.  
3.5.2.3 Method  3           
 
         It was reported by Siebum et al157 that galactose oxidase could transform a 
range of primary alcohols into the corresponding aldehydes by using molecular 
oxygen as an electron acceptor in the oxidation of alcohols to aldehydes (p: 157, 
section 3.4.2.3) 
Experiment (1)                                           
TLC   
        An experiment was done on a small scale to prepare for separation of the 
reaction mixture using TLC. Analysis of methyl-β-D-galactopyranoside (30 mg) in 
deionised water (1 mL) was attempted using a silica TLC plate with a mobile phase 
of MeOH, chloroform, acetic acid and deionised water (30:60:4:4 v/v). The TLC plate 
was dipped in potassium permanganate to allow visualisation of the spot.  
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Experiment (2)                         
 
With all fresh compounds                  
         A mixture of methyl-β-D-galactopyranoside (194 mg) galactose oxidase (8.1 
mg, 30 units), and catalase (14.4 µL, 4880 units) were dissolved in deionised water 
(7.5 mL). The aqueous solution was then added to the phosphate buffer (5.0 mL, 50 
mM, pH 7.0).  This reaction mixture was placed under an oxygen atmosphere and 
stirred at 4 ºC for 6 days. During this time the reaction was monitored by TLC (SiO2, 
MeOH, chloroform, acetic acid and deionised water (30:60:4:4 v/v). On completion of 
the reaction the sample was freeze dried. The 1H NMR spectrum was acquired by 
dissolving a small part of the dried sample in d6-DMSO (Fig. 125).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 126: 1H NMR spectrum of the reaction product 
 
                
         The 1H NMR spectrum exhibited many peaks along with the formation of a 
prominent peak at 9.0 ppm. The resultant 1H NMR showed the presence of many 
signals probably arising from impurities or side-products. 
 
3.03.54.04.55.05.56.06.57.07.58.08.59.0 ppm
2.62.83.03.23.43.63.84.04.24.44.64.8 ppm
β-s 
β-p 
α-p 
Chapter: 3                                         Enzymatic oxidation of galactose 
 
156 
 
3.5.2.4   Method  4        
 
         A different kind of enzymatic oxidation was used according to the paper of 
Osuga et al.,160 who proposed this protocol to attach amino acids and peptides to the 
C-6 hydroxyls of galactose and N-acetylgalactosamine by first oxidizing the C-6 
hydroxyls to aldehydes using galactose oxidase in the presence of small amounts of 
catalase. The method was highly specific as enzymes were used rather than 
chemicals.  
        The reaction mixture was prepared as follows; methyl-β-D-galactose (40 mg), 
galactose oxidase (122 mg, 450 U) and catalase (4 mg) were dissolved in phosphate 
buffer (1 mL, pH 6.0). The mixture was stirred on a hot plate at 25 ºC for 24 hrs and 
the reaction was monitored by TLC (SiO2, n-propanol/ethanol/water (3:2:1 v/v). 
        On completion of the reaction, TLC analysis was carried out using a silica plate. 
The aldehyde product was visualized using 0.4 % DNP in HCl. The product was 
observed clearly.  After 24 hrs the reaction mixture was heated to 95 ºC for 5 min (to 
denature the enzyme) and the protein precipitated was removed by centrifugation. 
The product obtained was freeze dried. The 1H NMR spectra of both samples were 
recorded in d6-DMSO and D2O, Fig. 126 (a) and (b). 
 
 
 
 
 
 
 
 
 
 
Figure 127: 1H NMR spectra of the oxidation reaction with methyl-β-D-galactopyranoside in 
d6-DMSO (a) and D2O (b) 
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3.5.2.5 Best oxidation method to use with rhenium complex (Complex-1)       
        Four different methodologies were investigated for the oxidation of methyl-β-D-
galactopyranoside using galactose oxidase. The best method was found to be 
method 2 as results obtained were in accordance with the results given in literature 
Parikka and Tenkanen154 which confirmed that the oxidation reaction has occurred. 
The same experiment protocol (as method 2) was used further to make samples to 
react with complex 1. The reaction scheme is given below in Fig. 127. The aim was 
to attach a rhenium complex to the galactose containing the aldehyde group to 
obtain a luminescent compound. 
 
 
 
 
 
 
 
Figure 128: Oxidation of methyl-β-D-galactopyranoside to form the product and subsequent 
reaction with complex 1  
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A) Reaction of oxidation product with Rhenium complex (complex-1) using 
Method 2       
 
TLC analysis 
The reaction mixture was analysed by TLC on a silica plate which gave clearly 
separated spots. It was decided to attempt purification using column 
chromatography. The reaction mixture was separated and fractions were collected; 
fractions 24-45 were combined, dried and dissolved in d6-DMSO and analysed using 
1H NMR (Fig. 128). 
 
 
 
 
 
 
 
 
 
Figure 129: 1H NMR spectrum of fractions 24-45 dissolved in d6-DMSO 
 
          The results showed the appearance of a peak at 9.2 ppm which was also 
observed during the oxidation reaction corresponding to the product. The sample 
was freeze dried for future use. Fractions 1-23 and fractions 46-70 were also 
analysed in d6- DMSO but only a small amount of product was observed in both 
fractions (Fig. 129 A and B).  
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Figure 130: 1H NMR spectra of fractions 1-23 (A) and fractions 46-70 (B) in d6-DMSO 
 
          From method 2 (section 3.5.2.2, experiment 3) the 1H NMR spectrum of 
fractions 24-45 gave more peaks of interest compared to the other fractions. For this 
purpose the reaction mixture was prepared as follows: complex 1 (10 mg) was 
dissolved in MeCN (5mL) and a few granules of CSA were added. This solution was 
added to fractions 24-45 and the reaction was left overnight. An aliquot (1 mL) was 
removed, dried and the 1H NMR spectrum was acquired in d6-DMSO (Fig. 130).  
(B) 
(A) 
23456789 ppm
12345678910 ppm
Chapter: 3                                         Enzymatic oxidation of galactose 
 
160 
 
 
 
 
 
                            
 
 
 
 
 
 
 
Figure 131: Stacked 1H NMR spectra of complex 1 plus fractions 24-45 (bottom) with 
complex 1 standard (top) in d6-DMSO 
 
        Fig. 130 clearly revealed the formation of many peaks and the signal at 9.2 ppm 
is common to other 1H NMR spectra previously described. At 7.6-8.6 ppm the signals 
became complex and a doublet was seen at 8.4-8.5 ppm. The result was 
encouraging so TLC analysis of the sample was carried out with 10% MeOH in DCM 
which showed fairly good results with good separation. The fractions were then 
separated using column chromatography. Two prominent bands were obtained 
which were dried and dissolved separately in CD3CN and analysed using NMR. It 
was found by comparison of both the fractions (1 and 2) that signals at 9.2-9.3 ppm 
were present in Fig 130 fraction 1. When the selected region between 7.0-10.5 ppm 
was expanded, it became clear that the proton NMR became complex and new 
peaks were seen (Fig. 131). 
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Figure 132: Comparison of 1H NMR in CD3CN, showing fraction 1 (centre) and fraction 2 
(bottom) with complex 1 (top) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 133: Comparison of selected regions of the 1H NMR spectra, in CD3CN, showing 
fraction 1 (centre) and fraction 2 (bottom) with complex 1 (top) 
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       When compared with the complex 1 standard it was observed that in the region 
between 6.8-8.0 ppm there was an increase in the peaks in fraction 1 but in fraction 
2, the peaks became less complex and a lone peak appeared at 9.8 ppm. It appears 
that fraction 2 contains mostly complex 1.  
      Next the sample was dissolved in MeCN (1 mL) and analysed using LC at 65% B 
and 0.5 mL/min flow rate. The chromatogram (Fig. 133) gave three peaks but the 
separation was not good. Different percentages of MeCN (B%) were tried to obtain a 
better separation. With 35% B and 0.5 mL/min flow rate very good separation was 
obtained (Fig.134). 
 
 
 
 
                                     
 
 
 
 
Figure 134: LC chromatogram of fraction 1 run at 65 % B, 0.5 mL/min flow rate, at 379 nm 
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Figure 135: Chromatogram of fraction 1 at 35 % B, 0.5 mL/min flow rate 
 
The results were good with 35% B and 0.5 mL flow rate. This method was successful 
in separating peaks between 11-19 min. It was decided to try the same conditions for 
fraction 2 (Fig. 135). 
 
 
 
 
 
 
 
 
 
Figure 136: Chromatogram of fraction 2 at 35 % B, 0.5 mL/min flow rate 
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         It was decided to use preparative HPLC to collect a workable amount of pure 
compound to attempt crystallization of the product. The LC sample was divided into 
two parts and was separated using preparative HPLC which recorded the 
chromatogram on a chart recorder. In order to get the pure form, fractions were 
collected after every 30 sec from the start i.e. t=0, for all 1.5 mL. Samples were 
collected and stored in labelled vials. 
         Two isomers were observed which were designated isomer 1 and isomer 2 in 
order of elution. For each isomer, fractions were collected. For isomer 1, fractions  
32 – 36 and 125-129 (Fig. 136) and for isomer 2, fractions 43 – 48 and 137 - 142 
were collected combined and the MeCN removed under vacuum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 137: Preparative HPLC chromatogram of the complex 1 and dialdehyde reaction 
product (65 % MeCN, 10 mL/min, run time 50 min) showing collection of fractions for the two 
isomers 
 
The samples were extracted with DCM, dried (MgSO4) and evaporated in vacuo and 
their 1H NMR spectra were acquired in CD3CN (Fig. 137). 
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Figure 138: 1H NMR spectra of fraction 1 (above) and fraction 2 (bottom) in CD3CN 
 
        Through comparison of the above spectra it becomes clear that there was a 
significant amount of starting material remaining in fraction 1 and 2. In fraction 1 the 
appearance of new signals around 8.0 and between 9.6 and 10 ppm were seen. The 
signals became very complex in the region from 3.2 to 4.2 ppm as compared to 
fraction 2.  The region was expanded between 6.0-10.0 ppm (Fig. 138) which clearly 
indicated that in the region between 7.1-8.2 ppm the signals became more complex 
as compared to fraction 2 (bottom) and a group of signals were present around 9.5-
9.9 ppm.  
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Figure 139: Selected regions of the 1H NMR spectra of fraction 1 (top) and fraction 2 
(bottom) in CN3CN 
 
 
 
B) Reaction of oxidation product with rhenium complex (complex-1) using 
Method 3    
    
         On the basis of the 1H NMR results the reaction mixture was separated using 
column chromatography and fractions 21-24 and 28-33 were combined and 
analysed using 1H NMR for fractions 21-24 and 28-33 (Fig. 139).  
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Figure 140: 1H NMR spectra of fractions 21-24 and 28-33 
 
         Comparing the proton NMR spectra of both the fractions clearly showed that a 
peak was present at 9.2 and 9.5 ppm in both fractions. Fractions 28-33 contained 
more material as the sizes of the signals were double in fractions 28-33 than 
fractions 21-24 (Fig. 139). The proton NMR spectrum was also recorded in d6-DMSO 
and compared with that of complex 1. The proton NMR spectrum obtained showed 
that no change in the aromatic region was observed and a significant peak for the 
aldehyde starting material was still present (Fig. 140).  
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Figure 141: 1H NMR spectra of complex 1 (standard) and reaction mixture of fractions 28-33 
with complex 1 
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3.6 Conclusion      
          Research presented in this thesis evaluates different methodologies using 
galactose oxidase for the enzymatic oxidation of methyl-β-D-galactopyranoside to 
form an aldehyde group at position 6 of the sugar. The best method for the 
enzymatic oxidation of the sugar was found to be method 2 (section 3.4.2.2) and the 
aldehyde product was successfully characterized by TLC, LC, column 
chromatography and 1D-NMR. The product was further reacted with complex 1 to 
obtain a luminescent sugar complex. The product was characterized using LC, 
preparative HPLC and NMR although the product could not be isolated in sufficient 
yield or purity for complete characterisation.  
3.7 Future Work 
       This research can be enhanced by extending it towards a range of alternative 
substrates with the aim of expanding the potential of galactose oxidase as a tool to 
prepare ligands for use in coordination chemistry. Enzymatic oxidation of other 
disaccharides and monosaccharides seems a good starting point. 
       Further work is required to complete the structural determination of the 1-
galactose product by using X-ray crystallography and more detailed 2D-NMR 
experiments are also required. 
        In many ways GO represents an ideal enzyme for use in these applications as it 
is a stable enzyme, easily purified in high quantities and does not require expensive 
cofactors in order to function. Parikka and Tenkanen145 demonstrated that oxidation 
of D-galactose by GO can lead to formation of multiple products and demonstrated 
that reaction conditions can be optimised to reduce formation of unwanted by-
products which would be important in developing an efficient process for use on 
larger scales.  
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